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Introduction
This thesis encompasses studies embedded in the Dutch national growth hormone trial for 
children with Prader-Willi syndrome (PWS). The syndrome was fi rst described by Prader,
Labhart, and Willi in 1956, reporting a combination of obesity, short stature, cryptorchidism,
oligophrenia, and neonatal hypotonia.1 To date, our knowledge about this syndrome has
grown vastly, although much remains to be elucidated. In concordance with this growing
knowledge, new questions and dilemmas are met. This chapter provides an overview of the
clinical manifestations of PWS and the chromosomal defects from which it originates. In
the scope of this thesis, several symptoms are described in detail and the effects of growth
hormone treatment are commented on. Subsequently, the issue of sudden death in children
with Prader-Willi syndrome is discussed. Finally, the objectives of the studies described in
the following chapters are presented.
1.1 Prader-Willi syndrome
Prader-Willi syndrome is a genetic disorder that originates from lack of expression of the
Prader-Willi region of the paternally derived chromosome 15. Clinical characteristics of 
children with PWS include hypotonia, short stature, psychomotor delay, hypogonadism,
behavioral problems, and hyperphagia resulting in obesity when uncontrolled. Symptoms are
often the result of hypothalamic dysfunction, to various extents. Based on epidemiological
surveys, the birth incidence is estimated to be around 1 in 30,000.2-5 PWS is not associated
with social-economic status and the distribution between both sexes is considered equal.
The symptoms of children with PWS vary with age and are usually subdivided into four 
phases: a fetal and neonatal phase, an infantile hypotonic phase, a childhood obese phase,
and an adolescent phase with particular behavioral features.
1.1.1 Prader-Willi syndrome during the fetal and neonatal phase
Although highly variable in nature and severity, a fetal phenotype of PWS can be
distinguished, comprising of decreased fetal movements, polyhydramnios and an abnormal
posture on an ultrasonogram of hands with fl exed wrists and dorsi-extended feet with fl exed
toes.6, 7 The incidence of breech delivery and delivery by caesarean section is increased.
Breech delivery has been related to hypotonia, but also fetal hypothalamic dysfunction
has been suggested to play an important role.8, 9 Both premature and postterm deliveries
are frequently observed, with delivery being more than 3 weeks early or late in about one
third of patients.6, 10 Birth weight is more severely reduced than birth length and is below -2
standard deviation score (SDS) in up to 20%.2 Neonates with PWS have severe hypotonia
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mainly affecting the neck and have a weak or absent cry (Figure 1).11, 12 Due to the severe
hypotonia and poor sucking refl ex, feeding via a nasogastric canula is usually required to
prevent failure to thrive, defi ned as descent across the centiles of weight or body mass
index (BMI). Hypoplasia of the external genitalia is common in both sexes. Nearly all boys
have cryptorchidism, a hypoplastic scrotum and a decreased penile length. Girls may have
hypoplastic labia, but this is less obvious and easily missed. The saliva is usually sticky and
rich in proteins. Additionally, the salivary fl ow is 20% of that in healthy children, severely
increasing the risk for caries later in life.13 Neonates with PWS often have temperature 
instability.14 With the availability of rapid genetic testing and recommendations to exclude
the diagnosis of PWS in any neonate with hypotonia, feeding diffi culties, low refl exes,
and/or hypoplasia of the external genitalia, the diagnosis is now usually confi rmed in the
neonatal period.2, 5, 15-17
1.1.2 Prader-Willi syndrome in the infant phase
After the neonatal phase, hypotonia becomes gradually less marked, although infants
with PWS persist to have feeding diffi culties, and failure to thrive (Figure 1). Psychomotor 
development is delayed, in particular gross motor development and speech development.
Body composition is abnormal, with a low lean body mass and a high body fat percentage,
even in infants who are underweight and have failure to thrive.18, 19 Although also present 
in the neonatal phase, typical dysmorphic features become more pronounced in the infant
and childhood phase, showing a narrow bifrontal diameter, almond-shaped eyes, a thin
downturned upper lip, and a narrow nose.14 Many children with PWS have hypopigmentation,
fair hair, and blue eyes, although these characteristics are primarily seen in children with a
deletion.20 Sleep-related breathing disorders (SRBD) are a common feature in PWS and are
seen in almost 100% of children, even at a very early age.21-23
1.1.3 Prader-Willi syndrome in childhood
In childhood (Figure 1), the hypotonia improves, although reduced physical activity remains
present. The original feeding diffi culties improve and excessive appetite with hyperphagia
may develop, which may result in extreme obesity, when uncontrolled by dietary measures.
Abnormal body composition persists in childhood, contributing to exercise intolerance.
Furthermore, children may have genu valgum and often develop scoliosis and kyphosis.24,
25 They have poor growth, resulting in short stature and small hands and feet, and have
behavioral problems, such as temper tantrums and obsessive compulsive behavior, often
in relation to food. Skin picking may be present. Many have mild to moderate learning
disability, but some children are able to attend regular schools.26
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Figure 1. Different phases of PWS.
PWS during the neonatal and infant phase in the same boy at 6 weeks (A) and 10 months of 
age (B). PWS in childhood in a boy of 3 years and 11 months (C). PWS in adolescence in a
boy of 11 years and 7 months (D) and a girl of 16 years (E). None of the children had received
growth hormone treatment. Photos are depicted with permission of parents and children.
1.1.4 Prader-Willi syndrome in adolescence
Due to hypogonadotropic hypogonadism, puberty in adolescents with PWS may be delayed,
incomplete, or even absent (Figure 1).27 Pubertal delay may be caused by a combination
of both hypothalamic dysfunction and primary hypogonadism. In these patients pubertal
signs should be pharmacologically induced. In contrast, some children have precocious
puberty.28 Isolated premature pubarche has been reported in 14% and is probably related
to early maturation of the zona reticularis of the adrenal gland.29, 30 Spontaneous growth
velocity is impaired and the pubertal growth spurt may be lacking, which both contribute to
a decreased adult height. In adolescence, behavioral abnormalities may become worse, in
particular in relation to daily life routines.31 Most patients with PWS have mental disability,
although there is a wide variation in severity. Psychosis may occur, in particular in children
with maternal uniparental disomy (UPD).32, 33
1.1.5 Prader-Willi syndrome in adulthood
The transition from childhood to adulthood is complex. In patients with PWS, this transition
is even more complicated due to behavioral and psychiatric problems.26, 34, 35 Pervasive food
seeking behavior warrants vigorous control, but ethical concerns should be appreciated,
especially with regard to autonomy of the patient. The clinical manifestation of PWS results
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in adults being incapable of living independently.26, 35 Although the concept of group homes
or living alone under continuous supervision may at fi rst be rejected by the patient, the
structure provided by these housing concepts improves quality of live and is later often
preferred. The change in health care settings and providers also produces challenges, but
disruption of comprehensive multidisciplinary care should be avoided.
Median adult height is 145 to 150 cm for women and 155 to 162 cm for men.35-37 In adults 
with compromised pubertal development and absence of pubertal induction, secondary sex
characteristics are often absent or incomplete.26, 35 In contrast, there are few case reports of 
pregnancy in females with PWS, although paternity in PWS has never been reported.2, 38, 39
The current adult population was usually diagnosed relatively late. The diagnosis was based
on the number of symptoms listed in the consensus diagnostic criteria, often when obesity
was already present.26, 40, 41 To date, the majority of patients are diagnosed during the fi rst
months of life by genetic testing.5, 42 An earlier diagnosis should allow earlier introduction of 
care aiming to reduce morbidity and improve quality of life. There are, however, no reports
available on the clinical picture of adult patients with PWS who have been diagnosed
early in life and have been treated from infancy onwards with diet, exercise, and hormonal
substitution. 
1.2 Genetics
Until 1981, the diagnosis of PWS was solely based on the appearance of a combination of 
symptoms listed in the consensus diagnostic criteria.14 In 1981, the chromosome affected in 
patients with PWS was fi rst identifi ed.43 This report showed that the majority of patients with 
PWS suffered a deletion in chromosome 15. In 1982, it was discovered that this deletion only
affected the paternally inherited chromosome.44 To date, Prader-Willi syndrome is defi ned
as the lack of expression of paternally inherited genes sited on chromosome 15 locus q11-
q13. Expression of these genes is lost due to either a deletion, a maternal uniparental
disomy, an imprinting center defect, or a Robertsonian translocation.2, 20, 45-50
1.2.1 Chromosomal defects
Deoxyribonucleic acid (DNA) contains the genetic instructions used in the development
and functioning of all known living organisms and some viruses. The main role of DNA 
molecules is the long-term storage of information. The DNA segments that carry the genetic
information are called genes. A gene consists of two strands of amino acids, which are
entwined and form the shape of a double helix (Figure 2). DNA is folded several times and
densely packed into chromosomes. Thus, a chromosome is a single piece of DNA that
contains many genes, regulatory elements and other nucleotide sequences.
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Chromosome 15 contains a region q11-q13, which is called the Prader-Willi region. As
implied by its name, this region is critical for the Prader-Willi syndrome. In healthy subjects,
the q11-q13 region of the maternally inherited chromosome 15 is silenced by a process
called imprinting, whereas this region of the paternally derived chromosome is not (Figure
3). Loss of the signal in this region of the paternally inherited chromosome causes Prader-
Willi syndrome.
Figure 2. Schematic overview of the DNA double helix and a chromosome during
duplication.
In patients with a deletion, the q11-q15 region is absent. According to literature, a deletion is
the most common chromosomal defect, present in 70% of patients.2, 20, 45 The defect occurs
either as a large deletion (type I) or as a smaller deletion with a more distal breakpoint (type
II). In children with maternal uniparental disomy (UPD), the paternally inherited chromosome
15 is absent, while two copies of the maternally inherited chromosome 15 are present.
UPD has been reported in 20 to 25% of patients.46, 47 In case of an imprinting center defect
(ICD), occurring in 5% of patients, the PWS region of the paternally inherited chromosome
15 is silenced (imprinted).48, 49 In less than 1% of patients, part of the paternally derived
chromosome 15 is situated on another chromosome, called a Robertsonian translocation.20,
50, 51 It should be underlined that prevalences of specifi c chromosomal defects are based on
studies which included patients diagnosed according to clinical criteria. Therefore, patients
with less evident forms of PWS were not included and these reported prevalences may be
biased. 
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Figure 3. Simplified schematic overview of the chromosomal defects described in Prader-Willi 
syndrome. 
P, paternally derived chromosome; m, maternally derived chromosome; UPD, maternal 
uniparental disomy; ICD, imprinting center defect causing imprinting of the paternal locus; 
Translocation, Robertsonian translocation to another chromosome. Grey squares represent 
silenced loci. Black represents a defect.
As the signal on the paternal chromosome 15q11-q13 is lost, genes only demonstrate a 
maternal imprint.50, 52 The diagnosis of PWS can therefore be confirmed or rejected by 
DNA methylation analysis, most commonly performed by using DNA methylation-specific 
techniques at the SNURF-SNRPN locus.2, 20, 53 If DNA methylation analysis shows only a 
maternal pattern, then PWS is confirmed. Further tests may then be performed to determine 
the genetic subtype. Genetic counseling is required, in particular with regard to the 
recurrence risk. In case of an imprinting center defect, the recurrence risk is up to 50% if the 
father is a carrier for the imprinting center deletion. In case of chromosomal translocations, 
the recurrence risk may be up to 10%. For the remaining genetic subtypes, the recurrence 
risk is the same as in the general population (less than 1%).49, 54
1.2.2 Genotype-phenotype correlations
The different chromosomal defects causing PWS result in an underexpression of paternally 
derived genes and/or overexpression of maternally derived genes. These differences in 
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Figure 4. The role of the hypothalamus is critical in the pathophysiology of PWS.
Hypothalamus
Pituitary gland
GHRH LHRH TRH CRH 
Liver  
Bone and muscle 
GH 
IGF-I 
Gonads
LH/FSH 
Thyroid Adrenal
TSH ACTH 
Oestrogen 
Testosterone 
T3 
T4 
Cortisol 
Figure 5. Simplifi ed schematic overview of hormonal secretory control by the hypothalamus.
GHRH, growth hormone releasing hormone; GH, growth hormone; IGF-I, insulin-like growth
factor I; LHRH, luteinizing hormone releasing hormone; LH, luteinizing hormone; FSH, follicle
stimulating hormone; TRH, thyrotropin releasing hormone; TSH, thyroid stimulating hormone;
CRH, corticotropin releasing hormone; ACTH, adrenocorticotropin releasing hormone.
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expression may explain the increasingly recognized genotype-phenotype correlations. For 
example, hypopigmentation is primarily seen in those with a deletion. The characteristic
facial phenotype is less pronounced in patients with UPD, but have a higher risk of 
psychosis. Fruthermore, patients with UPD have higher verbal intelligence scores and
less maladaptive behavior, compared to those with a deletion.20, 32, 33, 55-57 Intellectual ability,
academic achievement, and behavioral and psychological problems are more severely
infected in patients with a type I deletion than in those with a smaller type II deletion or 
UPD.58-62
1.3 Hypothalamic dysregulation
The hypothalamus is an “organic control center” situated in the brain. As most symptoms in
PWS are related to hypothalamic dysregulation, knowledge of the anatomy and function of 
the hypothalamus is critical for understanding the pathophysiology of PWS.9
1.3.1 Anatomy, function and dysregulation of the hypothalamus
The hypothalamus is an almond-sized control center situated in the middle of the brain, just
above the brain stem and under the thalamus (Figure 4). The hypothalamus is a portion of 
the brain that contains a number of small nuclei with a variety of functions. It is connected
to the pituitary gland via the infundibulum (pituitary stalk). One of the most important
functions of the hypothalamus is to link the nervous system to the endocrine system via
the pituitary gland. The hypothalamus synthesizes and secretes neurohormones, often
called hypothalamic releasing hormones, and these in turn stimulate or inhibit the secretion
of hormones from the anterior lobe of the pituitary gland. The pituitary hormones include
growth hormone (GH), the gonadotropins luteinizing and follicle stimulating hormones (LH/
FSH), thyroid stimulating hormone (TSH), and adrenocorticotropic hormone (ACTH) (Figure
5).
The hypothalamus is responsible for numerous metabolic processes and activities of 
the autonomic nervous system, including the control of body temperature, activity level,
appetite, anger, breathing, and circadian cycles. Symptoms in PWS that have been
related to hypothalamic dysregulation include abnormal temperature control, excessive
daytime sleepiness, sleep-related breathing disorders, abnormalities of sleep architecture,
insatiable hunger, decreased activity level and energy expenditure, temper tantrums,
hypogonadotropic hypogonadism, cryptorchidism, and growth hormone defi ciency or 
insuffi ciency.2, 9, 27, 63-68 Studies using magnetic resonance imaging (MRI) techniques, have
demonstrated neuroradiologic alterations in patients with PWS, such as absence of the
pituitary bright spot as a marker of hypothalamic-pituitary axis integrity and reduced pituitary
height possibly refl ecting hypothalamic insuffi ciency.69, 70
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1.3.2 Growth hormone and insulin-like growth factor I
The hypothalamus plays a central role in the control of the growth hormone and insulin-
like growth factor I axis (GH/IGF-I axis). Growth hormone releasing hormone (GHRH) is
produced in the arcuate nucleus of the hypothalamus and is carried by the hypothalamo-
hypophyseal portal circulation to the anterior pituitary gland where it induces GH secretion
by stimulating the GHRH receptor. GHRH is released in a pulsatile manner, stimulating
similar pulsatile release of GH. Peaks of GH secretion occur at 3- to 5-hour intervals lasting
10 to 30 minutes. Most GH is secreted during sleep: nearly 50% of GH secretion occurs
during the third en fourth cycle of REM sleep stages.71, 72
Much of the GH in the circulation is bound to a protein (growth hormone binding protein,
GHBP) which is derived from the growth hormone receptor. GH exerts its anabolic function
both directly and indirectly. It directly stimulates bone growth and increases muscle mass.
GH also stimulates production of insulin-like growth factor I (IGF-I), primarily in the liver.
IGF binding protein 3 (IGFBP-3) is the major carrier protein of IGF-I and binds 70-95%
of IGF-I as a binary complex or as a ternary complex together with the acid labile subunit
(ALS). IGF-I has growth-stimulating effects on a wide variety of tissues. IGF-I is also
independently generated within various tissues. Thus, IGF-I is considered both an endocrine
and an autocrine/paracrine hormone. IGF-I also has stimulatory effects on osteoblast and
chondrocyte activity to promote bone growth. Reduced production and secretion of GH is
called GH defi ciency. 
Depending on the cut-off levels used, 60-80% of children with PWS might be considered
GH defi cient. Spontaneous 24-hour GH secretion and the response to GH provocation
tests using arginine, clonidine, or insulin-induced hypoglycaemia are reduced.73-77 Low GH
levels are also found in children with non-syndromal obesity, then coinciding with normal
IGF-I levels. In contrast to non-syndromal obesity, the majority of patients with PWS have
reduced serum IGF-I levels.2, 28, 68, 74, 78 The GH defi ciency in PWS has often been suggested
to be of hypothalamic origin.2, 68, 74, 76
1.3.3 Growth hormone treatment
In 2000, an international group of pediatric endocrinologists agreed that medical evidence
indicated that dysregulation of the GH/IGF-I axis is nearly universal in children with Prader-
Willi syndrome (PWS), and thus, these patients should be offered GH treatment.79 Many
studies have shown that short-term GH treatment, administered for one or two years,
improves gain in height.28, 73, 74, 80-88 However, only few patients have been followed until adult
height.66, 89 It has been suggested that a normal adult height may be attained, particularly
when GH treatment is started before onset of puberty.
Short-term GH treatment improves, but does not normalize, body composition by decreasing
body fat percentage and increasing lean body mass.74, 82-84 Furthermore, GH treatment
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improves psychomotor development in the very young and has psychological and behavioral
benefi ts.74, 85, 88, 90 Although GH has been proven benefi cial for children with PWS during one 
or two years of treatment, reports on long-term effi cacy and safety were very scarce.66, 89, 91
One study showed a dose-dependent effect on height, body composition and resting energy
expenditure.91 In that study, short-term metabolic effects of GH treatment were optimal with 
a dose of at least 1 mg/m2·day. However, the decreased fat percentage was not sustained 
with 1.0 mg/m2·day. Lean body mass persisted to increase after 2 years of GH treatment, 
but SD-scores for both fat percentage and lean body mass were not calculated. As lean
body mass is highly correlated with height, it is unknown whether the increase in lean body
mass was merely the result of the increase in height or refl ected an increase in lean body
mass SD-score.
Glucose homeostasis and serum lipids were neither adversely affected by short-term GH
treatment, nor by long-term GH treatment in a small group of patients.66 Effects of GH
treatment on blood pressure in children with PWS were never reported. Thus, although GH
treatment seems benefi cial for children with PWS, results on long-term GH treatment in a
large group of children, followed for 4 consecutive years and continuously treated with one
standardized dose of 1 mg/m2·day before onset of puberty, have not been reported. Notably, 
GH treatment does not resolve all symptoms of PWS, but is part of the multidisciplinary care
involving many medical and allied health disciplines, with the ultimate goal of promoting
health and increasing quality of life.
1.4 Sudden death in children with Prader-Willi syndrome
The annual death rate in PWS patients is very high (3% under 30 years).3 Among the causes 
of death in older children and adults are cor pulmonale,26, 40 fatal apneas,92 unexpected 
bathtub drownings,93 and gastric necrosis.94 In 2002, the fi rst reports were published on
sudden death in young children with PWS.95, 96 Importantly, these patients died of respiratory 
and cardiorespiratory insuffi ciency. An interesting international series of cases and a review
reported that sudden death in children with PWS occurred particularly during mild to
moderate respiratory tract infection and primarily in the early morning during sleep.92, 97
Patients with PWS suffer from sleep-related breathing disorders, consisting of obstructive
and central sleep apneas. The sleep apneas are the result of a reduction in upper airway
diameter, hypoventilation, decreased pulmonary function, and/or a decreased ventilatory and
arousal response during hypercapnia.21-23, 65, 92, 98 Therefore, several authors hypothesized 
that fatal apneas could be a cause of sudden death in children with PWS (Figure 6). It was
postulated that GH treatment could compromise sleep-related breathing by causing tonsillar 
hypertrophy resulting in increased pharyngeal narrowness. In 2003, a warning label was
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applied stating that GH treatment is contraindicated in patients with severe obesity and/
or respiratory impairment. However, several studies, including ours, have shown that GH
treatment has no effect on sleep-related breathing in children with PWS.21-23 Interestingly,
two of these studies showed a marked increase in the number of obstructive and central
apneas during upper respiratory tract infections (URTI).22, 23 Thus, illness rather than GH
treatment seemed to cause an increase in preexisting sleep apneas resulting in sudden
death (Figure 6).
Sudden death 
Health Preexisting sleep apneas
Worsening of sleep apneas Upper respiratory tract infection
 Schematic overview of the hypothesis of sudden death in children with PWS.
There are however some limitations to this hypothesis. Not all children who died unexpectedly
had enlarged tonsils or an upper respiratory tract infection.97, 99 Furthermore, sudden deaths
also occurred in non-obese children without preexisting sleep apneas.22 In fact, the sudden
deaths in children with PWS often share a similar pattern: a sudden deterioration during
a mild or moderate infection, which is often – but not always – an upper respiratory tract
infection. One study reported small adrenal glands during autopsies in children who died
unexpectedly.99 These fi ndings, coinciding with hypothalamic dysregulation in patients with
PWS, might be indicative of central adrenal insuffi ciency. However, studies investigating the
integrity of the hypothalamus-pituitary-adrenal axis had not been conducted. Furthermore,
there were no published studies investigating the relationship between sleep-related
breathing and central adrenal insuffi ciency.
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1.5 Central adrenal insuffi ciency
The adrenal gland is the end organ of the hypothalamus-pituitary-adrenal axis (HPA-axis)
and produces and secretes cortisol. Cortisol is essential for survival, particularly during
stress, and regulates cardiovascular, metabolic, immunologic, and homeostatic functions.
Inability to produce and secrete suffi cient amounts of cortisol in reaction to stress, termed
adrenal insuffi ciency, may lead to an Addisonian crisis, ultimately resulting in death. 
 
ACTH 
CRH 
CORTISOL 
Brain 
Body 
Hypothalamus
Pituitary gland
Adrenal gland
Figure 7. Simplifi ed schematic overview of the HPA-axis.
Corticotropin releasing hormone (CRH) is secreted by the paraventricular nucleus of the
hypothalamus in response to stress (Figure 7). The hypothalamo-pituitary portal system
carries the CRH to the anterior lobe of the pituitary gland, where it stimulates corticotropes
to secrete adrenocorticotropic hormone (ACTH). ACTH is secreted in the blood stream and
transported to the adrenal glands where it induces production and secretion of cortisol. The
HPA-axis has a feedback mechanism. The increase or decrease in CRH, ACTH, and cortisol
levels automatically trigger a stimulation or inhibition of the HPA-axis thereby restoring the
important equilibriums between these hormones.
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Adrenal insuffi ciency may originate from the hypothalamus or pituitary gland (central) or from
the adrenal gland itself (peripheral or primary).100 Adrenal insuffi ciency may be diagnosed
by measuring the diurnal cortisol rhythm or by testing the integrity of the HPA-axis with a
variety of dynamic tests.101 The metyrapone test has the highest sensitivity and specifi city
for measuring central adrenal insuffi ciency (Appendix A).101-107
1.6 Scoliosis
Spinal deformity is a major concern for patients with PWS. Scoliosis is a spinal curve with
a Cobb’s angle of more than 10° on a standing posteroanterior radiograph (Figure 8). The
Cobb’s angle is the angle between the two steepest vertebrae, i.e. the upper border of the
upper vertebra in the curve and the lower border of the lower vertebra.108 The prevalence of 
adolescent idiopathic scoliosis in the general Dutch population is 2.7%,109 but the prevalence
of scoliosis in PWS was not precisely known.
Figure 8. A severe scoliosis (left) and measurement of Cobb’s angle (right).
Information on scoliosis in PWS was scarce and varied greatly.24, 25, 40, 110, 111 The prevalence
was estimated to be between 15% and 86%.24, 25, 40, 110, 111 All studies were retrospective
and included both adults and children, without and during GH treatment. Some calculated
prevalences from questionnaires, whereas others studied material assembled over a great
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time span. Thus, no accurate data concerning prevalence of scoliosis were available for 
children with PWS. Accelerated growth, either spontaneous or during GH treatment, has
been associated with the onset of scoliosis and scoliotic curve progression.112-117 Scoliosis 
was therefore often considered a contraindication for GH treatment. However, a randomized
controlled trial investigating the effect of GH treatment on onset and progression of scoliosis
had never been performed. 
1.7 Bone mineral density
Bone mineral density (BMD) is the result of the equilibrium between bone formation and bone
resorption. Adequate mineral acquisition during childhood is important for reaching peak
BMD in late adolescence. A decreased peak BMD is a major determinant for osteoporosis
and fracture risk later in life. Adequate gonadal hormone levels in pubertal development are
vital for attainment of peak BMD.118, 119 In cross-sectional studies of adults with PWS, BMD 
was decreased in 60% to 90% of subjects.120-122 Furthermore, osteoporosis is considered
a supportive fi nding in the diagnostic criteria of adult PWS.14 The decreased BMD may 
account for the higher risk of fractures during life and complications during spinal surgery in
patients with PWS.20, 24, 120, 122 Although childhood is the critical period for bone accumulation,
reports on BMD in children with PWS were very scarce.85, 123, 124 Due to short stature in
children with PWS, true BMD is underestimated by the standard areal measurement and
should be corrected for bone size by calculating lumbar spine bone mineral apparent density
(BMADLS).
125-129 As evaluation of BMD was not included in the aims of previous studies in
children with PWS, a correction for short stature was never applied and BMADLS was never 
reported.85, 123, 124
In patients with GH defi ciency, BMD is decreased but normalizes during GH treatment.127, 128
However, GH and IGF-I secretion are usually more affected in GH-defi cient children than
in those with PWS.77 The effects of GH treatment on BMD in children with PWS were
unknown.
1.8 Cardiovascular and metabolic risk factors
The prevalence of cardiovascular disease and diabetes mellitus type II is increased in adult
patients with PWS, resulting in increased mortality.5, 26, 40, 97, 121, 130 Microcirculatory dysfunction 
may be present at an early age.131 To reduce morbidity and prolong life expectancy, it is
important to have a clear view on the prevalence of cardiovascular risk factors in children
with Prader-Willi syndrome.
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1.8.1 Body composition, blood pressure, and serum lipids
Children with PWS have an unfavorable body composition, with a high fat percentage
(fat%), even in underweight infants.2, 74, 87, 91, 132, 133 The increased fat% in patients with PWS
is most likely in part due to GH insuffi ciency.2, 74, 87, 91, 132, 133 However, although fat%SDS
decreased in response to GH treatment, it did not completely normalize. This suggests that
GH insuffi ciency is not the only cause of the high fat%.
There was a paucity of knowledge regarding the metabolic and cardiovascular risk profi le
in young children with PWS. The high fat% is considered a cardiovascular and metabolic
risk factor, as well as a high blood pressure, but this was never investigated in children with
PWS. Dyslipidemia may be present, also before puberty.75, 134 In contrast, insulin resistance
was less than expected based on the degree of obesity, with higher adiponectin levels
compared to obese controls but still lower than lean controls.135-137 In addition, the presence
of the metabolic syndrome was never investigated in children with PWS. Furthermore,
reports describing effects of GH treatment on cardiovascular and metabolic risk factors
were very scarce. 
1.8.2 Acylation stimulating protein
Adipose tissue is a metabolically active organ producing numerous proteins, enzymes, and
hormones. Acylation stimulating protein (ASP, Figure 9), also known as C3adesArg, is a
hormone generated through activation of the alternative complement pathway proteins C3,
B, and adipsin, and is produced by adipocytes.138 ASP stimulates free fatty acid incorporation
into adipose tissue by increasing triglyceride synthesis and storage and inhibiting hormone-
sensitive lipase mediated triglyceride lypolysis.139-144 Furthermore, ASP increases glucose
uptake through enhanced translocation of glucose transporters to the plasma membrane
surface. Effects of ASP are both additive and independent of those of insulin.141-143 By
controlling the storage of triglycerides, ASP is an important factor in keeping lipid levels
within normal range.
In healthy subjects, an increase in ASP levels results in lower triglyceride levels and
accumulation of fat tissue. However, in obesity, insulin resistance, dyslipidemia, and
cardiovascular disease, both ASP and triglyceride levels are increased, suggestive of ASP
resistance.145-149 In vitro, this is demonstrated by reduced specifi c binding and response to
ASP of cells from subjects with high ASP levels.150, 151 Thus, ASP is an important marker 
for abnormal lipid metabolism and accumulation of fat tissue, whereas high ASP levels are
associated with an increased risk of cardiovascular disease.138, 147, 149
As earlier discussed, the cause of the high fat% in patients with PWS is multifactorial,
suggested by the fact that GH treatment does not completely normalize fat%.74, 87, 91, 132, 133
Given its critical role in triglyceride storage in adipose tissue, ASP may contribute to the
high fat% and may play a role in the lack of complete normalization of body composition
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during GH. As ASP increases glucose uptake, it might also be involved in keeping glucose
and insulin levels within normal range, despite the high fat% in children with PWS. However,
there were no reports on ASP levels in children with PWS.
C3
C3b
C3bB  
Factor B  
C3bBb  
Adipsin  
C3  C3a  ASP  
C3b 
CpB  
C3bBa  
Figure 9. Synthesis of ASP. C3bBb is the active convertase that cleaves C3 to C3a, of which 
the N-terminal arginine is cleaved of to produce ASP (C3adesArg). C3bBb is generated by
spontaneous conversion of C3 to activated C3b. C3b combines with factor B (C3bB), which is
cleaved by the enzyme adipsin to form C3bB. Enzymes are depicted in boxes.
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1.9 Aims of the studies and outline of the thesis
This thesis gives a detailed account of the various studies performed to improve the
knowledge of PWS and care for patients with PWS. Studies are not necessarily described
in the sequence in which these were carried out. The aims of the studies described in
this thesis were to evaluate general aspects of children with Prader-Willi syndrome and
to investigate the effi cacy and safety of GH treatment. The study populations consisted
of either a the total group of children initially recruited for the Dutch national randomized
controlled GH trial or a subset thereof. The design of the Dutch national GH trial and the
4-year multicenter follow-up study (the Dutch Cohort Study) are described in Appendix A. In
Appendix B, the metyrapone test is described.
Chapter 2 describes the study assessing the integrity of the HPA-axis (cross-sectional
study).
Chapter 3 reports the results of the study investigating the relationship between central
adrenal insuffi ciency and sleep-related breathing disorders (cross-sectional study).
Chapter 4 presents the outcomes of the study investigating the prevalence of scoliosis and
effects of age, gender, body mass index, lean body mass and genotype (cross-sectional
study).
Chapter 5 reports the effects of GH treatment on onset and progression of scoliosis
(multicenter randomized controlled trial).
Chapter 6 describes the effects of one or two years GH treatment on anthropometry and
body composition (randomized controlled trial).
Chapter 7 presents the outcomes of the study assessing bone mineral density and the
effects of GH treatment on bone mineral density (cross-sectional study and randomized
controlled trial).
Chapter 8 describes the cardiovascular and metabolic risk factors and ASP levels
and reports the effects of GH treatment on these outcomes (cross-sectional study and
randomized controlled trial).
Chapter 9 describes the long-term effects of 4 years GH treatment on body composition,
growth, bone maturation, and safety parameters (Dutch Cohort Study).
In Chapter 10, results and conclusions are discussed in light of the present literature.
Chapter 11 and 12 summarize the studies and the results described in this thesis in English
and Dutch, respectively.
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Appendix A: Metyrapone test
Rationale of the metyrapone test
The metyrapone test is used to evaluate whether the ACTH secretion by the pituitary gland
will increase suffi ciently in response to reduced cortisol secretion from the adrenal glands,
thereby mimicking a situation of stress, which causes a sudden demand for stimulation of 
the hypothalamus-pituitary-adrenal (HPA-) axis. Thus, the metyrapone test assesses the
quality of the hypothalamic CRH and pituitary ACTH response in case of stress. When the
response to metyrapone is inadequate, demonstrated by an insuffi cient increase in ACTH
levels, central adrenal insuffi ciency is diagnosed.
Adrenal gland  
 
 
11-deoxycortisol    cortisol 
Hypothalamus 
Pituitary 
ACTH
CRH Brain 
Body 
+
+  
+
CORTISOL 
11-β-hydroxylase
metyrapone  
Figure 1. Simplifi ed schematic overview of the HPA-axis activation in response to metyrapone.
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Figure 1 displays a simplifi ed schematic overview of the HPA-axis. There are many steps
involved in the conversion of cholesterol to cortisol, the last step being the conversion
of 11-deoxycortisol to cortisol involving the enzyme 11-β-hydroxylase. Metyrapone blocks
11-β-hydroxylase, thereby causing a decrease of serum cortisol levels. Due to the feedback
mechanism, the hypothalamus and pituitary gland should subsequently secrete CRH and
ACTH, respectively. In patients with central adrenal insuffi ciency, the increase in ACTH
levels is insuffi cient. In those with primary adrenal insuffi ciency, the 11-deoxycortisol levels
upstream of the enzyme blockade in the adrenal glands fail to accumulate, coinciding with
suffi ciently elevated ACTH levels.
Standard operating procedure of the metyrapone test
Metyrapone is administered orally at 2330 h in a dosage of 30 mg/kg with a maximum of 3
g. At 0400 h, 0600 h, and 0730 h blood is sampled for the measurement of ACTH, cortisol,
and 11-deoxycortisol levels. For patient safety, serum glucose levels are measured and
heart rate and oxygen saturation are monitored continuously, whereas blood pressure is
measured every thirty minutes. Should a rise in heart rate (30% or more) or a decrease in
blood pressure (10% or more) occur, blood pressure is measured every 15 minutes until
normalization. After the last fasting blood samples are taken at 0730 h, a single-dose of 
hydrocortisone (25 mg) is administered. Central adrenal insuffi ciency is diagnosed when
ACTH levels are below 33 pmol/l at 0730 h. Primary adrenal insuffi ciency is diagnosed
when ACTH increases suffi ciently, but 11-deoxycortisol levels fail to rise above 200 nmol/l
(chromatography and radioimmunoassay) or 260 nmol/l (radioimmunoassay alone).
Measurements of hormone levels performed throughout the night can be used to interpret
whether the cortisol blockade was suffi cient.
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Appendix B: Study designs
Project coordination
Both the Dutch multicenter randomized controlled GH trial and the multicenter follow-up
study (the Dutch Cohort Study) are coordinated by the Dutch Growth Research Foundation,
Rotterdam, The Netherlands. The PWS research team consists of one or two physicians/
researchers, a research nurse, and a psychologist. Three-monthly, 18 hospitals throughout
The Netherlands are visited by the researcher and research nurse, where children are
examined, in collaboration with the local pediatrician or pediatric endocrinologist (Figure
1). Standardized measurements take place at the Erasmus University Medical Center / 
Sophia Children’s Hospital, Rotterdam, The Netherlands at start, at 6 and 12 months, and
subsequently each year.
Figure 1. Participating centers.
R.F.A. de Lind van Wijngaarden, E.P.C. Siemensma, D.A.M. Festen, P.M.C.C. van Eekelen,
G.C.B. Bindels – de Heus, S.L.S. Drop, A.C.S. Hokken-Koelega, Erasmus University Medical
Center Rotterdam / Sophia Children’s Hospital, Rotterdam (in black); B.J. Otten, Radboud
University Nijmegen Medical Center; E.G.A.H. van Mil, P.E. Jira, Hieronymus Bosch Medical
Center, ‘s-Hertogenbosch; J. Rotteveel, VU University Medical Center, Amsterdam; R.J.H.
Odink, St. Catharina Hospital, Eindhoven; M. van Leeuwen, St. Jansdal Hospital, Harderwijk;
D.A.J.P. Haring, Diaconessenhuis, Leiden; G. Bocca, University Medical Center Groningen / 
Beatrix Children’s Hospital, Groningen; E.C.A.M. Houdijk, Haga Hospitals / Juliana Children’s
Hospital, The Hague; J.J.G. Hoorweg-Nijman, H. van Wieringen, St. Antonius Hospital, Utrecht;
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R.C.F.M. Vreuls, Medical Center Twente, Enschede; A.S.P. van Trotsenburg, Amsterdam
Medical Center, Amsterdam; E.J. Schroor, Isala Hospitals, Zwolle; J.W. Pilon, Ijsselmeer 
Hospitals, Lelystad; B.Bakker, T.C.J. Sas, D. Mul, J.M. Wit, Leiden University Medical Center,
Leiden; C. Westerlaken, Canisius-Wilhelmina Hospital, Nijmegen; E. van Pinxteren-Nagler,
Medical Center Leeuwarden, Leeuwarden; T.A. de Heer-Groen, Gelre Hospitals, Apeldoorn,
The Netherlands.
Patients
About 120 patients have currently (1-4-2009) been included in the randomized controlled
GH trial (Figure 2). All children continued GH treatment in a multicenter follow-up study (the
Dutch Cohort Study). For both studies, the following criteria were met:
Inclusion criteria:
Genetically confi rmed diagnosis of PWS;−
Age between 6 months and 16 years;−
Maximal bone age of less than 14 years in girls, or 16 years in boys.−
Exclusion criteria:
Non-cooperative behavior;−
Extremely low dietary intake of less than minimal required intake according to−
guidelines set by the World Heatlh Organization;
Medication to reduce weight (fat);−
In children above 3 years of age: height above 0 SDS, unless weight-for-height is−
above 2 SDS;
Previous treatment with GH (not applicable for the Dutch Cohort Study).−
Design
Infants
The infant group currently consists of 61 children aged between 6 months and 3 years
at start of study. Stratifi ed for age, they were randomized into either a GH-treated group
or a control group for the duration of one year (Figure 2). The GH-treated group received
somatropin 1 mg/m2·day, whereas the control group was not treated with GH. From 12 
months of study onwards, all children were treated with somatropin 1 mg/m2·day and were
prospectively followed in the Dutch Cohort Study in collaboration with pediatricians or 
pediatric endocrinologists throughout The Netherlands.
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Prepubertal group
The prepubertal group consists of 50 children; girls are aged between 3 and 12 years with
Tanner breast stage < 2 and boys between 3 and 14 years with Tanner genital stage < 2
and a testicular volume < 4 ml. Stratifi ed for BMI, children were randomized into either a
GH-treated group or a control group for the duration of two years (Figure 2). The GH-treated
group received somatropin 1 mg/m2·day, whereas the control group was not treated with
GH. Dietary advice and exercise training were offered to both groups and started three
months prior to study in order to minimize a priori between group differences. From 24
months of study onwards, all children were treated with somatropin 1 mg/m2·day and were
prospectively followed in the Dutch Cohort Study in collaboration with pediatricians pediatric
endocrinologists throughout The Netherlands.
Pubertal group
The pubertal group consists of 9 children; girls > 12 years and boys > 14 years, both
with spontaneous or induced puberty. All pubertal children were treated with GH, but were
randomized to receive either 1 mg/m2·day or 1.5 mg/m2·day until adult height (Figure 2).
Dietary advice and exercise training were offered to both groups and started three months
prior to study in order to minimize a priori between group differences.
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Pubertal children 
1 mg/m2day
Prepubertal children 
Dutch Cohort Study
Control 
1 mg/m2day
Control Control 
1 mg/m2day
1 mg/m2day
From 12 or 24 months -3 months 
Diet + exercise 
Start to 12 or 24 months 
Randomized controlled study
Infants 
1 mg/m2day 1 mg/m2day
1 mg/m2day
1 mg/m2day 1 mg/m2day 1 mg/m2day
1.5 mg/m2day 1.5 mg/m2day 1.5 mg/m2day
Figure 2. Design of the multicenter randomized controlled trial and the Dutch Cohort Study.
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Abstract
Context: The annual death rate of PWS patients is very high (3%). Many of these deaths
are sudden and unexplained.
Objective: Because most deaths occur during moderate infections and PWS patients suffer 
from various hypothalamic insuffi ciencies, we investigated whether PWS patients suffer 
from central adrenal insuffi ciency (CAI) during stressful conditions.
Design: Overnight single-dose metyrapone tests were performed. Metyrapone (30 mg/kg)
was administered at 2330 h. At 0400, 0600, and 0730 h, ACTH, 11-deoxycortisol, cortisol
and glucose levels were measured. Diurnal salivary cortisol profi les were assessed on a
different day at wake-up, 30 minutes after wake-up, at 1400 h and at 2000 h.
Setting: The study was conducted in a pediatric intensive care unit.
Patients: Patients included 25 randomly selected PWS patients.
Main outcome measure: Patients were considered as having CAI when ACTH levels
remained below 33 pmol/l at 0730 h.
Results: Median (interquartile range) age was 9.7 (6.8-13.6) years. Fifteen patients (60%)
had an insuffi cient ACTH response (CAI, p<0.001). There was no signifi cant difference in
age, gender, genotype and BMISDS between patients with CAI and those without. Morning
salivary cortisol levels and diurnal profi les were normal in all children, suggesting that CAI
becomes apparent only during stressful conditions.
Conclusions: Strikingly, 60% of our PWS patients had central adrenal insuffi ciency. The
high percentage of CAI in PWS patients might explain the high rate of sudden death in
these patients, particularly during infection-related stress. Based on our data, one should
consider treatment with hydrocortisone during acute illness in PWS patients, unless CAI
has recently been ruled out with a metyrapone test.
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Introduction
Prader-Willi syndrome (PWS) is characterized by hypotonia, short stature, hyperphagia,
obesity, hypogonadism, psychomotor delay, and sleep-related breathing disorders.1-4 PWS
results from the lack of paternal expression of the q11-q13 region of chromosome 15 caused
by deletion, uniparental disomy, imprinting center defect, or balanced translocation.1, 5
The annual death rate in PWS patients is very high (3%).6 Among the causes of death in older 
children and adults are cor pulmonale,7, 8 fatal apneas,9 unexpected bathtub drownings,10
and gastric necrosis.11 In some patients, low adrenal weight was reported.12, 13 Deaths 
in younger children are mostly related to only mild or moderate upper respiratory tract
infections (URTIs).9, 10 Many of the sudden deaths in PWS children are still unexplained.
PWS patients have hypothalamic dysregulations and show no or few signs of illness. Often,
they do not get fever, cannot vomit, and have a higher pain threshold. Also during URTIs,
PWS patients can appear less ill than they actually are. 
As hypothalamic dysfunction is responsible for many other endocrine defi ciencies in PWS
patients,14, 15 we hypothesized that PWS patients suffer from central adrenal insuffi ciency
(CAI) during stressful conditions.
We used the overnight single-dose metyrapone test, as this is the best dynamic test for 
the diagnosis of CAI.16-19 Metyrapone blocks the synthesis of cortisol by inhibiting 11-beta-
hydroxylase type 1, which converts 11-deoxycortisol (compound-S) to cortisol. The decline
in plasma cortisol stimulates ACTH production. The cut-off level for an appropriate ACTH
response is 33 pmol/l at 0730 h.19 Those failing to achieve such an ACTH response are
considered as having CAI.16, 17, 19-21
To investigate the basal cortisol secretion and in the search for other parameters for the
identifi cation of patients at risk of CAI, diurnal salivary cortisol profi les were studied.
Methods
Patients
Twenty-fi ve children with genetically confi rmed PWS were randomly selected from our 
outpatient clinics. Patients underwent a metyrapone test during overnight stay at the
Pediatric Intensive Care Unit of the Erasmus University Medical Center / Sophia Children’s
Hospital (Rotterdam, The Netherlands). Twelve patients had paternal deletion (63%), six
had maternal disomy (32%), and one an imprinting center mutation (5%). All were treated
with growth hormone, Genotropin 1.0 mg/m2·day (Pfi zer Inc., New York, NY), with a
median (interquartile range) duration of 33 months (20-43). The protocol was approved
by the Medical Ethics Committee of the Erasmus University Medical Center (International
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Standard Randomized Controlled Trial Number 49726762). Informed consent was obtained
from parents and children above 12 years of age.
Overnight single-dose metyrapone test
Metyrapone (30 mg/kg, Metopiron, Novartis Pharma BV, Arnhem, The Netherlands) was
administered at 2330 h. The maximal cortisol suppression has been reported to occur 
at 0400 h.18, 22 The decline in plasma cortisol stimulates ACTH production, which causes
11-deoxycortisol, before the enzyme blockade, to accumulate. Maximal levels of ACTH and
11-deoxycortisol are found at 0730 h.16-19
In 25 children, fasting blood samples were taken for the analysis of ACTH, 11-deoxycortisol,
cortisol, and glucose at 0730 h,16, 17, 19 and in 16 children also at 2330, 0400, and 0600 h.
During the metyrapone test, heart rate and oxygen saturation were measured continuously
and blood pressure was measured every thirty minutes. If a rise in heart rate (30% or more)
or a decrease in blood pressure (10% or more) occurred, blood pressure was measured
every 15 minutes until normalization. After the last fasting blood samples were taken at
0730 h, a single-dose of hydrocortisone (25 mg) was administered.
Diurnal cortisol profi le
Diurnal salivary cortisol profi les were assessed in 16 of the 25 PWS patients, on a different
day and during health, using Salivettes (Sarstedt, Nümbrecht, Germany), at spontaneous
wake-up (0600-0900 h), 30 min. after wake-up, at 1400 h, and at 2000 h. Maximal morning
salivary cortisol levels were defi ned as the highest cortisol level in the morning (wake-up
or 30 min. thereafter), and compared with those established in 237 healthy schoolchildren
(same laboratory with same assay). 
Assays
To rule out cross-reactivity of steroids,16, 23, 24 cortisol was measured by radioimmunoassay
(RIA) after extraction with dichloromethane and subsequent paper chromatography,
according to the method described earlier for cortisol measurement in plasma and saliva.24
The minimal detection level was 10 nmol/l for serum cortisol, 0.30 nmol/l for salivary cortisol,
and 0.17 nmol/l for serum 11-deoxycortisol. Plasma ACTH levels were measured with an
immunoradiometric assay (BioInternational, Gif sur Yvette, France) with a minimal detection
level of 1.1 pmol/l. Glucose levels were measured with the Hitachi 917 (Hitachi Device
Development Center, Tokyo, Japan), detecting glucose levels between 0 and 42 mmol/l.
Data analysis
Statistical analysis was performed with the Statistical Package for Social Sciences (SPSS
15.0, Chicago, Illinois, USA). Data are expressed as medians and interquartile ranges
47
C
ha
pt
er
 2
(iqr). Standard deviation scores (SDS) for height, weight, and BMI were calculated based
on Dutch reference data by Growth Analyser 3.0 (available at www.growthanalyser.org).25
Blood pressure SDS was calculated according to reference values reported by Rosner et
al.26 Spearman’s rho was calculated for the analysis of correlations.
Results
Median age of the PWS patients was 9.7 years (range: 3.7-18.6 years). Median (iqr) BMI
SDS was 0.8 (0.2-1.3); weight-for-height SDS 1.1 (0.3-1.6); and height SDS -0.9 (-1.8 to
0.5).
At start of the metyrapone test (2330 h), hormone levels were not signifi cantly different
between patients later diagnosed with central adrenal insuffi ciency (CAI) and those who
were not. In all children, metyrapone maximally suppressed cortisol concentrations at 0400
h (p=0.005 compared to baseline, Table 1). After 0400 h, cortisol levels increased as the
effect of metyrapone declined. ACTH and 11-deoxycortisol levels increased during the
entire test, with a maximum increase between 0400 and 0600 h (Table 1, Figure 1).
Adrenal insuffi ciency
Fifteen patients (60%, p<0.001) showed an insuffi cient ACTH response at the end of the
metyrapone test (0730 h, Table 1 and Figure 1). As metyrapone blocks cortisol synthesis,
it causes a sudden increased demand for ACTH production, a situation mimicking stress.
Patients with an insuffi cient ACTH response during the metyrapone test are, therefore,
considered as having CAI during stressful conditions. Directly from start of the enzyme
blockade, patients with CAI had a signifi cantly lower increase in ACTH levels than those
without CAI (Figure 1).
ACTH levels correlated signifi cantly with 11-deoxycortisol levels (r=0.5, p=0.03). Children
with CAI had lower 11-deoxycortisol levels than those without, but this did not reach statistical
signifi cance (p=0.08 at 0730 h, Table 1). All children without CAI had 11-deoxycortisol levels
above the classical cut-off level of 200 nmol/l at 0730 h. Seven of 11 children with CAI had
11-deoxycortisol levels below 200 nmol/l, suggesting adrenal atrophy.
At 0730 h, cortisol levels were still low in all children. Children with CAI had higher levels of 
cortisol at 0730 h than children without CAI (p=0.08), as was previously reported.19 Levels 
did not differ at 2330, 0400, and 0600 h (p=0.2, p=0.4, and p=0.2, respectively).
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Cortisol suppression did, therefore, not differ between children with CAI and those without.
There was no signifi cant difference in age, gender, BMI SDS, weight-for-height SDS, height
SDS, and genotype between patients with CAI and those without (data not shown).
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Figure 1. ACTH-response in PWS patients during a metyrapone test. Median (iqr) ACTH
levels during the metyrapone test in children with central adrenal insuffi ciency (CAI) and those
without (non-CAI). The cut-off level for a normal ACTH level is 33 pmol/l at 0730 h. In 16
children, ACTH levels were measured at 2330 h, 0400 h and 0600 h. *: p=0.048, †: p=0.01, ‡:
p<0.001, all CAI vs. normal. To convert ACTH in pmol/l to pg/ml, divide by 0.22.
Diurnal cortisol profi le 
Figure 2 shows that all PWS patients had normal morning cortisol levels and a normal
diurnal rhythm, with high levels in the morning decreasing during the day. This indicates that
CAI only occurs during stressful conditions. Patients with an insuffi cient ACTH response
during the metyrapone test had lower salivary cortisol levels at wake-up (2.7 (1.8-5.1)
vs. 6.8 (3.5-12.3) nmol/l, p=0.05). Cortisol levels at wake-up correlated with ACTH levels
at 0730 h during the metyrapone test, although this did not reach statistical signifi cance
(rho=0.5 with p=0.1). Salivary cortisol levels were not useful for identifying PWS patients
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at risk of CAI, due to low sensitivity. The highest accuracy was obtained at a cut-off of 2.8
nmol/l, with 99.2% specifi city, but only 55.6% sensitivity. Levels at wake-up of 12 nmol/l or 
above seemed indicative for absence of CAI (100% sensitivity), but such high levels were
only found in one patient.
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Figure 2. Diurnal salivary cortisol levels in PWS patients. Box-whisker plot of salivary cortisol
levels at wake-up, 30 minutes after wake-up (+30 min), 1400 h and 2000 h in PWS children
with central adrenal insuffi ciency (CAI) and without (Non-CAI), expressed as median (iqr).
Differences at wake-up did not reach statistical signifi cance (p=0.053). Median (iqr) reference
values for maximal morning cortisol levels (either at wake-up or 30 minutes thereafter): 5.7
(1.9-16.2) nmol/l. To convert cortisol in nmol/l to μg/dl, divide by 27.59.
Side effects
None of the patients reported side effects during the metyrapone test, such as nausea
and headache. Diastolic and systolic blood pressure SDS decreased signifi cantly between
0030 and 0730 h (Figure 3, p-values: 0.002-0.03 and 0.004-0.05, respectively). The overall
median systolic blood pressure SDS was lower in patients with CAI than in those without
(-0.5 (-1.6 to 0.5) vs. 0.2 (-0.5 to 1.3), p=0.07). The overall diastolic blood pressure SDS
correlated with cortisol (diastolic: rho=0.5, p=0.004; systolic: rho=0.3, p=0.07). Blood
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pressure SDS did not signifi cantly correlate with ACTH or 11-deoxycortisol.
All other vital parameters remained within the normal range: pulse ≥ 49/min, breathing
≥ 13/min, saturation ≥ 94%. Naturally, while fasting, glucose levels decreased signifi cantly
during the night, but were never below 3.9 mmol/l in any patient.
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Figure 3. Blood pressure SDS during the metyrapone test. Median diastolic and systolic blood 
pressure SDS decreased during the metyrapone test. Blood pressures at 2330 h, 0400 h, and
0600 h were excluded, because patients were awake.
Discussion
Strikingly, 60% of PWS patients had central adrenal insuffi ciency, with ACTH levels failing
to increase suffi ciently during a metyrapone test. As metyrapone blocks cortisol synthesis,
it causes a sudden increased demand for ACTH production, a situation mimicking stress.
Patients with an insuffi cient ACTH response during the metyrapone test are, therefore,
considered as having CAI during stressful conditions. The insuffi cient ACTH response was
apparent directly from start of the metyrapone test. The diagnosis of CAI is in line with the
presence of other hypothalamic insuffi ciencies and oral reports about hypoglycemias during
surgery in PWS patients.
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We are the fi rst to report an inappropriate ACTH response during a metyrapone test in a
large percentage of PWS children. In view of the importance of an adequate function of 
the hypothalamus-pituitary-adrenal (HPA) axis for survival, the high prevalence of CAI may
be an explanation for the high death rate in PWS patients (3%).6 In addition to CAI, the
condition of acutely ill PWS patients is further compromised by an increase in the number 
of sleep apneas during upper respiratory tract infections (URTIs)2 and a vague clinical
presentation, because PWS patients often have an increased pain threshold and do not
vomit or develop fever.
During a metyrapone test, only the ACTH response is measured. During illness, other 
factors than ACTH will infl uence the HPA-axis, such as cytokines and vasopressin.23, 27
Nevertheless, an adequate increase of ACTH is a prerequisite for an appropriate response
to stress. 
Naturally, the metyrapone test was only performed in healthy PWS children and no signs
of shock were present during the test. Despite the absence of acute illness, blood pressure
was low in the early morning hours in all patients, as previously reported,20 and correlated
signifi cantly with serum cortisol levels. The early morning hours might be the critical period
during which PWS patients with CAI are at risk of dying. This hypothesis is in line with the
fact that most PWS patients with mild infections (mostly URTIs) decease during the early
morning hours.9
Interestingly, Stevenson et al.12 reported autopsies in 4 children in whom the condition
rapidly worsened after mild or moderate infections. Adrenal weight was low in one and
severely low in the other three patients. Other reports also show low adrenal weight in
deceased patients.13 Adrenal size is related to the cause and duration of the various disease
states leading to adrenal insuffi ciency.28
In 11 of 15 children with CAI (ACTH < 33 pmol/l), enough blood was available for measurement
of 11-deoxycortisol levels. Of these 11 children with CAI, 7 had 11-deoxycortisol levels
below the classical cut-off level of 200 nmol/l,16, 17, 19, 21 suggesting that these children have
CAI with adrenal atrophy. Four children had CAI with 11-deoxycortisol levels above 200
nmol/l, suggesting that these patients have partial or no adrenal atrophy. This is in line with
reports showing that some but not all patients who died after mild or moderate infections
had low adrenal weight during autopsy.12, 13
All patients received growth hormone (GH) treatment. We do not believe that this infl uenced
the outcome of our study. Data on relationships between the GH-IGF-I system and the
HPA-axis are contradictory.29, 30 The prevalence of CAI is not increased in GH-treated
children with isolated GH defi ciency, Turner syndrome, or other disorders.29 l’Allemand et
al.31 reported a decrease in random morning cortisol levels at 12 and 42 months of GH
treatment. However, as stated by the authors, their study was not designed to examine the
effects of GH treatment on the HPA-axis and the statistical power for such an analysis was
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too low. Importantly, all cortisol levels remained within the normal range, as was also shown
by our normal diurnal salivary cortisol profi les during health. l’Allemand et al.31 found no
correlation between IGF-I and cortisol levels. Interestingly, there was a tendency towards a
negative correlation of cortisol levels with fat mass (r=0.48, p=0.082). Since GH treatment is
known to reduce fat mass in PWS patients,15, 32 GH could indirectly increase cortisol levels.
Possibly, in patients with PWS, any direct negative effect of GH and/or IGF-I on cortisol
levels may be outweighed by the positive effect of the reduction of fat mass on cortisol
levels. This may explain why a correlation between GH/IGF-I and cortisol was not found.
Moreover, the similar death rate in PWS patient with and without GH treatment,9 suggests
an intrinsic rather than an extrinsic cause of CAI.
Morning salivary cortisol levels were normal in all PWS children, as has been previously
reported,31 indicating that CAI occurs only during stressful conditions.17 Therefore, diurnal
salivary cortisol profi les are not useful in identifying children at risk. In our study, salivary
cortisol levels at wake-up (≥ 12 nmol/l) provided a sensitivity of 100%, but only one patient
met this criterion.
Based on our data, 60% of PWS patients worldwide may be at risk of CAI. There are two
possibilities for the therapeutical approach to this problem. The fi rst option is that all PWS
patients undergo a metyrapone test and should, in case of an impaired ACTH response,
receive hydrocortisone treatment during stressful conditions. However, PWS patients
suffer from (hypothalamic) hormonal insuffi ciencies of varying severity, not only between
patients,33 but also within patients.34 In non-PWS patients, CAI may become more severe
over time.19 Due to these inconsistencies, even an appropriate ACTH response during a
single metyrapone test will not rule out future development of CAI. More research needs to
be performed on this matter.
The second option is to treat all PWS patients with hydrocortisone during stress. In our study,
40% of PWS patients would have been treated unnecessarily. However, the prevalence
of CAI, a life threatening illness, is very high in PWS patients (60%). During moderate
stress, patients should take hydrocortisone capsules, in total 30-50 mg/m2·d in two to four 
times. During severe stress, parents should always contact a pediatrician or pediatric-
endocrinologist and a higher dose of hydrocortisone should be administered (in total 75
mg/m2·d in two to four times). For young children, suppositories are available. If the route
of administration is compromised and/or during severe stress, the physician may decide to
administer hydrocortisone intramuscularly or intravenously (50-100 mg/m2). PWS patients
show few signs of illness. Often, they cannot vomit and do not develop fever. The severity
of stress can, therefore, not be read from these classical symptoms. In our experience,
parents of children with PWS often know how the to classify the severity of stress of their 
child (mild, moderate, or severe). In order to guard the safety of PWS patients, a good
collaboration between parents and physicians is crucial.
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To our opinion, PWS patients should be considered to have CAI during stress, until proven
otherwise with a metyrapone test.
Conclusion
Strikingly, 60% of our PWS patients have central adrenal insuffi ciency. We expect that
the combination of an insuffi cient ACTH response during stress with an increased number 
of sleep apneas during illness, in the presence of reduced clinical symptoms, might lead
to an increased risk of sudden death in PWS patients. More research is required, but at
this moment it is important to consider hydrocortisone treatment for PWS patients during
stressful conditions, including mild upper respiratory tract infections.
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Abstract
Background: The annual death rate of patients with Prader-Willi syndrome (PWS) is high 
(3%). Many deaths of children are sudden and unexplained. Sleep apneas have been 
suggested to play a role in sudden deaths. Recently, we discovered that 60% of patients 
with PWS suffer from central adrenal insufficiency (CAI) during stress.
Objective: To study the relationship between CAI and sleep-related breathing disorders 
(SRBDs).
Design: In 20 children with PWS who underwent a metyrapone test (30 mg/kg at 2330 h), 
sleep-related breathing was evaluated by polysomnography prior to the metyrapone test. 
In addition, we recorded sleep-related breathing in 10 children with PWS during their 
metyrapone test. CAI was diagnosed when ACTH levels during the metyrapone test were 
below 33 pmol/l at 0730 h. All tests were performed during healthy condition.
Setting: Pediatric Intensive Care Unit and specialized sleep center.
Results: Median (inter-quartile range, iqr) age was 8.4 years (6.5-10.2). After metyrapone 
administration, median (iqr) central apnea index (number/hour) increased significantly, from 
2.2 (0.4-4.7) to 5.2 (1.5-7.9) (p=0.007). The increase tended to be higher in children with CAI 
[2.8 (2.0-3.9) vs. 1.0 (-0.2 to 2.6), p=0.09]. During polysomnography prior to the metyrapone 
test, sleep-related breathing was worse in children with CAI, who had a significantly higher 
central apnea index and tended to have a lower minimum oxygen saturation compared to 
those without CAI (p=0.03 and p=0.07).
Conclusions: In children with PWS, the central apnea index increased significantly after 
metyrapone administration, particularly in those with CAI during stress. In addition, children 
with CAI had a higher central apnea index compared to those without, several months prior 
to the metyrapone test.
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Introduction
Prader-Willi syndrome (PWS) is characterized by hypotonia, short stature, hyperphagia,
hypogonadism, psychomotor delay, and temper tantrums.1-5 PWS results from the lack of 
expression of the paternally derived chromosome 15q11-q13 caused by deletion, maternal
uniparental disomy, imprinting center defect, or balanced translocation.3,6 The annual death 
rate in patients with PWS is high [3%7]. Deaths in children are often related to only mild or 
moderate upper respiratory tract infections and many deaths remain unexplained.8-11
Patients with PWS often have sleep-related breathing disorders (SRBDs), consisting of 
obstructive and central sleep apneas. Sleep apneas are the result of a reduction in upper 
airway diameter, hypoventilation, decreased pulmonary function, and a decreased ventilatory
and arousal response during hypercapnia.11-17 The most common cause of sudden death 
in children with PWS is respiratory or cardiorespiratory failure, often in association with a
pulmonary or systemic infection and exacerbated by apneas.3,10-13 During upper respiratory 
tract infections, children with PWS show a marked increase in the number of obstructive 
and central apneas.12,13 The increase in central apneas may indicate a change in central
control of sleep-related breathing during illness.
We recently discovered a high prevalence (60%) of central adrenal insuffi ciency (CAI) during 
a metyrapone test in children with PWS, shown by an inappropriate adrenocorticotrophic 
hormone (ACTH) response.18 Our fi ndings are put in clinical perspective by the low adrenal
weight observed during autopsies in patients with PWS.9,19 The diurnal salivary cortisol 
rhythms, measured on a different day during healthy condition, were normal in all children 
in our study.18 Therefore, children with PWS are considered to be at risk of CAI only during 
stressful conditions, whereas CAI is not present during healthy conditions. The combination 
of an inappropriate ACTH response and mild or moderate infection may lead to sudden 
unexpected death.
In this study, we investigated the relationship between CAI and SRBD. A metyrapone 
test mimics a period of stress by causing a sudden increased demand for stimulation of 
the hypothalamus-pituitary-adrenal axis. We recorded sleep-related breathing during a 
metyrapone test. Our aims were to study the change in sleep-related breathing during 
the metyrapone test and to compare the change between children with and without CAI. 
Additionally, we evaluated whether sleep-related breathing during healthy condition some 
time before the metyrapone test was different in children with and without CAI and whether 
the severity of SRBD could be indicative for CAI.
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Methods
Patients
In 20 children with PWS, sleep-related breathing was evaluated by complete overnight
polysomnography prior to a metyrapone test. In 10 of these 20 children, sleep-related
breathing was also recorded during a metyrapone test. All children were in healthy
condition during the polysomnography and the metyrapone test. Prader-Willi syndrome was
genetically confi rmed in all children: 13 had a deletion, 6 a uniparental disomy and 1 an
imprinting center defect. All children were treated with growth hormone, Genotropin 1 mg/
m2·day (Pfi zer Inc., New York). All were naïve to glucocorticoid therapy.
Design
Of 20 children with PWS who underwent a metyrapone test,18 sleep-related breathing was
evaluated by complete overnight polysomnography in a specialized sleep center at 20.7
months (12.8-28.4) before the metyrapone test. The metyrapone test was performed in the
Pediatric Intensive Care Unit (PICU) of the Erasmus University Medical Center Rotterdam
/ Sophia Children’s Hospital, Rotterdam, The Netherlands. During the metyrapone test in
the PICU, sleep-related breathing was recorded simultaneously in 10 of 20 children, i.e.
in those for whom the sleep-recording device was available in the PICU. All tests were
performed during healthy condition.
The protocol was approved by the Medical Ethics Committee of the Erasmus University
Medical Center Rotterdam (ISRCTN 49726762). Written informed consent was obtained
from parents and from children above 12 years of age. Assent was obtained from children
under 12 years of age.
Metyrapone test
Metyrapone (30 mg/kg, Metopiron, Novartis Pharma BV, Arnhem, The Netherlands) was
administered orally at 2330 h. Metyrapone blocks cortisol synthesis by inhibiting 11-beta-
hydroxylase type 1, which converts 11-deoxycortisol (compound-S) to cortisol. The
decline in plasma cortisol stimulates ACTH production, which causes an accumulation of 
11-deoxycortisol prior to the enzyme blockade. The maximal cortisol suppression occurs at
0400 h.18,20,21 Maximal levels of ACTH and 11-deoxycortisol are found at 0730 h.20,22-27 The
cut-off level for an appropriate ACTH response is 33 pmol/l at 0730 h.23,24,26 Subjects failing
to achieve such an ACTH response are considered as having CAI.18,22-27 Fasting blood
samples were taken for the analysis of ACTH, 11-deoxycortisol, and cortisol at 2330 h, 0400
h, 0600 h, and 0730 h. During the metyrapone test, heart rate and oxygen saturation were
measured continuously and blood pressure was measured every thirty minutes. If a rise
in heart rate (30% or more) or a decline in blood pressure (10% or more) occurred, blood
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pressure was measured every 15 minutes until normalization.18 After the last fasting blood 
samples were taken at 0730 h, a single-dose of hydrocortisone (25 mg) was administered.
At time of the metyrapone test, children had been treated with growth hormone for a median
(interquartile range, iqr) duration of 32.8 months (19.7-43.2).
Assays
To rule out cross-reactivity of steroids22,28,29, cortisol and 11-deoxycortisol were measured
by radioimmunoassay (RIA) after extraction with dichloromethane and subsequent paper 
chromatography, as previously described.18, 9 The minimal detection level was 10 nmol/l
for serum cortisol and 0.17 nmol/l for serum 11-deoxycortisol. Plasma ACTH levels were
measured with an immunoradiometric assay (BioInternational, Gif sur Yvette, France) with
a minimal detection level of 1.1 pmol/l.
Serum IGF-I levels were measured using an immunometric technique on an Advantage
Automatic Chemiluminescence System (Nichols Institute Diagnostics, San Juan Capistrano,
California). The intra-assay CV was 4% and the inter-assay CV was 6%. Because of age
and sex dependency, IGF-I levels were transformed into SDS.30
Complete overnight polysomnography in a specialized sleep center
Complete overnight polysomnographic evaluation of sleep-related breathing was performed
in 20 children in one specialized sleep center (A.W.d.W., sleep specialist). Recordings
included an electroencephalogram, an electrooculogram, a one channel derivation of 
electrocardiogram, and a surface electromyography of the submental muscle and both
anterior tibial muscles. Nasal-oral airfl ow was monitored by nasal pressure prongs fi xed
in the nose, respiratory effort by thoracoabdominal strain gauges, and oxygen saturation
(SaO2) by pulse oximetry. The polygraphic records were scored according to criteria set by
Rechtschaffen and Kales and revised by the American Academy of Sleep Medicine.31,32 A
period of apnea or hypopnea was defi ned as a reduction in airfl ow of at least 90% (apnea)
or 50% (hypopnea) for the duration of three breaths or longer. For hypopneas, the additional
criterion was a reduction of SaO2 of 4% or more. An apnea was considered central when 
the airfl ow was decreased in concordance with a temporary cessation in respiratory effort.
Apneas were considered obstructive when absence of airfl ow occurred without a decrease
in respiratory effort. The central apnea index was defi ned as the total number of central
apneas divided by the total time span of sleep in hours (no/hr). The obstructive apnea
and hypopnea indices were calculated in a similar manner. If the value of the combined
apnea indices (apnea-hypopnea-index) was greater than one, sleep-related breathing was
considered pathological.33,34 Abnormal SaO2 was defi ned as a decrease in SaO2 below 92% 
or a reduction of 4% or more below nightly baseline values. We evaluated the following
polysomnographic results: the central apnea, obstructive apnea, and hypopnea indices (no/
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hr); the duration of the longest apnea (sec); the lowest SaO2 measured (%); the percentage
rapid-eye-movement (REM) sleep and slow wave sleep; and the number of awakenings
per hour.
At time of the polysomnography, children had been treated with growth hormone for a
median (iqr) duration of 7.1 months (6.1-10.5).
Metyrapone-related sleep registration at the PICU
Sleep-related breathing was recorded overnight during the metyrapone test in 10 of 20
children in the PICU with the Embla (Embla, Denver, CO, USA). Only one child had onset of 
sleep at 2100 h, whereas all others had onset of sleep before 2000 h. Recordings included a
three channel derivation of an electrocardiogram, nasal airfl ow measured by a nasal canula,
respiratory effort measured by thoracoabdominal strain gauges, and SaO2 measured by
pulse oximetry. All recordings were evaluated with the software Somnologica 3 (Embla,
Denver, CO, USA) by one person (S.v.d.B.). The polygraphic records were scored according
to criteria set by Rechtschaffen and Kales and revised by the American Academy of Sleep
Medicine31,32, as described above. A central apnea index greater than one was considered
pathological.33,34 The oxygen-desaturation index (ODI) was calculated by dividing the total
number of oxygen desaturations by the time span in hours. We evaluated the following
sleep-related breathing parameters: the central apnea index (no/hr), the duration of the
longest apnea (sec), the oxygen-desaturation-index (ODI: no/hr), and the lowest SaO2
measured (%).
Data analysis
Statistical analyses were performed with the Statistical Package for Social Sciences (SPSS
15.0, Chicago, Illinois, USA). As data were not normally distributed according to Levene’s
test, they are expressed as median with an inter-quartile range (iqr). Standard deviation
scores (SDS) for height and BMI were calculated with Growth Analyser 3.0 (available at www.
growthanalyser.org), based on Dutch reference data reported by Fredriks et al.35 Three sets
of analyses were performed. First we compared data of sleep-related breathing during the
metyrapone test between patients with CAI and those without. P-values for differences were
calculated with the Mann-Whitney U test (non-normal distribution). Secondly, we studied
the change in sleep-related breathing after metyrapone administration and whether this was
different between children with CAI and those without. P-values for differences between
the two time periods were calculated with the Wilcoxon Signed Ranks Test (non-normal
distribution). P-values for differences in change were calculated with the Mann-Whitney U
test. Thirdly, we evaluated the differences in previous polysomnographic records between
children with CAI and those without. P-values for these differences were calculated with
the Mann-Whitney U test. Correlation analyses were performed with Spearman’s tests.
P-values ≤0.05 were considered statistically signifi cant.
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Results
Eleven boys and nine girls with PWS were included. The median (iqr) age during
polysomnography and during the metyrapone test was of 6.0 years (4.2-9.2) and 8.4 years
(6.5-10.2), respectively (Table 1). As children were longer treated with GH at time of the
metyrapone test, heightSDS was signifi cantly higher than at time of the polysomnography.
BMISDS and IGF-I SDS at time of the metyrapone test did not signifi cantly differ from levels
at time of the polysomnography.
Table 1. Clinical characteristics during the polysomnography and metyrapone test.
Polysomnography Metyrapone test P-value
Age (years)  6.0 (4.2 to 9.2)  8.4 (6.5 to 10.2) <0.0001
HeightSDS -2.1 (-2.7 to -0.9) -0.8 (-2.0 to 0.2)   0.004
BMISDS  0.7 (0.3 to 1.3)   1.0 (0.3 to 1.5)   0.44
IGF-I SDS  2.2 (1.0 to 2.9)   2.4 (1.8 to 3.5)   0.72
Data are expressed as median (iqr). SDS, SD-score; BMI, body mass index; IGF-I, insulin-like growth
factor I.
Metyrapone test
CAI, defi ned as an ACTH level <33 pmol/l at 0730 h,23,24,26 was present in 13 of 20 children
with PWS (65%). Before the administration of metyrapone at 2330 h, there were no signifi cant
differences in ACTH and cortisol levels between children later diagnosed with CAI and those
not (both p=0.20). The enzyme blockade maximally suppressed cortisol levels at 0400 h,
causing a decrease of median (iqr) cortisol levels from 100.0 nmol/l (40.0-241.5) at 2330 h to
34.0 nmol/l (23.3-55.8) at 0400 h (p=0.005). The decline in serum cortisol levels was similar 
in children later diagnosed with CAI compared to those not, and resulted in increased ACTH
secretion in children with and without CAI, but the ACTH response was signifi cantly lower 
in children with CAI. The difference in ACTH levels between children with CAI and those
without was already signifi cant at 0400 h [9.0 pmol/l (7.3-10.5) vs. 32.2 pmol/l (12.0-55.9),
respectively; p=0.04] and became greater over time [0730 h: 18.9 pmol/l (12.8-26.8) vs. 74.2
pmol/l (56.4-81.5), respectively; p<0.0001]. In both groups, the increase in ACTH caused an
accumulation of 11-deoxycortisol upstream of the enzyme blockade, increasing from 0.41
nmol/l (0.09-2.49) at 2330 h to 229.5 nmol/l (166.8-319.3) at 0730 h (p=0.008). Glucose
levels and heart rate did not signifi cantly change during the metyrapone test. However,
systolic and diastolic blood pressures were signifi cantly lower during early morning hours
than at start. No metyrapone test had to be discontinued. Results of the metyrapone test in
this group of children with PWS have previously been described in detail.18
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Metyrapone-related sleep registration
During the night of the metyrapone test conducted in the PICU, sleep-related breathing was
recorded in 10 children from onset of sleep (before metyrapone administration) until wake-
up. Six children had CAI and four had not. During total sleep time in the PICU, children with
CAI had a central apnea index of 5.7 (3.1-6.8), compared to 1.1 (0.9-5.1) in those without
CAI (p=0.09). Before metyrapone administration, the maximum duration of apneas was
signifi cantly longer in children with CAI than in those without (p=0.03). The central apnea
index, oxygen-desaturation-index, and lowest SaO2 were not signifi cantly different (all
p=0.52). The obstructive apnea index was less than 1 in all children, similar to previously
published results,12 and did not change after metyrapone administration.
Table 2 shows the effects of metyrapone administration on sleep-related breathing. It
compares the results of the recordings of sleep-related breathing between two time
intervals: the time interval from onset of sleep until the administration of metyrapone at 2330
h, and the time interval after metyrapone administration until wake-up when cortisol levels
were suppressed. In the total group, sleep-related breathing worsened after metyrapone
administration, as the median (iqr) central apnea index in the total group signifi cantly
increased from 2.2 (0.4-4.7) before 2330 h to 5.2 (1.5-7.9) after 2330 h (p=0.007). In
children with CAI, the median (iqr) central apnea index signifi cantly increased from 3.6
(0.7-4.7) before metyrapone administration to 6.0 (4.4-7.9) after administration (p=0.03),
compared to an increase from 0.7 (0.4-4.2) before 2330 h to 1.4 (0.7-6.7) after 2330 h in
children without CAI (p=0.14). The difference in increase between children with CAI and
those without did not reach statistical signifi cance in our group of 10 children (Figure 1,
p=0.09).
In the total group, the maximum duration of apneas was 15.2 sec. (11.2-21.0) before 2330
h and 16.8 sec. (15.2-27.6) after 2330 h (p=0.12). The lowest SaO2 was 87.5% (82.8-91.0)
before 2330 h and 85.5% (76.0-87.5) after 2330 h (p=0.14). The change in duration of 
the longest apnea and lowest SaO2 did not signifi cantly differ between children with and
without CAI (p=0.62 and p=0.29, respectively). In children with CAI, the median oxygen-
desaturation-index increased with 2.1% after metyrapone administration, whereas the
median ODI decreased with 2.3% in the non-CAI group (p=0.09 for the difference in change
of ODI).
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Table 2. Results of sleep recording before and after metyrapone administration.
Before
metyrapone
After 
metyrapone
P-valuea
Before
vs. After
P-valueb
Δ CAI vs. 
non-CAI
To
ta
l
Central apnea index   2.2 (0.4-4.7)   5.2 (1.5-7.9) 0.007
Longest apnea 15.2 (11.2-21.0) 16.8 (15.2-27.6) 0.12
ODI   3.8 (1.7-6.7)   4.0 (2.4-6.4) 0.58
Lowest SaO2 87.5 (82.8-91.0) 85.5 (76.0-87.5) 0.14
C
A
I
Central apnea index   3.6 (0.7-4.7)   6.0 (4.4-7.9) 0.03 0.09
Longest apnea 19.0 (15.0-24.6)† 17.7 (14.1-40.1) 0.47 0.62
ODI   2.9 (1.7-6.6)   5.0 (2.4-13.5) 0.17 0.09
Lowest SaO2 86.5 (82.0-90.3) 85.5 (74.0-87.5) 0.50 0.29
N
on
-C
A
I Central apnea index   0.7 (0.4-4.2)   1.4 (0.7-6.7) 0.14 0.09
Longest apnea 11.2 (9.9-14.5)† 16.1 (15.1-20.9) 0.07 0.62
ODI   5.9 (1.4-7.2)   3.6 (1.2-4.7) 0.14 0.09
Lowest SaO2 88.5 (83.2-94.5) 85.5 (75.8-92.3) 0.07 0.29
Results of the recordings of sleep-related breathing before and after metyrapone administration at 2330
h. Data are expressed as median (iqr). a P-values for differences in variables before and after metyrapone
administration at 2330 h (Wilcoxon Signed Ranks Test); bP-values for differences in change after 
metyrapone administration between children with CAI and those without (Mann-Whitney U test). † Before
metyrapone administration, the maximum duration of apneas was signifi cantly longer in children with CAI
than in those without (p=0.03). ODI, oxygen-desaturation-index: the number of oxygen desaturations per 
hour; SaO2, oxygen saturation.
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Figure 1. Box-Whiskers plot depicting the central apnea index (no/hr) in children with CAI and
in those without, before and after the administration of metyrapone at 2330 h (30 mg/kg). The
increase in median (iqr) central apnea index was 2.8 (2.0-3.9) in children with CAI compared
to 1.0 (-0.2 to 2.6) in those without (p=0.09).
Complete overnight polysomnography prior to the metyrapone test
Twenty children who underwent a metyrapone test also had a complete overnight
polysomnography in a specialized sleep center at 20.7 months (12.8-28.4) before the test
(Table 3). During polysomnography, sleep-related breathing was considered pathological in
all children, defi ned as an apnea-hypopnea-index above 1.
Children who were later diagnosed with CAI had a signifi cantly higher central apnea index
than those not (p=0.03). The median (iqr) hypopnea index was 1.7 (0.6-3.9) in children with
CAI and 0.7 (0.0-1.7) in those without (p=0.14). The median (iqr) lowest SaO2 was 91.0%
(85.0-95.0) in children with CAI and 97.0% (90.0-100.0) in those without (p=0.07). Thus,
sleep-related breathing seemed less favorable in those later diagnosed with CAI compared
to those not. A polysomnography was also performed before start of GH treatment in 8
children with CAI and in 5 without. During this polysomnography performed 33.4 months
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(25.4-37.3) prior to the metyrapone test, the median (iqr) central apnea index was 4.6 (1.9-
6.0) in children with CAI versus 1.8 (1.5-3.1) in children without CAI (p=0.24). 
Although some time had elapsed between the polysomnography performed during GH
treatment and the sleep recording during overnight stay at the PICU, we found a signifi cant
correlation between the central apnea index during polysomnography and the central apnea
index during the metyrapone test, particularly after metyrapone administration (r=0.79,
p=0.006, Figure 2), but also before administration (r=0.73, p=0.02).
Table 3. Results of complete overnight polysomnography.
CAI No CAI P-value
N (m/f) 13 (7/6)  7 (4/3)
Age  6.0 (4.1-8.8)   6.1 (4.2-10.1)
Central apnea index (no/hr)  3.0 (2.2-4.9)   1.4 (1.0-1.9) 0.03
Obstructive apnea index (no/hr)  0.0 (0.0-0.1)   0.1 (0.0-0.3) 0.07
Hypopnea index (no/hr)  1.7 (0.6-3.9)   0.7 (0.0-1.7) 0.14
Longest apnea (sec) 18.0 (15.0-27.0) 19.0 (17.0-22.0) 0.81
Lowest SaO2 (%) 91.0 (85.0-95.0) 97.0 (90.0-100.0) 0.07
% REM sleep 24.0 (19.5-30.0) 22.0 (19.0-24.0) 0.28
% slow wave sleep 24.0 (20.8-29.0) 22.0 (18.0-31.0) 0.50
No. awakenings per hour  1.4 (1.1-1.8)   1.3 (1.0-1.9) 0.55
Polysomnographic records compared between patients with and without CAI. Data are expressed as
median (iqr). SaO2, oxygen saturation.
We also investigated if polysomnographic results were predictive for the later diagnosis of 
CAI and the severity thereof, refl ected by the ACTH response during a metyrapone test.
Notably, in our group of 20 children with PWS, the ACTH response during the metyrapone
test tended to correlate negatively with the central apnea index previously assessed by
polysomnography (r=-0.41, p=0.07). Two children without CAI had a central apnea index
below 1 during polysomnography. However, this was also seen in one girl later diagnosed
with CAI, who had the lowest central apnea index during polysomnography of all children
(0.42 per hour). It is not known whether this girl already suffered from CAI during the
polysomnography or that she acquired CAI afterwards. Unfortunately, a cut-off level for a
central apnea index indicating a normal stress response during a later performed metyrapone
test could not be provided. On the other hand, the four highest central apnea indices were
found in children later diagnosed with CAI, ranging from 4.15 to 9.31 per hour. The highest
central apnea index found in a child without CAI was 4.0 per hour. Thus, although a cut-off 
level for a central apnea index ruling out CAI could not be provided, a high central apnea
index seemed indicative for a high risk of having CAI.
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Figure 2. Scatterplot depicting the correlation between the central apnea index during
polysomnography prior to the metyrapone test and the central apnea index recorded in the
PICU after metyrapone administration. Spearman’s correlation coeffi cient r was 0.79, with a
corresponding p-value of 0.006.
Discussion 
We performed metyrapone tests in twenty children with PWS, who had undergone
polysomnographic evaluation of sleep-related breathing in a specialized sleep center prior 
to the metyrapone test. In ten of them, we also recorded sleep-related breathing during
their metyrapone test in the Pediatric Intensive Care Unit. All tests were performed during
healthy condition. Sleep apneas have been suggested to play a role in the sudden death of 
patients with PWS.3,10-13 We recently reported a prevalence of CAI during stress in children
with PWS of 60%.18 Further research should be performed to confi rm these results. CAI
during mild or moderate infection may contribute or lead to unexpected death. In children
with PWS, both CAI as well as the pathologic sleep-related breathing are likely to originate
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from the hypothalamus.18 In the present study, we hypothesized that PWS children with CAI
have more central sleep apneas than those without CAI, both before and during stress. The
combination of CAI and increased central apneas during stress might increase the risk for 
a fatal cascade leading to unexpected death. 
A metyrapone test mimics a period of stress by causing a sudden increased demand for 
stimulation of the hypothalamus-pituitary-adrenal axis, but without a concomitant increase
in cortisol response. Our results show a signifi cant increase of the central apnea index after 
metyrapone administration in all ten children, irrespective of adrenal status. This increase
could either refl ect a difference in sleep architecture between the period before and after 
metyrapone administration, or an alteration in the central ventilatory regulation due to
cortisol suppression which occurred in all children, both with and without CAI. In children
with an increased central apnea index due to a central hypoventilation disorder, central
apneas are most common during NREM sleep stages which are most abundant during
the fi rst part of the night.36 In contrast, our results showed more central apneas during the 
second part of the night. Thus, the increased central apnea index during the second part
of the night after metyrapone administration suggests an alteration in central ventilatory
regulation during stress in children with and without CAI. More research investigating the
change in sleep-related breathing during stress is warranted.
Our data showed that the increase in central apnea index as a response to metyrapone
administration tended to be higher in children later diagnosed with CAI than in those not.
As cortisol levels were maximally suppressed in all children, cortisol levels are not likely
to be related to these differences. The decreased cortisol levels caused a subsequent
sudden demand for hypothalamic corticotropin-releasing hormone (CRH) and pituitary
ACTH secretion. As patients with PWS suffer from hypothalamic dysregulations,3,18,37,38 CAI
is likely to result from an inappropriate CRH secretion by the hypothalamus. Low CRH
levels have been demonstrated to decrease EEG frequency, causing deeper sleep and
less wakefulness.39 A deeper stage of sleep is associated with a higher arousal threshold.40
Possibly, children with CAI may be more prone to have central sleep apneas due to lower 
CRH levels resulting in deeper sleep and an increased arousal threshold. This may also
account for the tendency toward a higher increase in oxygen-desaturation-index in response
to metyrapone in children with CAI.
Before metyrapone administration, the duration of the longest apnea was the only difference
between children with CAI and those without, whereas no signifi cant difference was found
after metyrapone administration. This may be due to the limited number of patients. However,
the number of patients that underwent a polysomnography prior to the metyrapone test
was larger. Our results show that during healthy condition prior to the metyrapone test,
sleep-related breathing was more severely disturbed in children with a later diagnosis of 
CAI, demonstrated by the signifi cantly higher central apnea index. Children with CAI during
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stress may possibly have lower CRH levels during healthy condition as well. As explained
above, lower CRH levels during health in CAI may result in children being more prone to
disturbed sleep-related breathing. On the other hand, CAI during stress and a high central
apnea index during health may be considered two independent symptoms, both resulting
from more severe dysfunction of the hypothalamus. Possibly, a more severe hypothalamic
dysregulation could result in a more severely disturbed adrenal function causing CAI
during stress, and concomitantly in more severely disturbed sleep-related breathing during
health.
Adequacy of cortisol suppression was assured by low cortisol levels at 0400 h and 0600 h.
All children had maximally suppressed cortisol levels at 0400 h and there was no signifi cant
difference between children with CAI and those without, neither in the decline of cortisol
levels from 2330 h to 0400 h, nor in the rise of cortisol levels thereafter. Thus, cortisol
synthesis was equally inhibited by metyrapone in both groups. Some authors suggested
a cut-off level of 220 nmol/l at 0730 h as a criterion for adequate cortisol suppression,
although it is used without any regard for cortisol levels at 0400 h and 0600 h. Application
of this criterion resulted in exclusion of only 1 and 2 children from analysis of the data of the
metyrapone-related sleep registration and polysomnography, respectively. These analyses
yielded similar results as in the total group. 
In our study, we also investigated whether polysomnographic results could be indicative
for the outcome of CAI in a metyrapone test. Interestingly, the ACTH response during
a metyrapone test tended to correlate with the central apnea index measured by
polysomnography prior to the metyrapone test. A central apnea index of 4.15 per hour and
higher seemed indicative for a higher risk of having CAI. However, this fi nding is based on
polysomnographic records of only 20 children with PWS. Thus, more research in a larger 
cohort is warranted. Our results could not provide a cut-off level for a central apnea index
ruling out CAI. We found a low central apnea index of 0.4 per hour in a girl later diagnosed
with CAI, indicating that either CAI and a concomitant increase in central apnea index
developed after the initial polysomnography, or that CAI can also be present without an
increased central apnea index. In the same line, we previously reported on the sudden death
of a three-year-old boy after a moderate upper respiratory tract infection.12 Because serum
cortisol one hour after death was undetectable, we suspected CAI as the cause of death.
During a polysomnography seven months prior to his demise, he had a central apnea index
of only 0.9 per hour. Thus, a low central apnea index is not a guarantee for a normal ACTH
stress response. Also, tests performed during healthy condition, such as a metyrapone test,
do not refl ect all changes in biological equilibriums during illness. Other factors such as
cytokines, interleukins and vasopressin play an important role during illness.28,41 Changes in
nocturnal respiratory parameters during illness may be much greater than those observed
during a metyrapone test. Future research should focus on the effect of illness on ACTH
response in combination with recording of sleep-related breathing.
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In conclusion, children with PWS and CAI during stress have a signifi cantly higher central
apnea index during healthy condition and a higher increase in central apnea index during
stress. The combination of CAI and compromised sleep-related breathing could aggravate
the deterioration of the condition of an acutely ill patient with PWS. This combination might
be the prelude of a fatal cascade during illness.
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Abstract
Objective: The reported prevalence of scoliosis in Prader-Willi Syndrome (PWS) children
varies from 15% to 86%. We studied the prevalence of scoliosis and the effects of age,
gender, body mass index (BMI), total lean body mass (LBM), LBM of the trunk (trunkLBM)
and genotype.
Design: Children visited our hospital where X-rays were taken, length and weight were
measured (BMI standard deviation scores (BMISDS) and body surface area (BSA)) and
dual energy x-ray absorptiometry (DXA) was performed, measuring LBM and trunkLBM.
Patients: Ninety-six children, median (interquartile range, iqr) age 4.8 years (2.1 to 7.5),
were included in a multi-centre study. None of them received growth hormone treatment.
Main outcome measures: Two types of scoliosis were identifi ed: 1) “long C-curve type”
scoliosis (LCS) and 2) “idiopathic” scoliosis (IS). Children were divided into age categories
(infants: 0-3 years, juveniles: 3-10 years, adolescents 10-16 years).
Results: The prevalence of scoliosis was 37.5% and increased with age (infants and
juveniles: ~30%, adolescents: 80%), 50% of children with scoliosis had a Cobb angle above
20°. Children with scoliosis were signifi cantly older than those without. Children with LCS
were younger and more hypotonic than those with IS: median (iqr) age 4.4 years (1.7-5.9)
vs. 11.1 years (6.5-12.1) (p=0.002) and trunkLBM:BSA 7080 (6745-7571) vs. 7830 (6932-
8157) (p=0.043). 
Conclusions: The prevalence of scoliosis in PWS children is high (37.5%) and many
children with scoliosis (13%) had undergone brace treatment or surgery. The type of 
scoliosis is affected by age and trunkLBM:BSA ratio.
77
C
ha
pt
er
 4
Introduction
Prader-Willi syndrome (PWS) is characterised by hypotonia, hypogonadism, short stature,
hyperphagia with obesity and psychological and behavioural problems.1-4
PWS results from the lack of paternal expression of the q11-q13 region of chromosome 15,
caused by deletion, uniparental disomy (UPD), imprinting centre defect causing maternal
imprinting (ICD), or balanced translocation.5-12 Hypothalamic dysfunction may be responsible
for many features of PWS.13-15 The birth incidence of PWS is 1:22.000 to 1:29.000. The 
overall annual death rate under the age of 30 years is 3%.16-18
Children with PWS may develop scoliosis.17,19-22 Scoliosis is a spinal curve with a Cobb
angle of more than 10° on a standing posteroanterior radiograph. The Cobb angle is the
angle between the two steepest vertebrae, i.e. the upper border of the upper vertebra in the
curve and the lower border of the lower vertebra.23
Information on scoliosis in PWS is limited and varies greatly. The prevalence of scoliosis
in PWS children was estimated to be between 15% and 86%.17,19-22 All studies were
retrospective and included both adults and children, without and during GH treatment.17,19-
21 Some calculated prevalences from questionnaires, whereas others studied material 
assembled over a great time span.17,19-22
We conducted a multi-centre study to investigate the prevalence and severity of scoliosis in
a large group of PWS children without growth hormone treatment and studied the effects of 
age, gender, body mass index (BMI), lean body mass (LBM) and genotype on scoliosis.
Methods
Patients
Patients were included from April 2002 until November 2006. Ninety-six children with
PWS (Table 1) were recruited through their paediatricians and paediatric endocrinologists
for a national study and fulfi lled the following inclusion criteria: 1) genetically confi rmed
diagnosis of PWS by positive methylation test; 2) age between 6 months and 16 years; and
3) bone age less than 14 years (girls) or 16 years (boys). None of the children were treated
with growth hormone. All children visited the Erasmus Medical Centre / Sophia Children’s
Hospital in Rotterdam, The Netherlands.
The study protocol was approved by the Medical Ethics Committee of ErasmusMC,
Rotterdam, The Netherlands. Informed consent was obtained from parents and children
above 12 years.
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Radiographics
Standing posteroanterior X-rays were taken of children who were able to stand. In young
and/or hypotonic children who were not able to stand, posteroanterior X-rays in supine
position were taken. Cobb angles were measured by two observers, a clinical research
fellow (RdL) and an experienced paediatric orthopaedic surgeon (LdK). A triage system was
used: one observer (RdL) measured all spinal X-rays, the other observer (LdK) examined
all scoliotic curves. Intra-observer variability (Intra-OV, RdL: mean (SD) difference –0.05°
(1.78°), ICC=0.998, rho=0.994, p=0.01, 95%C.I.=-0.91 to 0.80) and inter-OV (mean (SD)
difference -0.02° (3.1°), r=0.94, ICC=0.97, p=0.01, 95%C.I.=-0.89 to 0.85) were minimal.
Consistency between conventional and digital measurements was very high (mean (SD)
difference 0.03° (1.54°), r=0.969, ICC=0.98, p=0.01, 95%C.I.=-0.52 to 0.59).
A thoracic scoliosis was defi ned as a scoliosis with its apex between the second and eleventh
thoracic vertebra. A thoracolumbar scoliosis has its apex at either the twelfth thoracic or fi rst
lumbar vertebra. The apex is the most displaced vertebra in the scoliotic curve.
Two types of scoliosis were identifi ed: 1) “long C-curve type” scoliosis, often seen in children
with neuromuscular disorders (LCS); and 2) scoliosis behaving much like idiopathic scoliosis
and which could therefore be classifi ed according to the Lenke classifi cation system (IS,
Figures 1 and 2).24
Anthropometrics
Supine length was recorded below the age of 2.5 years. Thereafter, standing height was
measured with a Harpenden stadiometer. Weight was assessed on an accurate scale, and
BMI (kilograms per square meter) was calculated. Height and BMI were converted into
SDS according to Dutch references for age.25,26 Body surface area (BSA) was calculated.
Calculations were performed with Growth Analyser version 3.0 (www.growthanalyser.org). 
DXA
Lean body mass was measured with Dual Energy X-ray Absorptiometry (DXA, type Lunar 
Prodigy, GE Healthcare). Since no reference values for LBM in very young children were
available, a “lean body mass:body surface area” ratio (LBM:BSA) was used for total LBM
calculations and a trunkLBM:BSA ratio for calculations using only the LBM of the trunk.
TrunkLBM, a measure of central lean body mass, is the total amount of LBM in the chest,
abdomen and pelvis.
Data analysis
Data were analyzed for all children and for different age categories: infantile (0-3 years),
juvenile (3-10 years) and adolescent scoliosis (10-18 years).27,28 Statistical analysis was
performed with the Statistical Package for Social Sciences (SPSS 11.0, Chicago, IL). Most of 
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the data obtained in our patients were not Gaussian distributed. We therefore expressed our 
data as median and interquartile range (iqr). Nonparametric tests (Mann-Whitney U test) and
Chi-square tests were used to compare results between different age categories and types
of scoliosis. Correlations were calculated using Spearman’s correlation coeffi cient (r).
Results
Ninety-six children were included in this study (Table 1). Median (iqr) age was 4.8 years (2.1
years to 7.5 years) and BMISDS was 1.1 (-0.2 to 1.9). Height SDS was signifi cantly different
between the infant and juvenile group (p=0.02) and between the juvenile and adolescent
group (p=0.002). Weight SDS was signifi cantly different between all groups (infant and
juvenile p<0.0001, infant and adolescent p<0.0001, juvenile and adolescent p=0.002). Of 
82 children, the detailed genotype was known. Thirty-eight children had a deletion (46.3%),
35 UPD (42.7%), 8 ICD (9.8%) and one a balanced chromosomal translocation (1.2%).
Scoliosis in the total group of PWS children
Of 96 children, 36 had scoliosis (21 boys, 15 girls) at a median (iqr) age of 6.9 years (3.0-
11.5). The total prevalence of scoliosis in our group of PWS children was 37.5% (Table 1).
The prevalence was much higher than in the Dutch non-PWS population (scoliosis 2.7%,
10°-19° 2% and 20-39° 0.5%).29 Thirteen scoliosis (36%) were classifi ed as “long C-curve
type” scoliosis (LCS). Twenty-three (64%) were classifi ed as scoliosis resembling idiopathic
scoliosis (IS, Figures 1 and 2).
The median (iqr) Cobb angle of all scoliosis was 18.3° (12.9°-35.0°). Eighteen children (50%
of all with scoliosis, Table 1) had Cobb angles of 20° and more, the severity of scoliosis for 
which children are generally referred to an orthopaedic surgeon. Twelve children (13%) had
undergone conventional (Boston brace) or surgical treatment. 
There was no difference in the number of children with thoracic and thoracolumbar scoliosis
between those with IS and those with LCS.
Lenke classifi cation of 15 children with IS indicated that most of them (7 children, 47%)
had type 1B scoliosis (Figure 2), in which the main curve is thoracic and the centre sacral
vertical line (CSVL) is out of alignment, just touching the apical bodies.24
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There was no difference in prevalence, severity, location of the apex or Lenke classifi cation
between boys and girls and between different genotypes. Girls showed more IS than LCS
when compared to boys. This, however, did not reach statistical signifi cance (p=0.089),
possibly due to small numbers.
We did not fi nd congenital spinal anomalies, which is in line with Kroonen et al.20
Figure 1. Examples of “long C-curve type” scoliosis (LCS, Figure 1A) and scoliosis resembling
idiopathic scoliosis (IS, Figures 1B and 1C).
Infantile scoliosis
Nine of 30 PWS infants (30%) had scoliosis (Table 1). Six children had LCS (67%) and 3
had IS (33%, Figure 1). Two children had thoracic scoliosis and seven had thoracolumbar 
scoliosis. The median (iqr) Cobb angle of all infantile scoliosis was 15.5° (13.3°-21.5°). Two
children had Cobb angles greater than 20° and were, therefore, monitored by an orthopaedic
surgeon. At the time of measurement, none of them needed treatment yet (Table 1).
Scoliosis
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Figure 2. Lenke Classifi cation system for idiopathic scoliosis: from http://www.spinal-deformity-
surgeon.com/classifi cation.html by L.G. Lenke, MD. CSVL: center sacral vertical line. Most
children suffered from type 1B scoliosis.
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Juvenile scoliosis
Of 51 children aged 3 to 10 years, 15 had juvenile scoliosis (29%). Seven showed LCS
(47%) and 8 had IS (53%, Figure 1). Four children had thoracic scoliosis and eight had
thoracolumbar scoliosis. The median (iqr) Cobb angle of all juvenile scoliosis was 14.5°
(12.5°-35.0°). Six children had Cobb angles greater than 20°. Five of them (10% of children
with juvenile scoliosis) were treated, while one was still being monitored (Table 1).
Adolescent scoliosis
The prevalence of scoliosis in children of 10 years and older was 80%. Adolescent scoliosis
were all classifi ed as IS (Table 1, Figure 1). The median (iqr) Cobb angle of all adolescent
scoliosis was 35.0° (19.0°-41.5°). Ten children had Cobb angles greater than 20°. Seven
children (47% of children with adolescent scoliosis) were treated, while two were still being
monitored (Table 1).
Effects of age
Children with scoliosis were signifi cantly older than those without scoliosis (p=0.007, Table
2). Adolescent children showed signifi cantly more scoliosis than infant and juvenile PWS
children (p=0.002 and p=0.0001, respectively). There was no signifi cant difference in the
number of children with scoliosis between the infant and juvenile group (p=0.96).
Children with LCS were signifi cantly younger than children with IS (p=0.002, Table 2).
Adolescent children showed signifi cantly more IS than infant and juvenile PWS children
(p=0.001 and p=0.006, respectively). There was no signifi cant difference in type of scoliosis
(LCS or IS) between the infant and juvenile group (p=0.34).
A higher percentage of children was treated in the adolescent group than in the infantile
and juvenile group (p=0.0001 and p=0.001, respectively, Table 1). This difference did not
reach signifi cance between the infantile and juvenile group, probably due to small numbers
(p=0.077). Our data indicate that scoliosis in PWS children is progressive with age.
The difference in location of the apex between infants (mainly thoracolumbar scoliosis) and
adolescents (mainly thoracic scoliosis) was signifi cant (p=0.036).
BMI and LBM
The ratio of lean body mass of the trunk and body surface area (trunkLBM:BSA) was
signifi cantly different between infants and adolescents (p<0.0001) and between the juvenile
and adolescent group (p<0.0001, Table 1). BMISDS and trunkLBM:BSA were signifi cantly
correlated with age (r=0.40 with p=0.01 and r=0.54 with p=0.01, respectively). 
Children with scoliosis had a signifi cantly higher BMISDS than children without scoliosis
(p=0.05, Table 2). Children with LCS had signifi cantly lower BMISDS and trunkLBM:BSA 
than those with IS (p=0.026 and p=0.043, respectively). 
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Table 2. Differences between PWS children with and without scoliosis.
No scoliosis Scoliosis LCS IS
Age (years)* 3.7 (1.9 to 6.5) 6.9 (3.0 to 11.5) 4.4 (1.7 to 5.9) 11.1 (6.5 to 12.1)
BMI (SDS)** 0.6 (-0.2 to 1.7) 1.3 (-0.4 to 2.4) 1.1 (-0.8 to 1.5)    1.9 (1.0 to 2.6)
LBM:BSA (·104) 1.5 (1.5 to 1.6) 1.6 (1.5 to 1.7) 1.6 (1.5 to 1.6)    1.6 (1.5 to 1.7)
TrunkLBM:BSA(·103)† 7.3 (6.8 to 7.8) 7.5 (6.9 to 7.9) 7.1 (6.7 to 7.6)    7.8 (6.9 to 8.2)
Differences in age, BMISDS, LBM:BSA and trunkLBM:BSA for children with and without scoliosis, also
divided by type of scoliosis. Values are expressed as median (iqr).
* Children with scoliosis were older than those without (p=0.007) and children with LCS were younger than
those with IS (p=0.002).
** Children with scoliosis had a higher BMISDS than those without (p=0.05). Children with IS had a higher 
BMISDS than children with IS (p=0.026).
† Children with LCS had a signifi cantly lower LBM:BSA than children with IS (p=0.043).
Discussion
Our study shows a prevalence of scoliosis in PWS patients of 37.5%, increasing in
adolescence (30% in infants, 29% in juveniles and 80% in adolescents). Fifty percent of 
children with scoliosis had Cobb angles greater than 20° and 13% of them was treated. Our 
data show that scoliosis is a progressive deformity and that, therefore, the percentage of 
treated scoliosis increased with age. Children with scoliosis were older with higher BMISDS
than those without.
We identifi ed two types of scoliosis: “long C-curve type” scoliosis often seen in neuromuscular 
disorders (LCS) and scoliosis resembling idiopathic scoliosis (IS). Girls had more IS than
LCS when compared to boys, but this did not reach statistical signifi cance. More importantly,
infants mainly showed LCS, whereas adolescents only showed IS; juvenile children showed
both types of scoliosis. This could indicate a shift in a single patient from a LCS type to
an IS type scoliosis, or a transition as a total group evolving from regression of LCS and
new development of IS. The LCS type scoliosis showed a strong association with a low
trunkLBM:BSA, used as a proxy for hypotonia of the trunk. The decreasing number of LCS
type scoliosis with progressing age in PWS children might therefore be associated with an
increase in lean body mass of the trunk. This is an interesting matter for future research.
The prevalence of scoliosis of 37.5% was much higher than in the non-PWS Dutch
population (2.7%).29 Importantly, our study also shows a very high prevalence of both
infantile and juvenile scoliosis (~30%). Interestingly, Nagai et al.21 reported a prevalence
of 25% in patients aged 6-11 years. This study also reported that females were at greater 
risk of developing scoliosis,21 while Kroonen et al.20 treated more male patients. As could
be expected from these results, gender did not affect the prevalence of scoliosis in our 
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study. This is in contrast to the Dutch non-PWS population, in which the male:female ratio
is 1:1.2.29
Due to the high prevalence of scoliosis, it is advisable to perform frequent physical
examination of the spine (Adam’s Forward Bend Test) of PWS children during routine visits.
However, physical examination may not be reliable to detect scoliosis in PWS children with
obesity and/or hypotonia. In such children and in those with suspected scoliosis, yearly
radiographic examination (preferably standing posteroanterior radiographs) is advisable. We
recommend that all PWS patients with scoliosis of 20° or more be referred to an orthopaedic
surgeon. In our clinic, non-PWS children with progressive scoliosis of 20-25° or more are
treated with a Boston brace. In children with PWS, however, effi cacy of the bracing is very
limited due to hypotonia and obesity. And if effective, psychological problems (e.g. temper 
tantrums) may complicate the patients compliance. Children with a progressive scoliosis
despite bracing or with a scoliosis of 45° or more are a candidate for spinal surgery. Surgery
may be high-risk and contra-indicated in some PWS patients. However, severe progressive
scoliosis may become a life-threatening deformity in itself. In short, the choice for treatment
is complicated and the potential result should be weighed against possible complications.
Increased growth velocity during puberty and catch-up growth initiated by GH treatment have
caused development or progression of scoliosis in non-PWS patients, prone to developing
scoliosis.30-32 Because many PWS patients have a reduced growth velocity, they are often 
treated with growth hormone. It would be interesting to perform a longitudinal study on the
effects of growth and growth hormone treatment on the development or progression of 
scoliosis.
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Abstract
Context: The prevalence of scoliosis in children with Prader-Willi syndrome (PWS) is
30-80%, depending on age. Although reports about effects of growth hormone (GH)
treatment on scoliosis in children with PWS are limited, scoliosis is generally considered a
contraindication for GH treatment.
Objective: To study the effects of GH treatment on the onset of scoliosis and curve
progression in children with PWS.
Design:  A multi-center, randomized controlled GH study in infants, prepubertal and pubertal
children. Infants and prepubertal children were randomized into a GH-treated group (1.0
mg/m2·day) and a control group for one and two years, respectively. Pubertal children were
randomized to receive somatropin 1.0 or 1.5 mg/m2·day. Yearly, X-rays of the spine were
taken and height, weight, truncal lean body mass (trunkLBM with DXA), and IGF-I were
measured.
Patients: 91 children with PWS, median (iqr) age 4.7 (2.1-7.4) years.
Main outcome measures: Onset of scoliosis (Cobb>10°) and scoliotic curve progression.
Results: GH-treated children had similar onset of scoliosis and curve progression as
randomized controls (p=0.27-0.79 and p=0.18-0.98, respectively). GH treatment, IGF-I SDS,
and catch-up growth had no adverse effect on the onset of scoliosis or curve progression,
also not after adjustment for confounders. HeightSDS, trunkLBM and IGF-I SDS were
signifi cantly higher in GH-treated children than in randomized controls. At baseline, a higher 
IGF-I SDS was associated with a lower severity of scoliosis.
Conclusions: Scoliosis should no longer be considered a contraindication for GH treatment
in children with PWS.
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Introduction
Prader-Willi syndrome (PWS) is characterized by hypotonia, short stature, hyperphagia
with obesity, hypogonadism, and psychological and behavioral problems.1-7 PWS results 
from the lack of expression of the paternally derived chromosome 15q11-q13 caused by
deletion, uniparental disomy (UPD), imprinting center defect, or balanced translocation.1,8
Hypothalamic dysfunction may be responsible for many features of PWS.9-11
Spinal deformity is a major concern for patients with PWS. Scoliosis is defi ned as a spinal
curve with a Cobb angle of more than 10° on a standing posteroanterior radiograph. The
Cobb angle is the angle between the two steepest vertebrae, i.e. the upper border of the
upper vertebra in the curve and the lower border of the lower vertebra.12 The prevalence
of scoliosis in PWS is high (30% <10 years, 80% >10 years13-15 vs. 2.7% in the general 
Dutch adolescent population16). Children with PWS show two types of scoliosis (Figure 1):
“Long C-curve type” scoliosis (LCS) often seen in children with neuromuscular disorders
causing hypotonia, and scoliosis resembling idiopathic scoliosis (IS). Young children mainly
show LCS, associated with a low ratio of truncal lean body mass versus body surface area
(trunkLBM:BSA), which is a proxy for hypotonia. Older children mainly show IS.13
Growth hormone (GH) treatment is benefi cial for children with PWS, as it improves body
composition (increase in lean body mass, decrease in fat percentage) and psychomotor 
development.17-23 In a previous report by our group, the effects of GH treatment on height and
body composition of children with PWS have been described in detail.23 Accelerated growth, 
either spontaneous or during GH treatment, has been associated with the onset of scoliosis
and scoliotic curve progression.24-29 As scoliosis is often considered a contraindication for 
GH treatment in children with PWS, the need for controlled data about the effect of GH
treatment on scoliosis was emphasized.30-32 We therefore performed a large randomized 
controlled trial. We hypothesized that GH treatment would not affect scoliosis, because
it also increases truncal lean body mass which may counteract the adverse effects of 
accelerated growth on scoliosis. The primary aim of our study was to investigate the effects
of GH treatment on the onset of scoliosis. The secondary aim was to study the effects of GH
treatment on scoliotic curve progression. As age and gender are known to affect onset of 
scoliosis, while age, gender, and severity of scoliosis affect curve progression, we adjusted
for these factors in our analyses.
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Subjects and Methods
Subjects
Between April 2002 and January 2008, 104 children were enrolled in a large randomized
controlled trial investigating the effects of GH treatment in children with PWS (Table 1), after 
fulfi lling the following inclusion criteria: genetically confi rmed diagnosis of PWS by positive
methylation test and age between 6 months and 16 years. The study group was divided
in infants, prepubertal and pubertal children. The infant group consisted of children aged
6 months to 3.5 years. The prepubertal group consisted of girls aged 3.5 to 12 years
with Tanner breast stage < 2, and boys aged 3.5 to 14 years with Tanner genital stage
< 2 and a testicular volume < 4 ml.33 The pubertal group consisted of girls aged 12 to
16 years and boys aged 14 to 16 years with spontaneous or induced puberty. Caloric
intake and activity level of all participants were standardized. All children were naïve to
GH treatment at start of study. Children visited the Erasmus University Medical Center / 
Sophia Children’s Hospital in Rotterdam, The Netherlands, and the study protocol was
approved by the Medical Ethics Committee. Written informed consent was obtained from
parents and children over 12 years of age. Assent was obtained for children between 4
and 12 years of age.
Design
The primary objective of our study was to investigate the effects of GH treatment on the
onset of scoliosis. The secondary objective was to study the effects of GH treatment on
progression of scoliosis. Infants and prepubertal children were randomized into a GH-
treated group (1.0 mg/m2·day) and a control group for one and two years, respectively.
Pubertal children were randomly assigned to receive somatropin 1.0 or 1.5 mg/m2·day
(Genotropin, Pfi zer, New York) for a follow-up period of two years. The fi rst four weeks
of treatment, children received 0.5 mg/m2·day to prevent fl uid retention. In January 2008,
38 infants (<3.5 years) had completed the one-year follow-up, and 44 prepubertal and 9
pubertal children had completed the two-year follow-up. Thus, 91 children were eligible for 
analysis (Table 1).
Radiographics
At start and subsequently each year, standardized posteroanterior X-rays were taken. In
young and/or hypotonic children who were not able to sit or stand, posteroanterior X-rays
were taken in supine position. All X-rays were taken in one center (EMCR). Cobb angles
were measured independently by two observers (R.F.A.d.L.v.W. and L.W.L.d.K.), as
previously reported, with minimal intra- and inter-observer variance (ICC=0.998 and 0.97,
respectively).13 The orthopedic surgeon was fully blinded to the assigned treatment. If the
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independent measurements of Cobb angles differed between the two observers, the mean
of the Cobb angles was used for analysis. Onset of scoliosis was defi ned as the presence
of a Cobb angle of 10° or higher at 12 or 24 months of study in those without scoliosis at
baseline (outcome: yes/no). Progression of scoliosis was evaluated as the change in Cobb
angle over time in those with scoliosis at baseline and in those that developed scoliosis
during study. Because treatment of scoliosis (bracing and surgery) prevents further curve
progression, the effects of GH treatment on curve progression was only investigated in
children with untreated scoliosis. For baseline characteristics of the total study population
(Table 1), the Cobb angle of the scoliotic curve of children treated with a brace was set at
35° and the Cobb angle of those surgically treated at 55°. None of the children needed to
start treatment of scoliosis during the study.
Anthropometrics
Standing height was measured with a Harpenden Stadiometer and supine length with a
Harpenden Infantometer (Holtain Ltd., Crosswell, UK). Weight was assessed on an accurate
scale. Height and BMI SDS were calculated, adjusted for sex and age according to Dutch
references.34,35 Height SDS, BMI SDS and body surface area (BSA) was calculated with 
Growth Analyser 3.0 (available at www.growthanalyser.org). Growth was calculated as
the increase in heightSDS per year (ΔheightSDS) or the increase in centimeters per year 
(Δheight).
Severe scoliosis interferes with height and therefore also with Δheight(SDS). Lean body
mass is known to be highly correlated with height.23,36,37 In our study, these two parameters
also showed a strong correlation (rho=0.82, p<0.0001 and rho=0.67, p<0.0001 at 12
and 24 months, respectively). To analyze the effect of Δheight on the onset of scoliosis
and curve progression, we therefore also used the change in truncal lean body mass
(ΔtrunkLBM) as a proxy for Δheight.
DXA
Dual Energy X-ray Absorptiometry (DXA, type Lunar Prodigy, GE Healthcare) was performed
to measure the lean body mass of the trunk (trunkLBM), defi ned as the total amount of LBM
in the chest, abdomen and pelvis. Reference values of trunkLBM in very young children
were not available. To analyze the effects of GH treatment on relative muscle mass, we
used a ratio of trunkLBM versus body surface area (trunkLBM:BSA ratio), as previously
described.13
Assay
Serum IGF-I levels were measured using an immunometric technique on an Advantage
Automatic Chemiluminescence System (Nichols Institute Diagnostics, San Juan Capistrano,
Effects of GH treatment on scoliosis
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California). The intra-assay CV was 4% and the inter-assay CV was 6%. Because of age
and sex dependency, IGF-I levels were transformed into SDS.38
Data analysis
Data were analyzed for all children together as well as for different age categories. Statistical
analysis was performed with the Statistical Package for Social Sciences (SPSS 15.0,
Chicago, IL). Data are presented as median and inter-quartile range (iqr). A change in Cobb
angle of 5° or more was considered clinically relevant. Power calculation estimated a total
number of 40 patients (comprising infants and prepubertal children) to yield a power of 0.80,
in line with the international convention: Assuming a clinically relevant difference between
GH-treated children and controls of 0.80 in terms of Cohen’s d, an alpha level of 0.05 (one-
tailed) and a total number of required patients of 40, the power of the study was 0.80.39
In our primary analyses, effects of GH treatment on onset and progression of scoliosis
were analyzed after adjustment for confounders, using binary logistic regression models for 
onset of scoliosis (Table 3, odds ratios) and linear regression models for curve progression
(Table 4, in β). In order to allow comparison with other reports regarding scoliosis in PWS in
which these adjustments were not performed, we additionally analyzed differences in onset
of scoliosis and curve progression between GH-treated children and randomized controls
with Chi-square tests and Mann-Whitney U tests. 
To investigate risk of onset of scoliosis during study, we included all children without scoliosis
at start of study. Goodness of fi t of binary logistic regression models was assured by
performing the Hosmer and Lemeshow test (correct fi tting when p>0.05). R2 was calculated
as a measure of explained variance. To investigate curve progression, we included all
children with untreated scoliosis at start of study and those who had their onset of scoliosis
during the study. Tolerance of all variables within the linear regression models was assured
by calculating the variable infl ation factor as a measure of multicollinearity. Nagelkerkes R2
was calculated for all binary logistic and R2 for all linear regression models as a measure
of explained variance.
Mann-Whitney U tests and Chi-square tests were performed to compare outcomes between
two groups. Data obtained in the smaller pubertal group were analyzed separately. A p-value
below 0.05 was considered statistically signifi cant.
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Results
Table 1 shows the baseline clinical characteristics of the 91 children with PWS in our 
randomized controlled trial who completed the one- or two-year follow-up. The median
(interquartile range, iqr) age was 4.7 years (2.1-7.4). The genotype was specifi ed in 77
children: 35 had a deletion (46%), 33 had an UPD (43%), 8 an imprinting center defect
(10%), and one a balanced translocation (1%). Positive methylation test was demonstrated
in the remaining 14 patients, but the underlying genetic defect was not identifi ed.
Baseline data
At start of study (Table 1), 36% of children had scoliosis with a median (iqr) Cobb angle of 
19.0° (13.3°-36.0°). The prevalence of scoliosis increased with age (infants vs. pubertal:
p=0.03). With increasing age, there was a shift from a predominance of “long C-curve type”
scoliosis (LCS-type, Figure 1) in infants towards a predominance of scoliosis resembling
idiopathic scoliosis (IS-type, Figure 1) in older children (infants vs. pubertal: p<0.03). The
differences in prevalence of scoliosis and predominance of IS-type between prepubertal
and pubertal children did not reach statistical signifi cance, most likely due to the limited
number of pubertal children (p=0.09 and p=0.07, respectively). The number of children
treated for scoliosis was higher in older children. 
Figure 1. Examples of “Long C-curve type” scoliosis (LCS, A) and scoliosis resembling
idiopathic scoliosis (IS, B). Younger children mainly showed LCS, while pubertal children only
showed IS.
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Prepubertal children had a signifi cantly higher BMI SDS than infants (p<0.0001). Pubertal
children also had a higher BMI SDS than infants, but this did not reach statistical signifi cance
(p=0.07). Prepubertal children had a signifi cantly higher IGF-I SDS compared to pubertal
children (p=0.004), and compared to infants, but this did not reach statistical signifi cance
(p=0.06). The trunkLBM:BSA ratio increased with age and was signifi cantly different between
all age categories (p<0.0001 to p=0.02).
Children who were treated for scoliosis at start of study had lower IGF-I SDS than children
without scoliosis (-3.3 (-4.5 to -2.1) vs. -2.0 (-2.8 to -1.3), p=0.02), suggesting a protective
effect of higher IGF-I levels. Linear regression modeling for 91 children at start of study
showed a tendency for a less severe scoliosis in case of higher IGF-I levels (age: β=3.83,
p=0.059; IGF-I SDS: β=–0.26, p=0.08). 
Effects of GH treatment on growth and IGF-I levels
At baseline, there were no signifi cant differences in age, heightSDS, BMI SDS, trunkLBM:BSA 
ratio, IGF-I SDS, and prevalence and severity of scoliosis between the GH treatment
group and the randomized controls. In all children, GH treatment signifi cantly increased
heightSDS (ΔheightSDS) and IGF-I SDS compared to randomized controls (Table 2).
Growth in prepubertal GH-treated children was greatest during the fi rst year: median (iqr)
ΔheightSDS 0.9 (0.7-1.3) during the fi rst year versus 0.6 (0.3-0.7) during the second year 
(p<0.0001). Thus, catch-up growth was the most prominent during the fi rst year of GH
treatment. Compared to controls, BMI SDS tended to be lower in GH-treated children at 12
months of study (p=0.05), but was not signifi cantly different at 24 months of study (p=0.19).
GH treatment signifi cantly decreased the hypotonia of the truncal muscles, shown by an
increase in ΔtrunkLBM and ΔtrunkLBM:BSA. There was a signifi cant correlation between
IGF-I SDS and trunkLBM:BSA ratio (r=0.51 with p<0.0001 and r=0.41 with p<0.0001, at 12
and 24 months of study, respectively). During our study, there were no adverse effects of 
GH treatment.
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Effects of GH treatment on scoliosis
Infants (0-3.5 years)
During 12 months of study, there was no signifi cant difference between GH-treated infants
and randomized controls with regard to onset of scoliosis, curve progression (p=0.71 and
p=0.48, Table 2), and start of treatment for scoliosis (p=1.00).
Table 3 shows the odds ratios for the risk of onset of scoliosis. Corrected for age and
gender, GH treatment had no signifi cant effect on the risk of onset of scoliosis, with an
OR (95% confi dence interval) of 3.33 (0.41-27.2) (p=0.26, Model 1). Also, ΔtrunkLBM as a
proxy for Δheight did not affect the risk of onset of scoliosis, with an OR (95% CI) of 2.1 (0.3-
13.7) (p=0.45, Model 2). In our fi nal model (Model 3), both GH treatment and ΔtrunkLBM did
not increase the risk of onset of scoliosis in infants with PWS.
Table 4 shows the effect (β) of different variables on the progression of scoliosis. Corrected
for age and gender, IGF-I SDS had no signifi cant effect on the progression of scoliosis
during 12 months of study, with a β (95% CI) of 1.20 (-1.0 to 3.4) (p=0.24, Model 1). Also,
ΔtrunkLBM as a proxy for Δheight did not affect the progression of scoliosis during 12
months of study (β (95% CI): 7.19 (-19.1 to 33.5), p=0.51; Model 2). In our fi nal model
(Model 3), IGF-I SDS, ΔtrunkLBM, and the severity of scoliosis at start of study had no
signifi cant effect on the progression of scoliosis in infants with PWS.
Results were similar when ΔheightSDS was included in our models instead of ΔtrunkLBM.
Prepubertal children (3.5-12/14 years)
During 12 and 24 months of study, there was no signifi cant difference between GH-treated
prepubertal children and randomized controls with regard to onset of scoliosis, curve
progression (12 months: p=0.52 and p=0.60; 24 months: p=0.14 and p=0.27; Table 2), and
start of treatment for scoliosis (both p=1.00).
Table 3 shows the odds ratios for the risk of onset of scoliosis. Corrected for age and
gender, GH treatment had no signifi cant effect on the risk of onset of scoliosis after 12 and
24 months of study with an OR (95% CI) of 0.42 (0.07-2.7) at 12 months and 0.3 (0.05-1.5)
at 24 months of study (p=0.36 and p=0.16, respectively; Model 1). Also, ΔtrunkLBM as a
proxy for Δheight did not affect the risk of onset of scoliosis after 12 and 24 months of study,
with an OR (95% CI) of 0.46 (0.1-1.4) at 12 months and 0.47 (0.2-1.0) at 24 months of study
(p=0.17 and p=0.06, respectively; Model 2). In our fi nal model (Model 3), both GH treatment
and ΔtrunkLBM did not increase the risk of onset of scoliosis in prepubertal children with
PWS after 12 and 24 months of study.
Table 4 shows the effect (β) of different variables on the progression of scoliosis. Corrected
for age and gender, IGF-I SDS had no signifi cant effect on the progression of scoliosis
during the fi rst and second year of the study, with a β (95% CI) of -0.24 (-1.5 to 1.0) during
the fi rst year and 1.3 (-0.3 to 2.9) during the second year of study (p=0.69 and p=0.10,
Effects of GH treatment on scoliosis
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respectively; Model 1). Also, ΔtrunkLBM as a proxy for Δheight did not signifi cantly affect
the progression of scoliosis, with a β (95% CI) of -3.95 (-9.6 to 1.8) during the fi rst year and
3.7 (-3.9 to 11.3) during the second year of study (p=0.16 and p=0.32, respectively; Model
2). In our fi nal model with the highest explained variance (Model 3, R2=0.57), a more severe
scoliosis at start of study and a higher ΔtrunkLBM during the fi rst year were associated
with a tendency for regression of scoliosis (β (95% CI) of ΔtrunkLBM: -4.1 (-9.1 to 0.8)
with p=0.09; β (95% CI) of severity at start: -0.71 (-1.30 to -0.11) with p=0.03). During the
second year of GH treatment, IGF-I SDS, ΔtrunkLBM and Cobb angle at start of study had
no signifi cant effect on curve progression in prepubertal children with PWS.
Results were similar when ΔheightSDS was included in our models instead of ΔtrunkLBM.
Pubertal children (12/14-16 years)
A GH dose of 1.5 mg/m2·day in pubertal children (N=3) resulted in a higher height velocity
and IGF-I SDS compared with those treated with 1.0 mg/m2·day (N=6; p=0.046 and p=0.08,
respectively; data not shown). Three of nine pubertal children had no scoliosis at start of 
study and had no onset of scoliosis during study. Six pubertal children had scoliosis at start
of study, but there was no difference in the number of children treated for scoliosis or in
curve progression between those treated with a dose of 1.0 and 1.5 mg/m2·day (data not
shown). 
Discussion
Our randomized controlled trial shows that there was no signifi cant difference between
GH-treated children and randomized controls with regard to onset of scoliosis, curve
progression, and start of treatment of scoliosis. In both the infant and prepubertal group,
GH treatment, ΔheightSDS, ΔtrunkLBM (used as a proxy for Δheight), and IGF-I SDS were
not associated with an increased risk of onset of scoliosis or curve progression, both before
and after correction for confounders. Thus, GH treatment not only improves heightSDS and
trunkLBM of children with PWS,17-23 but has also no adverse effects on the onset of scoliosis
and curve progression.
Some authors have described an association between increased GH levels and a higher 
rate of curve progression in children without PWS.27-29 In contrast to these reports, our data
show that a higher baseline IGF-I SDS was associated with a lower severity of scoliosis,
suggesting a protective effect of higher IGF-I SDS in children with PWS. As IGF-I SDS was
also positively associated with the trunkLBM:BSA ratio, the protective effect may be due
to a higher truncal lean body mass. In our randomized controlled trial, GH-treated children
had a signifi cantly higher IGF-I SDS and ΔtrunkLBM, but IGF-I SDS was not associated
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with progression of scoliosis. The ΔtrunkLBM, however, was associated with a tendency for 
regression of scoliosis, but only during the fi rst year of study.
The prepubertal group provides the most accurate information about the effects of GH
treatment on scoliosis, because all X-rays were taken in standing position and children were
followed in a two-year randomized controlled trial. GH treatment and catch-up growth had
no adverse effect on the onset of scoliosis or curve progression. Notably, our results show
that those with a more severe scoliosis at start of study and a higher catch-up growth had a
tendency for regression of scoliosis during the fi rst year of study. This effect was not seen
during the second year. Our study is the fi rst randomized controlled trial investigating the
effects of GH treatment on scoliosis in a large group of children with PWS. Our data indicate
that even severe scoliosis should not be considered a contraindication for GH treatment in
children with PWS. The fi ndings are in line with a retrospective study demonstrating that GH
treatment did not affect scoliosis in these children.14
Although our main aim was to investigate the onset and progression of scoliosis in a
randomized controlled GH trial in infants and prepubertal children, we did not want to withhold
GH treatment from a small group of pubertal children PWS. In this group of pubertal children
we found that a higher dose of GH (1.5 mg/m2·day) increased height velocity and IGF-I SDS
and was not associated with an accelerated onset of scoliosis or curve progression.
Infants had a controlled period of one year and prepubertal children of two years. This period
is not very long for follow-up. However, in orthopedic practice visits are scheduled every four 
to six months to monitor progression. Therefore, changes occurring during GH treatment
can easily be noted during one or two years of follow-up. Moreover, if GH treatment would
have adverse effects on scoliosis by stimulating growth, one would especially notice this
during the period with the highest gain in heightSDS, i.e. catch-up growth during the fi rst
year of GH treatment. In our opinion, one or two years of follow-up is suffi cient to identify
the effects of GH-induced catch-up growth on the onset or progression of scoliosis. Our fi nal
models in infants and prepubertal children explained 20-57% of variances (R2). In future, 
when more data on the pathogenesis of scoliosis become available, perhaps our models
might be improved. 
In conclusion, our randomized controlled GH trial in a large group of children with PWS
shows that GH treatment had no adverse effects on the onset of scoliosis and curve
progression. A higher baseline IGF-I SDS was associated with a lower severity of scoliosis.
Thus, scoliosis should not be considered a contraindication for GH treatment in children
with Prader-Willi syndrome. Because of the high prevalence of scoliosis and the potential
associated morbidities in patients with PWS, it is recommended to perform frequent physical
examination and yearly radiographic examination, independently from GH treatment.
Effects of GH treatment on scoliosis
104
Acknowledgements
We express our gratitude to all participating children and their parents for their enthusiastic
participation in this study. The assistance of Ms. P.M.C.C. van Eekelen and Ms. M. Wevers
is greatly appreciated. We are grateful for the work of Ms. J.P. Sluimer. We acknowledge
Pfi zer for their Independent Research Grant.
105
C
ha
pt
er
 5
References
Cassidy SB, Schwartz S1.  1998 Prader-Willi and Angelman syndromes. Disorders of genomic
imprinting. Medicine (Baltimore) 77:140-151
Festen DA, de Weerd AW, van den Bossche RA, Joosten K, Hoeve H, Hokken-Koelega2.
AC 2006 Sleep-related breathing disorders in prepubertal children with Prader-Willi syndrome 
and effects of growth hormone treatment. J Clin Endocrinol Metab 91:4911-4915
Holm VA, Cassidy SB, Butler MG, Hanchett JM, Greenswag LR, Whitman BY, Greenberg3.
F 1993 Prader-Willi syndrome: consensus diagnostic criteria. Pediatrics 91:398-402
Goldstone AP4.  2004 Prader-Willi syndrome: advances in genetics, pathophysiology and 
treatment. Trends Endocrinol Metab 15:12-20
Gunay-Aygun M, Schwartz S, Heeger S, O’Riordan MA, Cassidy SB5. 2001 The changing
purpose of Prader-Willi syndrome clinical diagnostic criteria and proposed revised criteria.
Pediatrics 108:E92
McCandless SE, Cassidy SB6. 2006 Diagnostic criteria for Prader-Willi syndrome. In: Butler 
MG, Lee PDK, Whitman BY, Association P-WS eds. Management of Prader-Willi syndrome.
3rd ed. New York: Springer; 49-57
Bittel DC, Butler MG7. 2005 Prader-Willi syndrome: clinical genetics, cytogenetics and 
molecular biology. Expert Rev Mol Med 7:1-20
State MW, Dykens EM8. 2000 Genetics of childhood disorders: XV. Prader-Willi syndrome:
genes, brain, and behavior. J Am Acad Child Adolesc Psychiatry 39:797-800
Muscatelli F, Abrous DN, Massacrier A, Boccaccio I, Le Moal M, Cau P, Cremer H9. 2000
Disruption of the mouse Necdin gene results in hypothalamic and behavioral alterations
reminiscent of the human Prader-Willi syndrome. Hum Mol Genet 9:3101-3110
Swaab DF10. 1997 Prader-Willi syndrome and the hypothalamus. Acta Paediatr Suppl 423:50-
54
Swaab DF, Purba JS, Hofman MA11. 1995 Alterations in the hypothalamic paraventricular 
nucleus and its oxytocin neurons (putative satiety cells) in Prader-Willi syndrome: a study of 
fi ve cases. J Clin Endocrinol Metab 80:573-579
Cobb JR12. 1948 Outline for the study of scoliosis. In: Edwards JB ed. AAOS, Instructional
Course Lectures: Ann Arbor: The American Academy of Orthopaedic Surgeons; 261-275
de Lind van Wijngaarden RF, de Klerk LW, Festen DA, Hokken-Koelega AC13. 2008 Scoliosis
in Prader-Willi syndrome: prevalence, effects of age, gender, body mass index, lean body
mass and genotype. Arch Dis Child 93:1012-1016
Nagai T, Obata K, Ogata T, Murakami N, Katada Y, Yoshino A, Sakazume S, Tomita Y,14.
Sakuta R, Niikawa N 2006 Growth hormone therapy and scoliosis in patients with Prader-Willi
syndrome. Am J Med Genet A 140:1623-1627
Odent T, Accadbled F, Koureas G, Cournot M, Moine A, Diene G, Molinas C, Pinto G,15.
Tauber M, Gomes B, de Gauzy JS, Glorion C 2008 Scoliosis in patients with Prader-Willi
Syndrome. Pediatrics 122:499-503
Diepstraten A, Van Linge B, Swierstra B16. 2001 Afwijkingen van de wervelkolom. In:
Kinderorthopedie. 2 ed. Maarssen: Elseviers gezondheidszorg; 43-47
Carrel AL, Allen DB17.  2000 Effects of growth hormone on body composition and bone 
metabolism. Endocrine 12:163-172
Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB18. 2004 Growth hormone 
improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J
Pediatr 145:744-749
Effects of GH treatment on scoliosis
106
Eiholzer U, L’Allemand D, Schlumpf M, Rousson V, Gasser T, Fusch C19. 2004 Growth
hormone and body composition in children younger than 2 years with Prader-Willi syndrome.
J Pediatr 144:753-758
Festen DA, Wevers M, de Weerd AW, van den Bossche RA, Duivenvoorden HJ, Otten20. 
BJ, Wit JM, Hokken-Koelega AC 2007 Psychomotor development in infants with Prader-Willi
syndrome and associations with sleep-related breathing disorders. Pediatr Res 62:221-224
Ritzen EM, Lindgren AC, Hagenas L, Marcus C, Muller J, Blichfeldt S21.  1999 Growth hormone
treatment of patients with Prader-Willi syndrome. Swedish Growth Hormone Advisory Group. J
Pediatr Endocrinol Metab 12 Suppl 1:345-349
Whitman B, Carrel A, Bekx T, Weber C, Allen D, Myers S22.  2004 Growth hormone improves
body composition and motor development in infants with Prader-Willi syndrome after six
months. J Pediatr Endocrinol Metab 17:591-600
Festen DA, de Lind van Wijngaarden R, van Eekelen M, Otten BJ, Wit JM, Duivenvoorden23. 
HJ, Hokken-Koelega AC 2008 Randomized controlled growth hormone trial: Effects on
anthropometry, body composition, and body proportions in a large group of children with
Prader-Willi syndrome. Clin Endocrinol (Oxf):443-451
Burwell RG24.  2003 Aetiology of idiopathic scoliosis: current concepts. Pediatr Rehabil 6:137-
170
Docquier PL, Mousny M, Jouret M, Bastin C, Rombouts JJ25. 2004 Orthopaedic concerns in
children with growth hormone therapy. Acta Orthop Belg 70:299-305
Wever DJ, Tonseth KA, Veldhuizen AG, Cool JC, van Horn JR26.  2000 Curve progression and
spinal growth in brace treated idiopathic scoliosis. Clin Orthop Relat Res:169-179
Ahl T, Albertsson-Wikland K, Kalen R27.  1988 Twenty-four-hour growth hormone profi les in
pubertal girls with idiopathic scoliosis. Spine 13:139-142
Skogland LB, Miller JA28. 1980 Growth related hormones in idiopathic scoliosis. An endocrine
basis for accelerated growth. Acta Orthop Scand 51:779-780
Willner S, Nilsson KO, Kastrup K, Bergstrand CG29.  1976 Growth hormone and somatomedin
A in girls with adolescent idiopathic scoliosis. Acta Paediatr Scand 65:547-552
Diene G, de Gauzy JS, Tauber M30.  2008 Is scoliosis an issue for giving growth hormone to
children with Prader-Willi syndrome? Arch Dis Child 93:1004-1006
Goldstone AP, Holland AJ, Hauffa BP, Hokken-Koelega AC, Tauber M31.  2008
Recommendations for the diagnosis and management of Prader-Willi syndrome. J Clin
Endocrinol Metab 93:4183-4197
Odent T, Accadbled F, Koureas G, Cournot M, Moine A, Diene G, Molinas C, Pinto G,32. 
Tauber M, Gomes B, de Gauzy JS, Glorion C 2008 Scoliosis in patients with Prader-Willi
Syndrome. Pediatrics 122:e499-503
Tanner JM, Whitehouse RH33. 1976 Clinical longitudinal standards for height, weight, height
velocity, weight velocity, and stages of puberty. Arch Dis Child 51:170-179
Fredriks AM, van Buuren S, Burgmeijer RJ, Meulmeester JF, Beuker RJ, Brugman E,34. 
Roede MJ, Verloove-Vanhorick SP, Wit JM 2000 Continuing positive secular growth change
in The Netherlands 1955-1997. Pediatr Res 47:316-323
Fredriks AM, van Buuren S, Wit JM, Verloove-Vanhorick SP35. 2000 Body index measurements
in 1996-7 compared with 1980. Arch Dis Child 82:107-112
Boot AM, Bouquet J, de Ridder MA, Krenning EP, de Muinck Keizer-Schrama SM36.  1997
Determinants of body composition measured by dual-energy X-ray absorptiometry in Dutch
children and adolescents. Am J Clin Nutr 66:232-238
107
C
ha
pt
er
 5
Boot AM, Nauta J, de Jong MC, Groothoff JW, Lilien MR, van Wijk JA, Kist-van Holthe37.
JE, Hokken-Koelega AC, Pols HA, de Muinck Keizer-Schrama SM 1998 Bone mineral
density, bone metabolism and body composition of children with chronic renal failure, with and
without growth hormone treatment. Clin Endocrinol (Oxf) 49:665-672
Hokken-Koelega AC, Hackeng WH, Stijnen T, Wit JM, de Muinck Keizer-Schrama SM,38.
Drop SL 1990 Twenty-four-hour plasma growth hormone (GH) profi les, urinary GH excretion, 
and plasma insulin-like growth factor-I and -II levels in prepubertal children with chronic renal
insuffi ciency and severe growth retardation. J Clin Endocrinol Metab 71:688-695
Cohen J39. 1988 Statistical Power Analysis for the Behavioral Sciences. 2 ed. Hillsdale New 
Jersey: Lawrence Erlbaum Associates

Chapter 6
Randomized controlled GH trial: Effects on anthropometry,
body composition, and body proportions in a large
group of children with Prader-Willi syndrome
Dederieke A.M. Festen
Roderick F.A. de Lind van Wijngaarden
Mariëlle van Eekelen
Barto J. Otten
Jan Maarten Wit
Hugo J. Duivenvoorden
Anita C.S. Hokken-Koelega
Clinical Endocrinology 2008;69:443-451
Randomized controlled trial: Effects of GH treatment
110
Abstract
Background: Prader-Willi syndrome (PWS) children have impaired growth, and abnormal
body composition. Previous 1-year controlled studies showed improvement of height and
body composition during GH treatment.
Objective: To evaluate growth, body composition and body proportions during GH treatment
in a large group of PWS children.
Design and patients: We performed a randomized controlled GH trial in 91 prepubertal
PWS children (42 infants, 49 children, aged 3-14 years). After stratifi cation for age, infants
were randomized to GH treatment (GH-group; 1 mg/m2·day; N=20), or no treatment
(control group; N=22) for 1 year. In the second year all infants were treated with GH. After 
stratifi cation for BMI, children >3 years of age were randomized to GH treatment (GH-group;
1 mg/m2·day; N=27) or no treatment (control group; N=22) for 2 years. Anthropometric
parameters were assessed once in every 3 months. Body composition was measured by
Dual Energy X-ray Absorptiometry.
Results: Median (interquartile range, iqr) height SDS increased during 2 years of GH in
infants from -2.3 (-2.8 to -0.7) to -0.4 (-1.1 to 0.0) and in prepubertal children from -2.0 (-3.1
to -1.7) to -0.6 (-1.1 to -0.1). In non-GH-treated children height SDS did not increase. Head
circumference improved during 1 and 2 years of GH in infants and children, respectively.
Body fat percentage and body proportions improved in GH-treated children, but did not
completely normalize. Lean body mass SDS improved compared to the control group.
Serum IGF-I increased to levels above the normal range in most GH-treated children.
Conclusions: Our randomized study shows that GH treatment in PWS children signifi cantly
improves height, BMI, head circumference, body composition and body proportions. PWS
children are highly sensitive to GH, suggesting that monitoring of serum IGF-I is indicated.
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Introduction
Prader-Willi Syndrome (PWS) is a genetic disorder, caused by either a microdeletion on the
paternally derived chromosome 15q11-13 or a uniparental maternal disomy affecting the
same region.1 In rare cases, PWS is due to an imprinting centre mutation2 which results in
silencing of genes that are normally active in the paternally inherited chromosome 15q11-
13. PWS is characterized by muscular hypotonia, psychomotor delay, short stature and
feeding diffi culties in infancy. After the age of 2-4 years, excessive appetite may result in
rapid weight gain and obesity. Most of the characteristic features of PWS are thought to
result from hypothalamic dysfunction.3
Several endocrine abnormalities have been reported, including GH defi ciency and
hypogonadotropic hypogonadism.4 Twenty years ago, GH treatment was suggested to 
improve growth velocity in children with PWS.5 Nowadays, studies are available, showing 
that GH treatment improves growth velocity in GH-defi cient PWS children6-8 or in PWS
children treated irrespective of their GH status.9 The largest uncontrolled GH-study in PWS
children to date showed no change in BMI SDS, however, there was a wide variability in
GH dosage and age at start of study between children.10 In addition, body composition
improved, that is, body fat percentage decreased and lean body mass (LBM) (expressed in
kg) increased during 1 year of GH treatment.7,11,12
We hypothesized that GH treatment would normalize height, BMI and improve body
composition, both after correction for sex and age, and after correction for sex and height,
respectively. We therefore evaluated a large group of 91 not severely overweight PWS
children, according to a 1- and 2-year controlled design in infants and children, respectively.
We evaluated effects of GH on growth, LBM and body fat percentage, head circumference
(primary outcome measures), and body proportions (secondary outcome measures).
Patients and methods
Patients
Ninety-one patients were included in our randomized controlled GH trial. Forty-two children
below 3.5 years at start of study (infant group) were treated in a 1-year controlled study.
Forty-nine prepubertal children over 3.5 years at start of study (pre-pubertal group) were
treated in a 2-year controlled study. All participants fulfi lled the following inclusion criteria:
(i) genetically confi rmed diagnosis of PWS; (ii) age between 6 months and 14 years at
start of study; (iii) bone age <14 years (girls) or 16 years (boys); (iv) prepubertal at start of 
study, defi ned as Tanner breast stage ≤2 for girls and testicular volume <4 ml for boys13 and
with age below 12 or 14 years in girls or boys, respectively. Patients with noncooperative
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behavior or patients receiving medication to reduce fat were excluded, but in this group,
no patients were excluded for these reasons. Children were regularly seen by a dietician
and physiotherapist. The caloric intake and activity level of all children were standardized
at 3 months prior to start of study. Compliance to diet and exercise was evaluated by the
research nurse (MvE), in close collaboration with the dietician and the physiotherapist. All
children were naïve to GH treatment at the start of study. They were included irrespective
of their GH secretory status. Prior to randomization, infants were stratifi ed for age and
children (>3.5 years) for BMI. All participants were randomized to GH treatment (GH-group)
or no GH treatment (control group). A double blind placebo-controlled study was considered
unethical. The GH-group received recombinant human GH (Genotropin, Pfi zer, New York,
NY) 1 mg/m2 s.c. daily at bedtime.
The study protocol was approved by the Medical Ethics Committees of the 20 participating
Dutch centers. Written informed consent was obtained from the parents and children over 
12 years of age.
Anthropometry
At baseline, and at 3-monthly intervals, anthropometric measurements were performed.
Height (or supine length), and sitting height (only in children >3.5 years) were obtained
using a Harpenden stadiometer and a sitting height table. Weight was measured on an
accurate scale. Left foot length, left tibia length and span width were measured according
to Cameron14 using a Harpenden anthropometer. The mean of three measurements was
used for analysis. All measurements were obtained by three observers (DF, RdL, MvE).
Height, body mass index (BMI), and head circumference were expressed as SDS, adjusting
for age and sex.15,16 BMI and SDS of BMI, height, sitting height, head circumference, foot
length, span width and tibia length were calculated with Growth Analyser version 3.0 (www.
growthanalyser.org)
Body composition
Dual energy X-ray Absorptiometry (DXA, type Lunar Prodigy, GE Healthcare, Chalfont St
Giles, UK) was performed in all children and total fat mass, fat percentage and LBM were
measured. Fat mass, fat percentage and LBM were transformed into SD-scores adjusting
for sex and age (LBMage).
17 As body composition, particularly LBM, is strongly related to
height, LBM expressed as SDS for age and sex might result in an underestimation in short
stature. For this reason, LBM was also adjusted for height and sex (LBMheight). LBMheight SDS
was computed by comparing LBM of PWS children with LBM of healthy children with the
same height and sex. Reference values were obtained using the same instrumentation and
software.17 Because reference data for DXA (Lunar Prodigy) were not available for children
aged 0-4 years, only children >4 years were included in this analysis.
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IGF-I and IGFBP-3
Blood samples were collected in the morning after a 12 h overnight fast, immediately
centrifuged and stored at -20°C until assayed. Samples were pooled and assayed in one
session, to minimize variation. Serum IGF-I and IGFBP-3 were measured using a specifi c
RIA in one laboratory.18 The intra-assay CV was 4% and the interassay CV was 6%. For 
IGF-I and IGFBP-3, sex- and age-matched Dutch references were available. Because of 
the age- and sex dependency, IGF-I and IGFBP-3 levels were transformed to SDS.
Statistical analysis
Statistical analysis was performed by the Statistical Package for Social Sciences (SPSS
Version 11.0, Chicago, IL). Most of our data were not Gaussian distributed, and therefore
expressed as median (interquartile range, iqr). Differences compared to baseline within
groups were calculated using Wilcoxon signed rank test. Differences in change compared
to baseline between groups were calculated using Mann-Whitney U tests. We used
Bonferroni’s correction for multiple testing for both inter- and intra-individual testing. We
used the binomial test to compare results of SD-scores in PWS children with healthy
reference data (0 SDS). Correlations were calculated using Spearman’s rank correlation
coeffi cient (rho).
Results
Infants
Clinical charactheristics
Table 1 lists the characteristics of 42 PWS infants and toddlers. After 1 year, 31 of them
were re-evaluated (11 did not complete 1 year of study). After 1 year, the control group also
started with GH. After 2 years, 24 of them were re-evaluated (seven did not complete the
second year of study) (Figure 1). Infants with repeated measurements had similar BMI SDS
and height SDS compared to infants who did not yet fi nish 2 years of study. Infants with
repeated measures were, however, older (p=0.025), which might refl ect early diagnosis of 
PWS during recent years. One infant of the GH-treated group received T4 therapy for low
free T4 levels prior to start of GH. Fifteen infants had a paternal deletion, 13 had uniparental
maternal disomy, and in 14, PWS was confi rmed by a positive methylation test, but the
underlying genetic defect was yet unknown.
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Control
N=15
GH  
N=21 
Control Control 
N=15
At start
After 1 year 
After 2 years 
Prepubertal subjects included in the study
April 2002- April 2006
N =91
                                             Excluded: N=2
– CPAP, psychosis, scoliosis
– High IGF-I levels
2-year controlled study
47 prepubertal children 
(>3.5 years at start)
1-year controlled study
42 infants 
(<3.5 years at start)
Not yet completed 
first year 
N=11 N=21
Not yet completed 
first year 
N=5
GH
N=12
GH
N=12
Not yet completed 
second year 
N=7
GH  
N=20
Control 
N=20
Not yet completed 
second year 
N=2
Figure 1. Flow chart of eligible patients.
Height, BMI, and head circumference
At start, BMI was not signifi cantly different from 0 SDS, but all other median SD-scores were 
signifi cantly below 0 (Table 1). Anthropometric parameters were similar in the two groups 
(Figure 2a-c). Median head circumference SDS was relatively high compared to height 
SDS: -0.8 versus -2.3 SDS in the GH-treated group and -1.1 versus -2.1 in the control 
group.
In the GH-treated group, median height SDS increased signifi cantly after 1 and 2 years 
(Table 1, Figure 2a). After 2 years of GH, all infants had a height SDS above -2 SDS. In the 
control group, median height SDS remained low in the fi rst year, but increased signifi cantly, 
when GH was started in the second year (Figure 2a). Also median head circumference SDS 
increased accordingly (Figure 2c). BMI SDS increased progressively in both groups, but 
remained within the normal range in most patients (Figure 2b).
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Figure 2 a-c. Anthropometric data in PWS infants, during 2 years of follow-up. In the fi rst
year only the GH group received GH treatment; during the second year both groups were
treated. Data are expressed in SDS for age and sex and represented by boxplots. The lower 
boundary is the 25th percentile and the upper boundary is the 75th percentile. The line in the
box represents the median. Lines are drawn from the smallest observed value to the largest
observed value that is not an outlier. Open circles are outliers. Signifi cantly different compared
with baseline 1p<0.05, 2p<0.01, 3p<0.005, 4p<0.001. Signifi cantly different change in GH group
vs. control group: height SDS after 12 months (p<0.001) and after 24 months (p<0.05), head
circumference after 12 months (p<0.001).
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Figure 3 a-c. Anthropometric data in pre-pubertal PWS children, during the 2-year controlled
study. Data are expressed in SDS for age and sex and represented by boxplots. Signifi cantly
different compared with baseline: 1p<0.05, 2p<0.01, 3p<0.005, 4p<0.001. Signifi cantly different
change in GH-treated group versus the control group: height SDS after 12 months (p<0.001)
and after 24 months (p<0.001), BMI SDS after 12 months (p<0.001) and after 24 months
(p<0.005), head circumference after 24 months (p<0.05).
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Body composition in pre-pubertal PWS children, during the 2 year controlled
study. Data are expressed in SDS for age and sex or SDS for sex and height and represented
by boxplots. Signifi cantly different compared with baseline: 1p<0.05, 2p<0.01, 3p<0.005,
4p<0.001. Signifi cantly different change in GH-treated group versus the control group: LBMage
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121
C
ha
pt
er
 6
IGF-I and IGFBP-3 levels
IGF-I increased during GH treatment to a median above +2 SDS (Table 1). After 1 year 
of GH treatment, 8 of 12 infants (67%) had an IGF-I level >+2 SDS, and after 2 years, 5
of 7 (71%). In the control group, IGF-I only increased during GH in the second year, with
6 of 7 (86%) infants having an IGF-I level >+2 SDS. IGFBP-3 levels increased during GH
treatment, but remained low during the fi rst year in the control group. However, as IGFBP-3
levels remained within the normal range during GH, the IGF-I to IGFBP-3 ratio increased
from -0.9 to 2.4 after 2 years (p=0.056) in the GH-treated group and from -0.3 to -1.1 after 
1 year without GH to 2.5 after 1 year of GH (p=0.056) in the control group.
Prepubertal children
Clinical characteristics
Of the 49 prepubertal PWS children, two were excluded from the present analysis. In one
patient, GH dose was reduced because IGF-I levels increased to +5 SDS. A second patient
had spinal surgery for scoliosis, CPAP for sleep-related breathing disorders, and Risperdal
after he had two psychotic episodes, all prior to start of GH. As a result, 47 children were
eligible for baseline analysis. After 1 year, 42 were re-evaluated (21 in the GH-treated group
and 21 in the control group), and after 2 years 40 of them were re-evaluated (20 in the GH-
treated group and 20 in the control group) (Figure 1). Children with repeated measurements
had similar SD-scores of BMI and height compared to those who did not yet fi nish 2 years
of study. Three children (one in the GH-treated group and two in the control group) received
T4 replacement therapy prior to start of GH to correct low free T4 levels.
Twelve children had a paternal deletion, 14 had a uniparental maternal disomy, and 5 had
an imprinting centre mutation. In 16 patients, PWS was confi rmed by a positive methylation
test, but the underlying genetic defect was unknown.
Height, BMI, and body proportions
At start of study, BMI was signifi cantly higher than 0 SDS. Ten out of 47 children (21%)
were considered overweight, defi ned as BMI > +2 SDS. All other median SD-scores were
signifi cantly below zero (Table 2). Head circumference SDS, however, appeared to be
relatively high compared to other anthropometric parameters. At start, height SDS and BMI
SDS were highly correlated (r=0.44, p=0.002), but neither height SDS nor BMI SDS were
related to IGF-I SDS. Baseline anthropometric parameters were not signifi cantly different
between the GH-treated and control group.
During GH treatment, median height SDS increased signifi cantly compared to baseline after 
1 and 2 years (Table 2). In the control group, who did not receive GH for 2 years, height
SDS remained low (Figure 3a). BMI SDS decreased signifi cantly during the fi rst year of GH
treatment and then stabilized, at a level that was not signifi cantly higher than 0 SDS (p=0.08
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and p=0.12 after 1 and 2 years, respectively), whereas in the control group BMI remained
signifi cantly higher than 0 SDS (Figure 3b). Head circumference increased signifi cantly
to completely normal values during GH treatment (Figure 3c), whereas tibia length, foot
length, arm span and sitting height signifi cantly improved, but remained signifi cantly lower 
than 0 SDS (Table 3).
Body composition
At start of study, LBM corrected for age and sex (LBMage), and for height and sex (LBMheight)
was signifi cantly below 0 SDS and body fat percentage was signifi cantly higher than 0 SDS
in the total group. During GH treatment, median LBMage SDS increased signifi cantly from
-1.7 to -0.5 after 1 year, and to -0.1 (p=0.10 cmopared to baseline) after 2 years, resulting in
a LBMage not signifi cantly below 0 SDS after 1 and 2 years of GH treatment (Table 3, Figure
4a). In the control group, LBMage SDS signifi cantly declined over time from -1.9 to -2.5 after 
2 years and body fat percentage remained high. However, LBM corrected for height and
sex, LBMheight SDS, did not signifi cantly increase in the GH-treated group from -1.7 to -1.5
to -1.9 after 2 years (Figure 4b). Notably, in the control group there was a progressive and
signifi cant decrease in LBMheight SDS from -1.4 to -1.9 to -1.3, resulting in a signifi cantly
different change in LBMheight between the GH-treated group and the control group after 1
and 2 years. Median body fat percentage SDS decreased signifi cantly from 2·1 to 1·5 to 1·9
but body fat percentage was still signifi cantly higher than 0 SDS, after 1 and 2 years of GH
(Figure 4d). Trunk fat (%) decreased signifi cantly in the fi rst year of GH, and increased in
the second year to a level still signifi cantly below baseline. In contrast, in the control group,
trunk fat increased gradually, resulting in signifi cantly higher levels after 2 years.
IGF-I and IGFBP-3
IGF-I SDS was signifi cantly lower than 0 at start of study (Table 1). After 1 year of GH
treatment, IGF-I SDS had signifi cantly increased, and remained high. After 2 years, 17 of 
19 children (89%) had IGF-I SDS above +2. IGF-I SDS remained low in the control group,
with levels below 0 SDS during 2 years. During GH treatment, IGFBP-3 also increased, but
not to the same SDS as IGF-I.
Safety aspects
GH was well tolerated. Compared to randomized controls, children with GH treatment
did not show disadvantageous effects of GH on carbohydrate metabolism, sleep-related
breathing disorders and thyroid hormone levels. The results of these safety aspects have
been published separately.19-21
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Discussion
Our study demonstrates that height and head circumference signifi cantly increased in
GH-treated infants and children, resulting in a complete normalization after 2 years of GH
in prepubertal PWS children. Also length of foot and tibia, arm span, sitting height and
body fat percentage improved in GH-treated children. LBM, corrected for sex and age,
signifi cantly improved. LBM corrected for height and sex (LBMheight) did not increase during
GH treatment, but signifi cantly declined in non-GH-treated controls. Thus, GH appeared
to prevent reduction in LBM as seen in the controls. During GH-treatment, IGF-I levels
increased to levels above normal ranges in many patients. Also, IGFBP-3 increased, but to
a lesser extent, resulting in an increased IGF-I to IGFBP-3 ratio.
Median height SDS and IGF-I SDS, prior to start of GH treatment, were relatively low
compared to previously reported levels.7,11,22 This may be explained by the fact that our 
PWS children were not severely overweight in contrast to previously reported studies.
In non-syndromal obese children, stimulated GH values are low as well as the 24-h GH
secretion, but IGF-I levels are high or normal.23,24 It might be that in more severely obese
PWS children, the low IGF-I levels are counteracted by the obesity-related IGF-I increase. 
Head circumference SDS was less depressed than median SD-scores of height, foot length,
arm span and sitting height. This was in contrast to our expectations, because usually,
in syndromal short stature, head circumference and other anthropometric parameters
are equally or more impaired. Our results are in line with previous studies in young PWS
children.12,25
Two years of GH-treatment resulted in a normal median height SDS, whereas height SDS
in non-GH-treated children remained low. This is in line with previous studies11,26,27 although 
so far, no 2-year controlled studies were available.
The most important effect of GH, in our opinion, is the prevention of loss of LBM as was
found in the non-GH-treated children. Low LBM in PWS most likely refl ects a reduced muscle
mass, and may therefore contribute to clinical hypotonia, poor physical performance, and
as a result, reduced energy expenditure.4 LBM corrected for height and sex (LBMheight), did 
not increase during GH-treatment, LBMheight did signifi cantly decrease in the control group, 
which suggests that GH prevents reduction in LBM. The decrease in LBM in non-GH-treated
PWS children is in line with previous studies.28 In previous GH studies, LBM was expressed
in kilograms, not taking into account height-dependency of LBM. Only one study expressed
LBM in SDS (for both height and age) in GH-treated PWS subjects compared to baseline.29
Our study is the fi rst one showing that, although LBMheight did not increase in the GH-treated 
group, loss of LBMheight was prevented by GH.
Trunk fat percentage decreased during GH-treatment and increased in the control group,
indicating that GH decreases trunk fat percentage. However, trunkal fat percentage includes
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both subcutaneous trunk fat and visceral fat. It remains to be established whether GH-
treatment is benefi cial for decreasing visceral fat in PWS children.
It has previous been suggested that a normalization of small hands and feet during GH-
treatment, would suggest that those features are the result of GH defi ciency rather than
directly caused by the genetic defect.26 Our results, however, show that the size of the feet,
arm span and sitting height improve, but do not normalize during GH-treatment, indicating
that GH defi ciency cannot fully explain these features. We did not measure hand length,
because in our experience, a reliable assessment of hand length is diffi cult in young PWS
subjects.
During GH, median IGF-I levels rapidly increased to levels above the upper limit of normal,
whereas IGFBP-3 increased more gradually to levels completely within the normal range.
IGFBP-3 is the major carrier protein of IGF-I and binds 70-95% of IGF-I as a binary complex
or as a ternary complex together with the acid labile subunit (ALS).30 Only a minor fraction
of IGF-I circulates in its free form, which is considered the biologically active form.31 An
increase of the IGF-I to IGFBP-3 ratio therefore suggests a large increase in free IGF-I.
IGF-I levels in the supraphysiological range are in line with those reported by others in
prepubertal PWS children and infants/ toddlers.7,22,32 In one of our patients, the GH dose had
to be decreased in order to keep IGF-I levels within reasonable limits. It is not known why
PWS patients seem more responsive in terms of IGF-I than GH defi cient children.33 In our 
study, samples were collected and stored, as all assessments were performed afterwards.
We therefore did not adjust GH dose in most children. Based on our data, we do now
recommend to monitor IGF-I levels regularly, to prevent extremely high levels of IGF-I. One
might consider treating PWS subjects with a lower GH dose. However, it has previously
been shown that in order to optimally benefi t the metabolic effects of GH, PWS children
should be treated with at least 1 mg/m2·day.34 Future studies should evaluate the optimal
GH dose in PWS children. 
In conclusion, GH resulted in a signifi cant improvement of height, BMI and head circumference,
in PWS children. Foot length, arm span, tibia length, sitting height and body fat percentage
also improved signifi cantly, but did not completely normalize. GH appeared to prevent
reduction in LBM, as was found in the controls. IGF-I levels increased to supraphysiological
levels in most PWS children, indicating that PWS children are highly sensitive to GH and
that monitoring of IGF-I is warranted to keep IGF-I levels within reasonable limits.
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Abstract
Background: Bone mineral density (BMD) is unknown in children with PWS, but is
decreased in adults with PWS. In patients with growth hormone (GH) defi ciency, BMD
increases during GH treatment.
Objectives: To evaluate BMD in children with PWS and to study the effects of GH
treatment.
Design: We conducted a randomized controlled GH trial. Forty-six prepubertal children
were randomized into either a GH-treated group (1.0 mg/m2·day) or a control group for two
years. At start, 6, 12, and 24 months of study, total body and lumbar spine BMD (BMDTB
and BMDLS) were measured by Dual-Energy X-ray Absorptiometry (DXA) and bone mineral
apparent density (BMADLS) was calculated. 
Results: Baseline BMDTBSDS and BMDLSSDS were normal [mean ± SD: -0.2 ± 1.1 and
-0.4 ± 1.2 SDS, respectively]. BMADLSSDS, which corrects for short stature, was also
normal [mean ± SD: 0.40 ± 1.1 SDS]. BMDTBSDS decreased during the fi rst six months
of GH treatment (p<0.0001), but increased during the second year of GH treatment. After 
24 months of study, BMDTBSDS, BMDLSSDS, and BMADLSSDS did not signifi cantly differ 
between GH-treated children and randomized controls (p=0.30, p=0.44, and p=0.47,
respectively). Results were similar when corrected for BMISDS. Repeated measurements
analysis showed a signifi cant positive association between IGF-I SDS and BMDTBSDS and
BMDLSSDS, but not with BMADLS.
Conclusions: Our results show that prepubertal children with PWS have a normal BMD.
GH treatment had no effect on BMD, except for a temporary decrease of BMDTBSDS in the
fi rst 6 months.
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Introduction
Prader-Willi syndrome (PWS) is characterized by hypotonia, short stature, hyperphagia,
hypogonadism, scoliosis, psychomotor delay, and temper tantrums.1-7 PWS results from
the lack of expression of the paternally derived chromosome 15q11-q13.3,6 Hypothalamic 
dysfunction may be responsible for many features of PWS.8,9 Growth hormone (GH) treatment 
is benefi cial for children with PWS, as it improves height, body composition (increase in
lean body mass, decrease in fat percentage) and psychomotor development.10-15
Bone mineral density (BMD) is the result of the equilibrium between bone formation and bone
resorption. Adequate mineral acquisition during childhood is important for reaching peak
BMD in late adolescence. A decreased peak BMD is a major determinant for osteoporosis
and fracture risk later in life. Adequate gonadal hormone levels during pubertal development
are vital for attainment of peak BMD.16,17 In cross-sectional studies of adults with PWS, BMD
was decreased in 60% to 90% of subjects.18-20 In addition, osteoporosis is considered a
supportive fi nding in the diagnostic criteria of adult PWS.2 The decreased BMD may account
for the higher risk of fractures during life and complications during spinal surgery.3,18,20-22
Although childhood is the critical period for bone accumulation, reports on BMD in children
with PWS are very limited.12,23,24 Due to short stature in children with PWS, true BMD is 
underestimated by the standard areal measurement and should be corrected for bone size
by calculating lumbar spine bone mineral apparent density (BMADLS).
25-29 As evaluation
of BMD was not included in the aims of previous studies in children with PWS,12,23,24 a
correction for short stature was never applied and BMADLS was never reported. 
Patients with PWS have many symptoms resembling GH defi ciency, including short stature,
small hands and feet, an increased fat percentage, a decreased lean body mass, and low
IGF-I levels.6,7,30,31 In patients with GH defi ciency, BMD is decreased but normalizes during
GH treatment.27,28 However, GH and IGF-I secretion are usually more affected in GH-
defi cient children than in those with PWS.7 The effects of GH treatment on BMD in children
with PWS are unknown.
The aims of our study were to evaluate BMD and BMADLS in prepubertal children with PWS 
and to investigate the effects of GH treatment. We hypothesized that the low BMD in adult
patients with PWS is mainly the result of hypogonadotropic hypogonadism and only partly
due to GH insuffi ciency. We therefore expected BMD and BMAD to be within the low-normal
range in our group of prepubertal children and expected a small effect of GH treatment.
To investigate our hypotheses, we performed the present study within our randomized
controlled GH trial in prepubertal children with PWS.
Bone mineral density and GH treatment
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Methods
Patients
The study population comprised 46 prepubertal children with a genetically confi rmed
diagnosis of PWS by positive methylation test. At time of inclusion, girls were 4 to 12 years
old with Tanner breast stage <2 and boys were between 4 and 14 years with Tanner genital
stage <2 and a testicular volume <4 ml.32 None of the children had onset of puberty during
24 months of study. Caloric intake and activity level of all participants were standardized
three months before inclusion. All children were naïve to GH treatment at start of study.
The study protocol was approved by the Medical Ethics Committees of the Erasmus
University Medical Center / Sophia Children’s Hospital in Rotterdam, The Netherlands, and
of collaborating centers. Written informed consent was obtained from parents and from
children over 12 years of age. Assent was obtained from children under 12 years of age.
Design
The primary objective of our study was to evaluate total body and lumbar spine BMD standard
deviation scores (BMDTB SDS and BMDLS SDS) and lumbar spine bone mineral apparent
density SDS (BMADLS SDS) in prepubertal children with PWS. The secondary objectives
were to investigate the effects of GH treatment on BMD and to study the relationship
between scoliosis and BMD. After stratifi cation for age and BMI, all children were randomly
assigned either to a GH-treated group (1.0 mg/m2·day) or a control group for two years.
Biosynthetic GH (Genotropin, Pfi zer, New York) was administered subcutaneously once
daily at bedtime. The fi rst four weeks of GH treatment, children received 0.5 mg/m2·day
to prevent fl uid retention. Three-monthly, children were seen by the PWS research team
of the Dutch Growth Research Foundation in collaboration with pediatric endocrinologists
and pediatricians. At each visit, the GH dose was corrected to the calculated body surface
area.
All measurements described in this study were performed in the Erasmus University Medical
Center Rotterdam / Sophia Children’s Hospital, at start and at 6, 12, and 24 months of 
study.
Dual-Energy X-ray Absorptiometry
In all children, bone mineral content (BMC, grams), bone mineral density of the total body
and the lumbar spine (BMDTB and BMDLS, grams/cm
2), fat mass, and lean body mass
(LBM), were measured by Dual-Energy X-ray Absorptiometry (DXA, type Lunar Prodigy, GE
Healthcare, Chalfont St. Giles, UK). Quality assurance was performed daily. The coeffi cient
of variation (CV) was 0.64% for BMC and BMDTB and 1.04% for BMDLS. The CV for lean
tissue and fat tissue was 1.57% to 4.49% and 0.41% to 0.88%, respectively. In children
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with short stature, true BMD is underestimated by the areal presentation and should be
corrected for bone size by calculating the bone mineral apparent density (BMADLS).
26
BMADLS was calculated using the model: BMADLS = BMDLS · [4 / (π · width)], with the width
as the mean width of the second to fourth lumbar vertebral body. This model has been
extensively validated by in vivo volumetric data obtained from magnetic resonance imaging
of the lumbar vertebrae.26 BMD standard deviation scores were calculated according to 
age- and sex-matched reference values from the Dutch population.33,34
Fat mass was expressed as percentage of total body mass. Fat percentage SDS and LBM
SDS were calculated according to sex- and height-matched reference values of the Dutch
population.33,34
Anthropometrics
Standing height was measured with a Harpenden Stadiometer (Holtain Ltd., Crosswell,
UK). Weight was assessed on an accurate scale (Servo Balance KA-20-150S). HeightSDS
and BMISDS were calculated with Growth Analyser 3.0 (available at www.growthanalyser.
org), according to age- and sex-matched reference values from the Dutch population.35
Scoliosis
At start and subsequently each year, standardized posteroanterior X-rays were taken in
standing position. Scoliosis is defi ned as a spinal curve with a Cobb angle of more than 10°
on a posteroanterior radiograph. The Cobb angle is the angle between the two steepest
vertebrae, i.e. the upper border of the upper vertebra in the curve and the lower border of 
the lower vertebra. As previously reported,36,37 Cobb angles were measured independently 
by two observers with minimal intra- and inter-observer variance (intraclass correlation
coeffi cient=0.998 and 0.97, respectively).
Assay
Serum IGF-I levels were measured using an immunometric technique on an Advantage
Automatic Chemiluminescence System (Nichols Institute Diagnostics, San Juan Capistrano,
California). The intra-assay coeffi cient of variation (CV) was 4% and the inter-assay CV was
6%. IGF-I SDS was calculated according to age- and sex-matched reference values of the
Dutch population.38
Data analysis
Statistical analyses were performed with SPSS 15.0 (SPSS Inc., Chicago, Illinois, USA) and
with SAS 9.1 (SAS Institute Inc., Cary, North Carolina). All data had a normal distribution,
based on a p-value above 0.05 with Levene’s test for normal distribution. Therefore, all data
were expressed as means with standard deviations (SD). To correct for multiple testing,
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the changes over time and differences between GH-treated children and randomized
controls were analyzed using repeated measures of variance.39 Repeated measurements
analysis was also performed to investigate the effects of different variables on BMD during
study. Additional analyses were performed correcting for the effect of BMISDS on BMD
parameters. Effects are presented as β with 95% confi dence intervals (C.I.). SD-scores
were compared with -2, 0, and +2 SDS using Student’s one sample t-test. P-values less
than 0.05 were considered statistically signifi cant.
Results
Baseline
Clinical data
Forty-six prepubertal children with PWS (21 boys, 25 girls) were included in our randomized
controlled GH trial (Table 1). At start of study, the mean (SD) age was 7.1 years (2.2). The
genotype was specifi ed in 40 children: 18 (45%) had a deletion of chromosome 15q11-q13,
17 (43%) a maternal uniparental disomy, and 5 (13%) an imprinting center defect. Positive
methylation test was demonstrated in the remaining 6 patients, but the underlying genetic
defect was not identifi ed. Children had short stature, with a baseline height signifi cantly
below -1 SDS (p<0.0001). Baseline BMI was high, but still signifi cantly lower than 2 SDS
(p<0.0001). Body composition showed an increased fat mass and decreased lean body
mass. Twenty-two children had a baseline IGF-I SDS below -2 SDS.
Bone mineral density
Bones in the total body consist for 80% of cortical bone, whereas the lumbar spine mainly
consists of trabecular bone. Therefore, BMD was divided into total body and lumbar spine
BMD (BMDTB and BMDLS). At baseline, the mean ± SD BMDTB was -0.23 SDS ± 1.1, which
did not signifi cantly differ from 0 SDS (Table 2, Figure 1). The mean ± SD baseline BMDLS
was -0.44 SDS ± 1.2. Baseline BMDLS SDS was signifi cantly lower than 0 SDS (p=0.01),
but still signifi cantly higher than -2 SDS (p<0.0001). BMDLS SDS correlated signifi cantly with
age (r=0.38, p=0.01, Figure 1). In children with PWS, BMD should be corrected for height
by calculating the lumbar spine bone mineral apparent density (BMADLS). The mean ± SD
baseline BMADLS was 0.40 SDS ± 1.1, which was even signifi cantly higher than 0 SDS
(p=0.02), but still signifi cantly lower than 2 SDS (p<0.0001).
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Figure 1. Scatterplots depicting baseline results on the y-axes and age on the x-axes. All
circles represent values at baseline. BMDTB SDS, total body bone mineral density SDS; BMDLS
SDS, lumbar spine bone mineral density SDS; and BMADLS SDS, lumbar spine bone mineral
apparent density (volumetric BMDLS) SDS.
BMISDS was associated with BMDTB SDS [β (95% C.I.)=0.35 (0.06-0.65), p=0.02], BMDLS
SDS [β (95% C.I.)=0.73 (0.46-0.99), p<0.0001], and BMADLS SDS [β (95% C.I.)=0.33
(0.02-0.64), p=0.04]. The normal BMD in prepubertal children could be related to the
high-normal BMISDS. We therefore calculated the BMD parameters after correction for 
BMISDS. Corrected for BMISDS, the BMDTB SDS and BMDLS SDS were within normal
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range with a mean ± SD of -0.70 ± 1.0 and -1.40 ± 0.9 SDS, respectively. The BMADLS
was -0.04 ± 1.1 SDS when corrected for BMISDS and did not signifi cantly differ from 0
SDS (p=0.88). This indicates that prepubertal children with PWS have a normal BMD,
independently from BMISDS.
BMDTB SDS, BMDLS SDS, and BMADLS SDS did not signifi cantly differ between boys and
girls, nor between children with different genotypes. Furthermore, BMDTB SDS, BMDLS SDS,
and BMADLS SDS did not signifi cantly differ between children with an IGF-I level below -2
SDS and those with a level above -2 SDS and did not correlate with IGF-I levels and IGF- I
SDS.
Twenty children (44%) had scoliosis at start of study, defi ned as a Cobb’s angle of 10° or 
above. The mean ± SD baseline Cobb angle was 22.6 ± 12.5 degrees. BMDTB SDS, BMDLS
SDS, and BMADLS SDS did not signifi cantly differ between children with scoliosis and those
without.
Growth hormone treatment
Effects on height, BMI, body composition, and IGF-I levels
HeightSDS increased in GH-treated children and was signifi cantly higher than in randomized
controls at 6, 12 and 24 months of study (Table 1). In contrast to the control group, BMISDS
decreased in GH-treated children during the fi rst year and was still signifi cantly lower than
baseline after 24 months of study. LBMSDS signifi cantly increased during the fi rst year 
of GH treatment, but returned to baseline values thereafter. In contrast, the LBMSDS of 
the control group declined continuously during 24 months of study. Fat percentage SDS
signifi cantly decreased during GH treatment, but did not signifi cantly change in the control
group. Also, IGF-I SDS signifi cantly increased in GH-treated children, but did not change in
randomized controls.
Effects of GH treatment on BMDTB
BMDTB SDS fl uctuated in GH-treated children, whereas it did not signifi cantly change
in randomized controls (Table 2 and Figure 2). In the GH-treated group, BMDTB SDS
signifi cantly decreased during the fi rst six months of treatment (p<0.0001), but did not
signifi cantly change during the second six months of treatment. BMDTB SDS increased
during the second year of GH treatment (p=0.04 compared to randomized controls). After 
24 months of study, BMDTB SDS did not signifi cantly differ between GH-treated children and
randomized controls.
The fl uctuation in BMDTB SDS may be the result of a disturbed equilibrium between bone
expansion and mineral acquisition. Concurrently with the temporary decrease in BMDTB
SDS during the fi rst six months, the total body bone area increased signifi cantly more in
GH-treated children than in randomized controls (p=0.001). Although the increase in total
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body bone area during the second six months and the second year also was signifi cantly
greater in GH-treated children compared to randomized controls (p=0.02 and p=0.001,
respectively), the BMDTB SDS did not signifi cantly differ between GH-treated children and
randomized controls after 24 months of study. This indicates that the equilibrium between
bone expansion and mineral acquisition had restored.
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Figure 2. Results depicted as means with error bars representing 95% confi dence intervals.
BMDTB SDS, total body bone mineral density SDS; BMDLS SDS, lumbar spine bone mineral
density SDS; and BMADLS SDS, lumbar spine bone mineral apparent density (volumetric
BMDLS) SDS. Circles, GH-treated group; Squares, control group.
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Results in Table 2 were similar when corrected for BMISDS.
Repeated measurements analysis showed a signifi cant positive association between IGF-I
SDS and BMDTB SDS at 24 months of study [β (95% C.I.)=0.17 (0.06-0.29), p=0.004]. LBM
and fat mass corrected for age and gender were both signifi cantly associated with BMDTB
SDS [β=0.05 (0.01-0.09), p=0.01; and β=0.05 (0.02-0.07), p=0.0001, respectively].
Effects of GH treatment on BMDLS
BMDLS SDS did not signifi cantly change during study, both in GH-treated children and in
randomized controls (Table 2 and Figure 2). Thus, BMDLS SDS did not signifi cantly differ 
between GH-treated children and randomized controls after 24 months of study, nor did the
change in BMDLS SDS.
The lumbar spine mainly consists of trabecular bone, which has a higher rate of bone
turnover than cortical bone.25 The equilibrium between bone formation and bone expansion
is therefore earlier restored in trabecular bone. We found no signifi cant fl uctuation in
BMDLS SDS during 24 months of study, while the increase in lumbar spine bone area was
signifi cantly greater in GH-treated children than in randomized controls. 
BMISDS was signifi cantly associated with BMDLS SDS during 24 months of study [β
(95% C.I.)=0.36 (0.19-0.53), p<0.0001]. After correction for BMISDS, the BMDLS SDS at
24 months of study was signifi cantly greater compared to baseline in GH-treated children,
but not in randomized controls (p=0.009 and p=0.55, respectively). However, corrected for 
BMISDS, there was no signifi cant difference in BMDLS SDS at 24 months of study between
GH-treated children and randomized controls (p=0.19).
IGF-I SDS was signifi cantly associated with BMDLS SDS at 24 months of study [β
(95% C.I.)=0.19 (0.05-0.35), p=0.01]. LBM and fat mass corrected for age and gender were
both signifi cantly associated with BMDLS SDS [β=0.08 (0.03-0.12), p=0.002; and β=0.05
(0.02-0.08), p=0.002, respectively].
Effects of GH treatment on BMADLS
BMADLS is the BMD corrected for height. BMADLS SDS did not signifi cantly change
during study, both in GH-treated children and in randomized controls (Table 2 and Figure
2). Therefore, BMADLS SDS did not signifi cantly differ between GH-treated children and
randomized controls after 24 months of study. Results in Table 2 were similar when corrected
for BMISDS.
IGF-I SDS was not associated with BMADLS SDS during 24 months of study (p=0.62).
Furthermore, LBM and fat mass corrected for age and gender were not signifi cantly
associated with BMADLS SDS.
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Discussion
Our study shows that BMDTB, BMDLS, and BMADLS are normal in prepubertal children with
PWS. BMADLS SDS, which corrects for short stature, was even signifi cantly above zero
SDS, indicating that BMD is not decreased in prepubertal children with PWS. 
The normal BMADLS SDS is in contrast to results from cross-sectional studies in adults,
showing osteoporosis in a high percentage of them.18-20 These studies, however, did not 
correct for the short stature of persons with PWS. It is on the other hand likely that adults with
PWS do have a decreased BMADLS as the prevalence of osteoporosis in older subjects with 
PWS is up to 90% and associated complications are frequently reported.18-20 Presumably,
there is a change from a normal BMADLS SDS in prepubertal children towards a low BMADLS
SDS in adults. We postulate that this decrease results from delayed and abnormal pubertal
development due to hypogonadotropic hypogonadism in many patients with PWS, which
will lead to a lack of increase in BMD and a lower peak bone mass. As hypogonadotropic
hypogonadism more often affects men than women with PWS, it would be interesting to
investigate whether the prevalence of a decreased BMD in adults with PWS varies with
gender. Unfortunately, no data are available regarding gender-specifi c BMD in adults with
PWS. In prepubertal children with PWS, our results show no effect of gender on BMD.
The mean BMISDS in our group of children was within normal range, but was higher than 0
SDS. Although BMISDS was signifi cantly associated with BMD parameters, BMADLS did not
signifi cantly differ from 0 SDS after correction for BMISDS. This indicates that prepubertal
children with PWS have a normal BMD, independently from BMISDS. We did not measure
DHEAS levels in our patients. Other studies have demonstrated high levels of DHEAS
in children with PWS,40,41 which may contribute to the normal BMD demonstrated in our 
patients.42
We evaluated the effects of GH treatment on BMD. BMDTB SDS signifi cantly decreased
during the fi rst six months of treatment, whereas the total body bone area increased
signifi cantly more in GH-treated children than in randomized controls. This fi nding suggests
that the rate of bone expansion is higher than the rate of mineral acquisition. This has also
been suggested in studies of other patient populations.27,28 In contrast to bones in the total 
body which consist for 80% of cortical bone, the lumbar spine mainly consists of trabecular 
bone which has a higher rate of bone turnover.25 Therefore, the equilibrium between bone
expansion and mineral acquisition is earlier restored, which most likely explains why no
signifi cant decrease in BMDLS SDS was found during the initial phase of GH treatment
despite a signifi cantly higher increase of lumbar spine bone area in GH-treated children.
The decrease in BMDTB SDS in our study was temporary and we found no signifi cant 
difference in BMDTB SDS between GH-treated children and randomized controls after 24
months of study. The fl uctuation in BMDTB SDS during GH treatment was not described by
Bone mineral density and GH treatment
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Carrel et al. and Myers et al.,12,23 who studied a group of infants and toddlers with PWS.
Their data suggested a normal BMDTB and no effect of GH treatment on BMDTB in young
children with PWS. However, as measurements were not performed at six months of study,
a fl uctuation in BMDTB could not be detected. Additionally, our results suggest that long-term
GH treatment might increase BMDTB SDS as well as BMDLS, suggested by the signifi cant
positive association with IGF-I SDS at 24 months of study. We have evaluated BMADLS as
the best presentation of true BMD in children with PWS.29 Our study showed that BMADLS
SDS did not signifi cantly change during GH treatment and was not signifi cantly associated
with IGF-I SDS. Children with GH defi ciency have a low BMD which normalizes during GH
treatment. In contrast, baseline BMD is not decreased in prepubertal children with PWS.
Therefore, it is not unexpected to fi nd no effect of GH treatment on BMD in this patient
population. As BMADLS SDS did not signifi cantly change during the study, we conclude that
GH treatment has no signifi cant effect on BMD in prepubertal children with PWS during 24
months of study. Future research evaluating the effect of GH treatment on BMD in children
with PWS and hypogonadotropic hypogonadism is warranted.
In line with other reports,43,44 LBM and fat mass corrected for age and gender were signifi cantly
associated with BMDTB SDS and BMDLS SDS. In contrast to reports on adolescents with
idiopathic scoliosis,45 we found no signifi cant difference in BMD between children with
scoliosis and those without. Thus, our study shows that the high prevalence of scoliosis in
children with PWS36,37,46 is not caused by a decreased BMD.
In conclusion, our study shows that prepubertal children with PWS have a normal BMDTB
SDS, BMDLS SDS, and BMD corrected for short stature (BMADLS SDS). BMDTB SDS
temporarily decreased during the fi rst six months of GH treatment. After 24 months of study,
BMDTB SDS, BMDLS SDS, and BMADLS SDS did not signifi cantly differ between GH-treated
children and randomized controls.
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Abstract
Context: Reports on the cardiovascular and metabolic risk profi le in children with PWS
and the effects of GH treatment are scarce. Acylation stimulating protein (ASP) stimulates
glucose uptake and triglyceride storage in adipose tissue.
Objectives: To study the metabolic and cardiovascular risk profi le and ASP levels and to
investigate the effects of GH treatment.
Design: Randomized controlled trial: infants and prepubertal children received GH
(1 mg/m2·day) or were followed as controls for 12 and 24 months, respectively. 
Patients: Eighty-fi ve children with PWS; mean ± SD age of 4.9 ± 3.0 years.
Main outcome measures: Fat% with DXA, blood pressure, fasting insulin and glucose
levels, serum lipids, and ASP levels.
Results: Mean ± SD fat% was 28.4 ± 6.2 in infants and 36.9 ± 8.5 in prepubertal children.
Fat%SDS was elevated in 95% of prepubertal children. In addition to high fat%, 63% of 
infants and 73% of prepubertal children demonstrated at least one cardiovascular risk factor.
The metabolic syndrome was demonstrated in 5% of all children; at least one component
was present in 40%. Mean ± SD baseline ASP was 107 ± 45 nmol/l (normal<58 nmol/l) and
correlated with fat mass and TG levels. GH improved fat%SDS and the HDLc/LDLc ratio
(p<0.0001 and p=0.04). GH had no effect on ASP levels.
Conclusions: Many children with PWS have dyslipidemia and high ASP levels. GH improves
fat% and HDLc/LDLc, but not ASP. High ASP levels may prevent complete normalization
of fat%SDS during GH treatment, but may contribute in keeping glucose and insulin levels
within normal range.
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Introduction
Prader-Willi syndrome (PWS) is characterized by hypotonia, short stature, hyperphagia,
hypogonadism, scoliosis, psychomotor delay, and temper tantrums.1-8 PWS results from
the lack of expression of the paternally derived chromosome 15q11-q13 caused either 
by a deletion, uniparental disomy, imprinting center defect, or a balanced translocation.3,6
Hypothalamic dysfunction may be responsible for many features of PWS.9-11
The prevalence of cardiovascular disease is increased in adult patients with PWS, resulting
in increased mortality.12-15 Microcirculatory dysfunction may be present at an early age.16
Children with PWS have an unfavorable body composition, with a high fat percentage (fat%),
even in underweight infants.6,17-21 A high fat% is considered a risk factor for cardiovascular 
disease and diabetes mellitus type 2. However, there is limited knowledge about the
presence of other cardiovascular and metabolic risk factors in young children with PWS.
Dyslipidemia may be present, also before puberty.22,23 In contrast, insulin resistance is less
than expected based on the degree of obesity, with higher adiponectin levels compared to
obese controls but still lower than lean controls.24-26 Growth hormone (GH) treatment has a
benefi cial effect on body composition by decreasing fat%, but reports about the effects on 
serum lipids are very scarce.22,23
Adipose tissue is a metabolically active organ producing numerous proteins, enzymes, and
hormones. Acylation stimulating protein (ASP) is a hormone generated through activation
of the alternative complement pathway from the precursor protein C3 and is produced by
adipocytes.27 ASP stimulates free fatty acid incorporation into adipose tissue by increasing 
triglyceride synthesis and storage and increases glucose uptake through enhanced
translocation of glucose transporters to the plasma membrane surface.28-32 These effects are
both additive and independent of those of insulin.30-32 Furthermore, ASP reduces triglyceride
lipolysis in adipocytes by inhibiting hormone-sensitive lipase.33 By controlling the storage of 
triglycerides, ASP is an important factor in keeping lipid levels within normal range. 
In obesity, insulin resistance, dyslipidemia, and cardiovascular disease, ASP and serum
triglyceride levels are both increased, suggestive of ASP resistance.34-38 In vitro, this is
demonstrated by reduced specifi c binding and response to ASP of cells from subjects with
high ASP levels.39,40 Thus, ASP is an important marker for abnormal lipid metabolism and
accumulation of fat tissue, whereas high ASP levels are associated with increased risk
factors for cardiovascular disease.27,36,38
There is a paucity of data regarding the cardiovascular and metabolic risk factors in young
children with PWS and the effect of GH treatment on these risk factors. In view of the
abnormal body composition in young children with PWS, we hypothesized that these
children may have an unfavorable cardiovascular and metabolic risk profi le, even at an early
age. Based on the lipolytic effect of GH, we hypothesized that GH might have favorable
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effects on these risk factors. The increased fat mass in patients with PWS6,17-21 may result
in high ASP levels. Given its critical role in triglyceride storage into adipose tissue, high
ASP levels may in turn contribute to the sustainment of an increased fat mass. The high
fat mass in children with PWS does not completely normalize during GH treatment.17-21
We hypothesized that in children with PWS high ASP levels may be involved in preventing
complete normalization of fat mass during GH treatment. We therefore expected no effect
of GH on ASP levels. We assessed the cardiovascular and metabolic risk profi les and ASP
levels in prepubertal children with PWS and investigated the effects of GH treatment on
these factors in a randomized controlled trial.
Methods
Patients
The study population comprised of 85 children with a genetically confi rmed diagnosis of PWS
by a positive methylation test. The study group was divided in an infant and a prepubertal
group. The infant group consisted of 35 children (21 boys and 14 girls) aged 6 months to
3 years. The prepubertal group consisted of 50 children: 26 girls aged 3.5 to 12 years with
Tanner breast stage <2 and 24 boys aged 3.5 to 14 years with Tanner genital stage <2 and
a testicular volume <4 ml.41 None of the children had onset of puberty during 24 months of 
study. Caloric intake and activity level of all participants were standardized three months
prior to inclusion. All children were naïve to GH treatment at start of study. The study protocol
was approved by the Medical Ethics Committee of the Erasmus University Medical Center 
/ Sophia Children’s Hospital in Rotterdam, The Netherlands. Written informed consent was
obtained from parents and from children over 12 years of age. Assent was obtained from
children between 4 and 12 years of age.
Design
The primary aim of our study was to assess the cardiovascular and metabolic risk profi le
and ASP levels in children with PWS. The secondary aim was to investigate the effects of 
GH treatment on cardiovascular and metabolic risk factors and ASP levels.
Cardiovascular risk factors were defi ned as a systolic or diastolic blood pressure >2 SDS or 
dyslipidemia (TC, LDLc, TG, or Lp(a) levels above normal range; HDLc levels below normal
range). Metabolic risk factors were defi ned as a BMISDS >2 SDS; systolic or diastolic
blood pressure >2 SDS; triglyceride level ≥1.7 mmol/l; HDLc level <1.03 mmol/l; glucose
≥5.6 mmol/l; based on the criteria for children by Weiss et al.42 and De Ferranti et al.43 and
revised by the International Diabetes Federation.44 The metabolic syndrome was defi ned as
the presence of at least three metabolic risk factors. Fat% and ASP levels were described
separately.
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Infants and prepubertal children were randomly allocated to either a GH-treated or a control
group for one and two years, respectively. Biosynthetic GH (1.0 mg/m2·day, Genotropin, 
Pfi zer, New York) was administered subcutaneously once daily at bedtime. The fi rst four 
weeks of GH treatment, children received 0.5 mg/m2·day to prevent fl uid retention. Three-
monthly, children were seen by the PWS research team of the Dutch Growth Research
Foundation in collaboration with local pediatric endocrinologists and pediatricians throughout
The Netherlands. At each visit, the GH dose was adjusted to the calculated body surface
area. All anthropometric measurements were performed in the Erasmus University Medical
Center Rotterdam / Sophia Children’s Hospital, at start and at 6, 12, and 24 months of study.
Assays were performed in a central laboratory.
Anthropometrics and blood pressure
Standing height was measured with a Harpenden Stadiometer and supine length with a
Harpenden Infantometer (Holtain Ltd., Crosswell, UK). Weight was assessed on an accurate
scale (Servo Balance KA-20-150S). SD-scores (SDS) for height and body mass index (BMI)
were calculated with Growth Analyser 3.0 (available at www.growthanalyser.org), according
to age- and sex-matched reference values from the Dutch population.45
Systolic and diastolic blood pressure were measured while in a sitting position. The mean
of two measurements was used for analysis. Because height is an important determinant of 
blood pressure in childhood, blood pressure SDS was calculated according to height- and
sex-matched reference values.46 None of the children received antihypertensive therapy.
Dual energy x-ray absorptiometry
Fat% and LBM were measured by dual energy x-ray absorptiometry (type Lunar Prodigy,
GE Healthcare, Chalfont St. Giles, UK). Quality assurance was performed daily. The
coeffi cients of variation for fat tissue and lean mass were 0.41% to 0.88% and 1.57% to
4.49%, respectively. Fat mass was expressed as percentage of total body mass. Fat%SDS
and LBMSDS were calculated for children ≥87 cm, according to height- and sex-matched
reference values from the Dutch population.47,48
Assays
Fasting blood samples were collected for measurement of serum insulin-like growth factor I
(IGF-I), insulin, glucose, total cholesterol (TC), high- and low-density lipoprotein cholesterol
(HDLc and LDLc), triglycerides (TG), lipoprotein a [Lp(a)], ASP, and C3 levels.
Serum IGF-I levels were measured using an immunometric technique on an Advantage
Automatic Chemiluminescence System (Nichols Institute Diagnostics, San Juan Capistrano,
California), with an intra- and interassay CV of 4% and 6%, respectively. IGF-I SDS was
calculated.49 Serum TC, HDLc, LDLc, TG, and Lp(a) levels were determined on an Abbott
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Architect analyzer (type ci8200, Abbott Diagnostics, Abbott Park, IL), with an intra and
interassay CV <5%. Serum insulin levels were measured by immunoradiometric assay
(Medgenix, Biosource Europe, Nivelles, Belgium) with an intra- and interassay CV of 2%
to 4.7% and 4.2% to 11.3%. Serum glucose levels were assessed on an Abbott Architect
Clinical Chemistry Analyzer (Abbott Diagnostics, Abbott Park, IL), with an intra- and
interassay CV of 0.7% and 0.8%.
Plasma ASP was measured using a sandwich ELISA immunoassay method as previously
described in detail 35, with an intra- and interassay CV of <4% and <8%, respectively. C3
was measured by immunonephelometry.
Elevated levels were defi ned as: TC >5.0 mmol/l; LDLc ≥3.2 mmol/l; TG ≥1.7 mmol/l;
Lp(a) ≥300 mg/l; glucose ≥5.6 mmol/l; insulin ≥15 mU/l; ASP >58 nmol/l; and C3 >1.45 g/l.
Reduced HDLc was defi ned as levels <1.03 mmol/l.
Homeostatic model assessment of insulin resistance (HOMA-IR) was performed using the
model HOMA-IR=(fasting insulin x fasting glucose)/22.5.50 The atherogenic index of plasma
(AIP) was calculated with the model AIP=Log(TG/HDLc).51 A higher HOMA-IR and higher 
AIP are associated with a higher risk for metabolic and cardiovascular disease.50, 51
Data analysis
Statistical analyses were performed with SPSS 15.0 (SPSS Inc., Chicago, Illinois, USA)
and with SAS 9.1 (SAS Institute Inc., Cary, North Carolina). Data were normally distributed
according to Levene’s test and were therefore expressed as mean ± standard deviation
(SD). Two analyses were performed: one for prepubertal children during 24 months and
one for the total group during 12 months of study. Differences at baseline were calculated
with Student’s t-tests and chi-square tests. The changes over time were corrected for 
age and gender and were analyzed using repeated measures of variance in order to
correct for multiple testing.52 Effects are presented as β with 95% confi dence intervals
(C.I.). Spearman’s correlation coeffi cients were calculated. P-values less than 0.05 were
considered statistically signifi cant.
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Results
The total group consisted of 85 children with a mean ± SD age of 4.9 ± 3.0 years. Thirty-six
children (48%) had a deletion of chromosome 15q11-q13, 34 (45%) a uniparental disomy,
and 5 (7%) an imprinting center defect. Positive methylation test was demonstrated in the
remaining 10 patients, but the underlying genetic defect was not identifi ed. In the infant
group (Table 1), the baseline heightSDS was low-normal, with 49% having a height below -2
SDS. The mean ± SD baseline BMISDS was 0.13 ± 1.7. Nine infants (26%) had a baseline
IGF-I SDS below -2 SDS.
In the prepubertal group (Table 1), 30 children (60%) had a baseline height below -2 SDS.
The mean ± SD baseline BMISDS was 1.33 ± 1.0. Twenty-one children (42%) had an IGF-I
level below -2 SDS. 
Baseline
Infant group (0-3 years)
The mean ± SD baseline fat% was 28.41 ± 6.2. Mean ± baseline systolic and diastolic
blood pressure SDS was normal (Table 2); only one infant had an elevated systolic blood
pressure.
TC levels were elevated in 26% of infants, whereas 33% had elevated LDLc levels and 11%
had reduced HDLc levels. Lp(a) levels were elevated in 31% of infants. In 63% of infants
at least one of the following factors was present: systolic or diastolic blood pressure > 2
SDS; elevated serum TC, LDLc, TG, or Lp(a) levels; or reduced HDLc levels; indicating an
unfavorable cardiovascular profi le in addition to a high fat%. In 33% of infants, at least two
of these factors were present.
Fasting glucose levels were elevated in two children with a fat% of 31% and 35% (Tables 2
and 3). Serum insulin levels were normal in all infants. BMI was above 2 SDS in 5 children
(Table 3). None of the infants met the criteria for metabolic syndrome in children.42-44
However, 43% of infants had at least one component of the metabolic syndrome.
ASP levels were elevated in 68% of children (Table 2) and were signifi cantly higher than the
normal value of 58 nmol/l (p=0.002). C3 levels were elevated in 46% of infants.
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Prepubertal group (3-12/14 years)
The mean ± SD fat% in prepubertal children was 36.88 ± 8.5, which corresponded with 2.81
± 0.5 SDS (Table 2). The fat%SDS was signifi cantly higher than 2 SDS (p<0.0001). Notably,
the fat%SDS was elevated in 95% of prepubertal children, who had a signifi cantly higher 
fat% than infants (p<0.0001). The mean ± SD systolic blood pressure SDS was normal,
but 12% of prepubertal children had an elevated systolic blood pressure. Diastolic blood
pressure was normal in all children. TC levels were elevated in 35% of prepubertal children,
whereas 46% had elevated LDLc levels and 20% had reduced HDLc levels. Lp(a) levels
were elevated 11%. In 73% of prepubertal children at least one of the following factors
was present: systolic or diastolic blood pressure >2 SDS; elevated serum TC, LDLc, TG,
or Lp(a) levels; or reduced HDLc levels; indicating an unfavorable cardiovascular profi le
in addition to an elevated fat%SDS. In 49% of prepubertal children, at least two of these
factors were present.
Fasting glucose levels were elevated in one child, whereas insulin levels were elevated
in another child, both with a fat% of 3.1 SDS (Tables 2 and 3). Prepubertal children had
signifi cantly higher insulin levels than infants (p=0.001). Although fat%SDS was elevated
in 95% of prepubertal children, BMISDS was elevated in 24% (Table 3). Therefore, three
children met the criteria for metabolic syndrome listed in Table 3. These three children,
aged 3.9, 7.6 and 7.6 years, had a fat% of 3.0 to 3.1 SDS and a BMISDS of 2.6 to 3.7 SDS.
Notably, 41% of prepubertal children demonstrated at least one component of the metabolic
syndrome. When an elevated fat%SDS was included as a criterion instead of BMISDS, 95%
demonstrated at least one metabolic risk factor, whereas 43% demonstrated at least two
metabolic risk factors.
ASP levels were signifi cantly higher than normal (p<0.0001), with 94% of prepubertal
children having elevated ASP levels (Table 2). C3 levels were elevated in 44% of prepubertal
children.
Cardiovascular and metabolic risk profi le
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Table 3. The metabolic syndrome in children with PWS.
Total Infants Prepubertal 
children
Total N (%) Total N (%) Total N (%)
BMI > 2 SDS 85 17 (20) 35 5 (14) 50 12 (24)
SBP > 2 SDS 67  7 (10) 17 1 (6) 50   6 (12)
DBP > 2 SDS 67  0 (0) 17 0 (0) 50   0 (0)
TG ≥ 1.7 mmol/l 73  4 (6) 27 0 (0) 46   4 (9)
HDLc < 1.03 mmol/l 73 12 (16) 27 3 (11) 46   9 (20)
Glucose ≥ 5.6 mmol/l 78  3 (4) 32 2 (6) 46   1 (2)
≥ 3 criteria present 60  3 (5) 14 0 (0) 46   3 (7)
≥ 1 criteria present 60 25 (42) 14 6 (43) 46 19 (41)
Overview of the number of children fulfi lling criteria for the metabolic syndrome. Total, the total number 
of children of whom data were available. N (%), number of children fulfi lling the criterion for metabolic
syndrome. BMI, body mass index; SDS, SD-score; SBP, systolic blood pressure; DBP, diastolic blood
pressure; TG, serum triglyceride level; HDLc, serum high density lipoprotein cholesterol level. The
metabolic syndrome was defi ned as the presence of three or more risk markers.42-44
Effects of growth hormone treatment
HeightSDS and IGF-I SDS were signifi cantly higher in GH-treated infants and prepubertal
children compared to randomized controls (all p<0.0001, Table 1). BMISDS did not
signifi cantly differ between GH-treated infants and controls. In prepubertal children, GH
treatment resulted in a signifi cant decrease in BMISDS (p<0.0001).
In prepubertal children, GH treatment induced a signifi cant decline in fat%SDS during 24
months of study, corrected for age and gender [β (95% C.I.)=-0.85 SDS (-1.1 to -0.7),
p<0.0001; Table 4]. GH treatment did not result in a signifi cant change in systolic and
diastolic blood pressure SDS. Serum lipids and AIP did not signifi cantly change, but the
HDLc to LDLc ratio signifi cantly improved in response to GH [β (95% C.I.)=0.05 (0.0 to 0.1),
p=0.04]. GH had no signifi cant effect on fasting glucose and insulin levels and HOMA-IR,
nor on ASP and C3 levels.
When results were analyzed for the total group of 85 children that followed a randomized
controlled design for a shorter duration of 12 months, we found similar results. GH treatment
signifi cantly improved fat mass, fat% and the HDLc to LDLc ratio (p<0.0001, p<0.0001, and
p=0.049).
Cardiovascular and metabolic risk profi le
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Correlations
In the total group at baseline, fat mass correlated signifi cantly with systolic blood pressure
SDS, glucose and insulin levels, HOMA-IR, and ASP levels (r=0.35, p=0.005; r=0.25,
p=0.03; r=0.48, p<0.0001; r=0.48, p<0.0001; and r=0.46; p=0.001). At 12 months of study,
fat mass correlated signifi cantly with ASP levels (r=0.42, p=0.004) and with systolic and
diastolic blood pressure, when corrected for age and gender (r=0.32, p=0.02; and r=0.29,
p=0.03, respectively). Systolic blood pressure correlated with diastolic blood pressure
(r=0.43, p<0.0001). TC levels correlated inversely with the HDLc to LDLc ratio (r=-0.42,
p=0.001) and positively with TG levels (r=0.25, p=0.046), indicating that those with higher 
TC levels had a more unfavorable lipid profi le. A more favorable HDLc to LDLc ratio was
associated with a more favorable atherogenic index in plasma (r=-0.29, p=0.02). ASP levels
correlated inversely with TG levels (r=-0.32, p=0.03). IGF-I SDS did not correlate with fat
mass, but did correlate with fat% (r=-0.33, p=0.005).
Discussion
Our study shows that many young children with PWS have a high fat% and dyslipidemia,
whereas blood pressure and glucose homeostasis are normal in nearly all patients.
Furthermore, our results demonstrate two-fold higher ASP levels, which is in concordance
with the high fat%, but also coincided with normal TG levels. GH-treated children showed
signifi cant improvement of heightSDS, BMISDS, and IGF-I SDS during 12 and 24 months of 
treatment compared to randomized controls. In addition, GH reduced fat mass and fat%SDS
and increased the HDLc to LDLc ratio. GH treatment had no effect on glucose homeostasis,
serum lipids, and plasma ASP and C3 levels.
Our results demonstrate that 95% of children in the prepubertal group had a baseline fat%
above 2 SDS. Notably, fat mass corrected for age and gender was signifi cantly correlated
with systolic and diastolic blood pressure, even in this young group of children with PWS.
In 63% of infants and 73% of prepubertal children, at least one of the following factors was
present: systolic or diastolic blood pressure >2 SDS; elevated serum TC, LDLc, TG, or 
Lp(a) levels; or reduced HDLc levels; indicating an unfavorable cardiovascular profi le in
addition to the high fat%. The high prevalence of cardiovascular risk factors demonstrated
in our study, is in line with two reports in smaller groups of children with PWS.22,23 In contrast
to these studies, our results do not show a benefi cial effect of GH treatment on HDLc,
and LDLc. However, in line with Carrel et al.,22 we did fi nd a signifi cant benefi cial effect 
of GH on the HDLc to LDLc ratio. Thus, GH treatment may have a favorable effect on the
cardiovascular risk profi le by reducing fat%SDS and increasing the HDLc to LDLc ratio.
Cardiovascular and metabolic risk profi le
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About 40% of infants and prepubertal children demonstrated at least one component of 
the metabolic syndrome.42-44 Notably, 7% of children in the prepubertal group had three
or more components and could therefore be diagnosed with the metabolic syndrome. The
elevated glucose and insulin levels were found in children with a high fat%SDS or BMISDS.
This underlines the importance of monitoring insulin and glucose levels in children with
PWS, preventing excessive food intake as this may result in obesity when uncontrolled.
GH treatment, corrected for age and gender, had no signifi cant effect on serum insulin and
glucose levels and HOMA-IR, which is in line with other reports.24,26,53
Fat% and insulin levels were signifi cantly higher in prepubertal children than in infants.
However, serum lipids did not signifi cantly differ between both groups, indicating that the
unfavorable lipid profi le is most likely present from infancy onwards, although this should
be confi rmed in studies investigating neonates with PWS. Future studies may investigate
the need for and effectiveness of early pharmacological intervention in normalizing serum
lipids in children with PWS.
Our study demonstrated high ASP levels in young children with PWS, coinciding with an
increased fat mass, but normal TG levels. ASP is produced by adipose tissue and stimulates
free fatty acid incorporation into adipose tissue by increasing TG synthesis and storage
and by inhibiting hormone-sensitive lipase mediated TG lipolysis.27-33 This is shown by the
positive correlation of ASP with fat mass and the negative correlation with TG levels, as
demonstrated in our study. Thus, ASP is produced by adipose tissue, but is also involved
in the accumulation of adipose tissue. High ASP levels are suggestive of ASP resistance,
also shown in subjects with obesity, insulin resistance, dyslipidemia and cardiovascular 
disease.34-38 In subjects with ASP resistance, however, high ASP levels coincide with high
TG levels and may show a positive correlation with TG levels. In contrast, most of our 
children with PWS had normal TG levels, which correlated inversely with ASP, indicating an
effective function of ASP in TG storage. Thus, high ASP levels in PWS seem to contribute
in keeping TG levels within normal range. Furthermore, ASP increases glucose uptake
through enhanced translocation of glucose transporters to the plasma membrane surface.28-
32 We found normal glucose and insulin levels in nearly all children, despite high fat%. High
ASP levels without ASP resistance results in increased TG storage as well as in increased
glucose uptake. High ASP levels may therefore not only contribute to the high fat%, but may
also keep glucose and insulin levels within normal range, as has also been suggested for 
adiponectin.24-26
GH treatment does not result in complete normalization of fat mass in children with PWS,17-21
which suggests that GH insuffi ciency is not the only factor involved in the mechanism leading
to abnormal body composition in PWS. ASP levels were high in most children with PWS
and were not signifi cantly different between GH-treated children and randomized controls.
Furthermore, ASP levels correlated positively with fat mass and inversely with TG levels.
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This indicates that high ASP levels may contribute to the sustainment of high fat%, even
during GH treatment. Thus, the high ASP levels do not change in response GH treatment
and may play a role in preventing complete normalization of fat mass during GH in children
with PWS.
In conclusion, the majority of young children with PWS have a high fat% and dyslipidemia,
indicating an unfavorable cardiovascular and metabolic profi le. Systolic and diastolic blood
pressure were normal in most children, as well as insulin and glucose levels. As ASP
stimulates glucose uptake and TG synthesis and storage into adipose tissue, the high ASP
levels in children with PWS may contribute to the high fat%. The high ASP levels may also
keep glucose and insulin levels within normal range. GH improved fat% and the HDLc to
LDLc ratio, but had no effect on blood pressure, glucose homeostasis, and serum lipids.
The high ASP levels did not change in response to GH and may therefore contribute to the
lack of complete normalization of fat% during GH treatment in patients with PWS.
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Abstract
Background: Children with Prader-Willi syndrome have abnormal body composition and
impaired growth. Short-term growth hormone (GH) treatment has benefi cial effects.
Objectives: To investigate effects of long-term continuous GH treatment on body
composition, growth, bone maturation, and safety parameters.
Setting: A multicenter prospective trial.
Design: Fifty-fi ve children with a mean ± SD age of 5.9 ± 3.2 years were followed during 4
years of continuous GH treatment (1 mg/m2·day). Data were annually obtained in one center:
fat percentage (fat%) and lean body mass (LBM) by dual-energy x-ray absorptiometry,
height, weight, head circumference, bone age, blood pressure, and fasting IGF-I, IGFBP-3,
glucose, insulin, HbA1c, total cholesterol, HDL, and LDL. SD-scores were calculated
according to Dutch and PWS reference values (SDS and SDSPWS). 
Results: Fat%SDS was signifi cantly lower after 4 years of GH treatment (p<0.0001).
LBMSDS signifi cantly increased during the fi rst year (p=0.02), but returned to baseline
values the second year and remained unchanged thereafter. Mean ± SD height normalized
from -2.27 ± 1.2 SDS to –0.24 ± 1.2 SDS (p<0.0001). Head circumference SDS increased
from -0.79 ± 1.0 at start to 0.07 ± 1.1 SDS after 4 years. BMISDSPWS signifi cantly decreased.
Mean ± SD IGF-I and the IGF-I/IGFBP-3 ratio signifi cantly increased to 2.08 ± 1.1 and 2.32
± 0.9 SDS, respectively. GH treatment had no adverse effects on bone maturation, blood
pressure, glucose homeostasis, and serum lipids.
Conclusions: Our study in children with PWS shows that long-term continuous GH
treatment (1 mg/m2·day) improves body composition, by decreasing fat%SDS and stabilizing
LBMSDS, and head circumference SDS and normalizes heightSDS without adverse effects.
Thus, long-term continuous GH treatment is an effective and safe therapy for children with
PWS.
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Introduction
Prader-Willi syndrome (PWS) is characterized by hypotonia, short stature, hyperphagia,
hypogonadism, scoliosis, psychomotor delay, and temper tantrums.1-7 PWS results 
from the lack of expression of the paternally derived chromosome 15q11-q13, caused
by deletion, uniparental disomy, imprinting center defect, or balanced translocation.3,6
Hypothalamic dysfunction may be responsible for many features of PWS.8-10 Patients with 
PWS have symptoms resembling growth hormone (GH) defi ciency, such as increased
fat mass, decreased lean body mass, short stature, small hands and feet, a decreased
spontaneous and provoked GH secretion, low insulin-like growth factor I (IGF-I) levels,
and a positive response to GH treatment.6,7,11-18 Short-term GH treatment administered
for 1 or 2 years improves, but does not normalize, body composition by decreasing fat
percentage (fat%) and stabilizing lean body mass (LBM).12,13,15,19-25 Furthermore, it increases 
height-for-age11-14,19-22,26, improves psychomotor development in the very young, and has 
psychological and behavioral benefi ts.13,24,25,27 GH does not increase the risk for the onset
and progression of scoliosis during 2 years of treatment and has no adverse effects on 
glucose homeostasis.28, 29
Although GH has been proven benefi cial for children with PWS during 1 or 2 years of 
treatment, reports on long-term effi cacy and safety are very limited.29-32 Some studies
showed a normalization of adult height when GH treatment was started before onset of 
puberty.30,31,33,34 Carrel et al.32 showed a dose-dependent effect on height, body composition 
and resting energy expenditure. In that study, short-term metabolic effects of GH treatment 
were optimal with a dose of at least 1 mg/m2·day. However, the decreased fat% was not 
sustained with 1 mg/m2·day after 2 years. LBM persisted to increase after 2 years of GH
treatment, but SD-scores for both fat% and LBM were not calculated. It is therefore unknown 
whether the increase in lean body mass was merely the result of the increase in height or 
refl ected an increase in lean body mass SD-score.
Thus, although GH treatment seems benefi cial for children with PWS, results on long-
term GH treatment in a large group of prepubertal children, continuously treated for 
4 consecutive years with a standard dose of 1 mg/m2·day, have not been reported. We 
therefore performed a multicenter prospective follow-up study evaluating effi cacy and 
safety of long-term continuous standard-dose GH treatment in children with PWS, started 
before onset of puberty.
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Methods
Patients
Patients were initially recruited for a randomized controlled GH trial.22,28 Depending on age
and randomization, children started GH treatment either directly, or after 1 or 2 years. All
children had a genetically confi rmed diagnosis of PWS by positive methylation test and were
naïve to GH treatment at time of inclusion. In the present study, we describe a total group
of 55 children, who were prepubertal at start of GH treatment and who were prospectively
followed for 4 consecutive years. Puberty was defi ned in girls as Tanner breast stage ≥2 and
in boys as Tanner genital stage ≥2 and a testicular volume ≥4 ml.35 During 4 years of study,
nine girls and fi ve boys had either spontaneous or induced onset of puberty at a mean ±
SD age of 11.3 ± 1.3 years and 14.4 ± 1.3 years, respectively. One child died after 1 year,
most likely due to central adrenal insuffi ciency during an upper respiratory tract infection.36
Additionally, one child stopped participation, but not GH treatment, after 3 years. Data of 
these patients were included in the analyses.
Change in anthropometric results may be infl uenced by absent or delayed puberty, especially
when expressed as change in SDS according to reference values for healthy Dutch children.
We therefore also performed a subgroup analysis in 37 children who remained prepubertal
during the total study period and who were aged less than 11 years (girls) or less than 12
years (boys) at the end of the study.
Design
The primary objective of our study was to investigate the long-term effect of GH treatment
on body composition. The secondary objectives were to assess effi cacy of GH treatment
by studying the effect on height, BMI, head circumference, anthropometric data, and
bone age and to assess safety of GH treatment by studying the effect on blood pressure,
fasting serum insulin-like growth factor I (IGF-I), IGF binding protein 3 (IGFBP-3), glucose
homeostasis and serum lipids. Children participating in our multicenter prospective follow-
up study were continuously treated with somatropin 1 mg/m2·day (Genotropin, Pfi zer Inc.,
New York) for 4 consecutive years. Somatropin was administered subcutaneously once
daily at bedtime. The fi rst four weeks of GH treatment, children received 0.5 mg/m2·day to
prevent fl uid retention. Three-monthly, children were seen by the PWS research team of 
the Dutch Growth Research Foundation in collaboration with pediatric endocrinologists and
pediatricians. At each visit, the GH dose was adjusted to the calculated body surface area.
In addition, children annually visited the Erasmus University Medical Center Rotterdam / 
Sophia Children’s Hospital, Rotterdam, The Netherlands, where the following data were
obtained: fat mass, lean body mass (LBM), height, weight, head circumference, length of 
the hand, foot, and tibia, arm span, bone age, blood pressure, and fasting blood levels of 
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insulin-like growth factor I (IGF-I), IGF binding protein 3 (IGFBP-3), glucose, insulin, HbA1c,
total cholesterol, and high and low density lipoproteins cholesterol (HDL and LDL). The
study protocol was approved by the Medical Ethics Committees of the Erasmus University
Medical Center / Sophia Children’s Hospital in Rotterdam, The Netherlands, and of each
collaborating center. Written informed consent was obtained from parents and from children
over 12 years of age. Assent was obtained from children under 12 years of age.
Dual energy x-ray absorptiometry
Fat mass and lean body mass (LBM) were measured in all children by dual-energy x-ray
absorptiometry (type Lunar Prodigy, GE Healthcare, Chalfont St Giles, UK). Quality
assurance was performed daily. The coeffi cient of variation for fat tissue and lean mass
was 0.41% to 0.88% and 1.57% to 4.49%, respectively.37 Fat mass was expressed as 
percentage of total body mass (fat%). Fat%SDS and LBMSDS were calculated, according
to reference values for gender and height of the Dutch population for children with a height
above 87 cm.38,39
Anthropometry
Standing height was measured with a Harpenden Stadiometer and supine length with a
Harpenden Infantometer (Holtain Ltd., Crosswell, UK). Weight was assessed on an accurate
scale (Servo Balance KA-20-150S). In children above 3 years at start of study, length of 
the left hand, foot and tibia, and arm span were measured according to Cameron using a
Harpenden anthropometer.40 The mean of three measurements was used for analysis. All
measurements were obtained by three observers (R.F.A.d.L.v.W., D.A.M.F., and research
nurse). Target height (TH) was calculated.41 Birth weight and length were retrieved from
patient records or reported by parents. Standard deviation scores (SDS) were calculated
with Growth Analyser 3.0 (available at www.growthanalyser.org), according to age- and 
sex-matched reference values of the Dutch population and of a population with PWS.41-43
Assessment of bone maturation
Radiographs of the left hand and wrist were taken annually. Bone age was assessed by two
observers (R.F.A.d.L.v.W. and E.P.C.S.) using the method of Greulich and Pyle.44 The mean
of measurements was taken for analysis. Inter-observer variability was minimal [mean (95%
confi dence interval) difference = -0.11 years (-0.2 to 0.0); intraclass correlation coeffi cient
= 0.98, p<0.0001]. The “bone age to calendar age” ratio (BA/CA) and the “change in bone
age to change in calendar age” ratio (ΔBA/ΔCA) were calculated.
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Blood pressure
Systolic and diastolic blood pressure were measured while in a sitting position. The mean
of two measurements was used for analysis. Because height is an important determinant of 
blood pressure in childhood, blood pressure was expressed as SDS adjusted for height and
gender.45 None of the children were receiving antihypertensive therapy.
Assays
Fasting blood samples were collected for measurement of IGF-I, IGFBP-3, glucose,
insulin, HbA1c, total cholesterol, HDL and LDL. Samples were investigated in one central
laboratory.
The fi rst 2 years of study, serum IGF-I and IGFBP-3 levels were measured using an
immunometric technique on an Advantage Automatic Chemiluminescence System (Nichols
Institute Diagnostics, San Juan Capistrano, California). The intra- and interassay coeffi cient
of variation (CV) were 4% and 6%, respectively. After 2 years, IGF-I and IGFBP-3 were
measured with the Immulite 2000 (Siemens Healthcare Diagnostics, Deerfi eld, Illinois)
with an interassay CV of 6.5% and 8%, respectively. The fi rst 2 years of the study, serum
glucose levels were assessed on an Abbott Architect Clinical Chemistry Analyzer (Abbott
Laboratories, Irving, Texas), with an intra- and interassay CV of 0.7% and 0.8%. After two
years, glucose levels were measured with the Hitachi 917 (Hitachi Device Development
Center, Tokyo, Japan), detecting glucose levels between 0 and 42 mmol/liter. The fi rst
2 years, serum insulin levels were measured by immunoradiometric assay (Medgenix,
Biosource Europe, Nivelles, Belgium) with an intra- and interassay CV of 2% to 4.7% and
4.2% to 11.3%, respectively. Thereafter, insulin levels were measured with the Immulite
2000 (Siemens Healthcare Diagnostics, Deerfi eld, Illinois) with an interassay CV of 4.4%.
The fi rst 2 years, HbA1c levels were measured using an automatic HPLC analyzer (DIAMAT;
Bio-Rad Laboratories Inc., Edgemont, California) with an intra- and interassay CV of 1.3%
and 7.0%. Thereafter, HbA1c levels were measured using an automatic HPLC analyzer (HA-
8160, A. Menarini Diagnostics International, Florence, Italy) with an intra- and interassay
CV less than 3%. Serum total cholesterol, HDL, and LDL were determined enzymatically
using a homogeneous assay on a Hitachi 917.
SD-scores were calculated for IGF-I, IGFBP-3, and the IGF-I/IGFBP-3 ratio, according to
age- and sex-matched reference values from the Dutch population.46 To allow comparison
between two assays, IGFBP-3 SDS and IGF-I/IGFBP-3 SDS measured with the second
assay were converted to match samples measured with the fi rst assay by using the model:
Y = μ1 + SD1 [(X – μ2) / SD2], in which Y is the converted value of a sample with an original
value X; μ1 and μ2 are the group means of the values of the fi rst and second laboratory,
respectively; and SD1 and SD2 are the standard deviations of the values of the fi rst and
second laboratory, respectively.47 After conversion, results did not signifi cantly differ between
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assays. Homeostatic model assessment of insulin resistance (HOMA-IR) was performed
using the model HOMA-IR=(fasting insulin x fasting glucose)/22.5.48
Data analysis
Statistical analyses were performed with SPSS 15.0 (SPSS Inc., Chicago, Illinois, USA)
and with SAS 9.1 (SAS Institute Inc., Cary, North Carolina). Data are expressed as mean
± standard deviation (SD). To correct for multiple testing, the changes over time were
analyzed using repeated measures of variance.49 Repeated measurements analysis was
also performed to investigate the effects of different parameters on various outcomes.
Effects are presented as β with 95% confi dence intervals (C.I.). SD-scores were compared
with -2, 0, and +2 SDS using repeated measurements analysis and Student’s one sample
t-test. P-values less than 0.05 were considered statistically signifi cant. Effi cacy and safety of 
GH treatment was studied in the total group of children. Subgroup analyses were performed
investigating the effects of GH treatment on anthropometric results in a prepubertal group.
Results
The total group consisted of 55 children, all prepubertal at start of study, with a mean ±
SD age of 5.9 ± 3.2 years. Twenty-six (51%) had a deletion of chromosome 15q11-q13, 21
(41%) an uniparental disomy and 4 (8%) an imprinting center defect. Positive methylation
test was demonstrated in the remaining 4 patients, but the underlying genetic defect was
not identifi ed. Birth weight SDS and birth length SDS were low, but still within normal range
(Table 1). Body composition was unfavorable, as baseline fat%SDS was signifi cantly higher 
than 2 SDS and LBMSDS was signifi cantly lower than 0 SDS (both p<0.0001). Baseline
heightSDS was signifi cantly lower than 0 SDS (p<0.0001), but was normal according to
PWS reference values (heightSDSPWS). Notably, the distance to THSDS was signifi cantly
greater than 2 SDS (p=0.003). BMISDS was normal compared to Dutch and PWS reference
values. Mean IGF-I SDS and IGFBP-3 SDS were signifi cantly lower than 0 SDS.
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Table 1. Baseline characteristics.
Total group Prepubertal group
N (m/f) 55 (29/26) 37 (23/14)
Age    5.9 ± 3.2  4.1 ± 1.9
Birth weight SDS   -1.20 ± 1.1b    -1.12 ± 1.1c
Birth length SDS   -1.47 ± 2.1a -1.01 ± 1.5a
Fat%SDS    2.89 ± 0.6a  3.08 ± 0.6a
LBMSDS   -1.94 ± 2.5a -1.92 ± 3.1c
HeightSDS   -2.27 ± 1.2a -2.29 ± 1.3a
HeightSDSPWS   -0.09 ± 1.0 -0.06 ± 0.9
Distance to THSDS    2.51 ± 1.2a  2.60 ± 1.2a
BMISDS    0.92 ± 1.6a   0.64 ± 1.8d
BMISDSPWS   -0.43 ± 0.9
b -0.43 ± 0.8c
IGF-I SDS   -1.97 ± 1.1a -1.90 ± 1.0a
IGFBP-3 SDS   -2.11 ± 2.9a -2.71 ± 1.1c
Results at baseline of the total and prepubertal group. Data are expressed as mean ± SD. SDS, SD score
according to age- and sex-matched Dutch reference values41; SDSPWS, standard deviation score according
to age and sex-matched PWS reference values43; TH, target height; BMI, body mass index; IGF-I, insulin-
like growth factor type I; IGFBP-3, IGF binding protein type 3.
a p≤0.0001, b p≤0.001, c p≤0.01, d p≤0.05, compared to 0 SDS.
Effi cacy of growth hormone treatment
Body composition
Mean ± SD baseline fat% was 2.89 ± 0.6 SDS. Fat%SDS decreased signifi cantly during the
fi rst year of GH treatment to 2.14 ± 0.7 SDS (p<0.0001, Figure 1) and did not signifi cantly
change thereafter. After 4 years of treatment, fat%SDS was still signifi cantly lower than
at baseline (p<0.0001), but remained higher than 2 SDS (p=0.02). LBMSDS signifi cantly
increased during the fi rst year of GH treatment (p=0.02), but returned to baseline values
during the second year and did not signifi cantly change thereafter. After 4 years of treatment,
LBMSDS was not signifi cantly different from baseline. Thus, GH treatment stabilized
LBMSDS, but LBMSDS did not normalize as it was signifi cantly lower than -2 SDS at 4
years of study (p=0.04). Results were similar when a subgroup analysis was performed in
children that remained prepubertal throughout the study.
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Figure 1. Body composition and growth in the total group of children with PWS during 4
years of continuous GH treatment. Fat percentage SDS (fat%SDS) and lean body mass
SDS (LBMSDS) were calculated sex- and height-matched reference values from the Dutch
population.38, 39 HeightSDS and head circumference SDS according to sex- and age-matched 
reference values from the Dutch population.41,42 Error bars represent means with 95% 
confi dence intervals. *: p<0.0001, #: p<0.05, compared to baseline.
Anthropometry
HeightSDS signifi cantly increased during the fi rst 3 years of GH treatment (Table 2 and
Figure 1), but did not change during the fourth year of treatment. HeightSDS was not
signifi cantly different from 0 after 3 and 4 years of treatment (p=0.08 and p=0.16). However,
distance to target heightSDS (THSDS) remained signifi cantly greater than 0 (p<0.0001). 
Baseline head circumference was signifi cantly lower than 0 SDS (p<0.0001, Table 2 and
Figure 1). Head circumference SDS signifi cantly increased during the fi rst 2 years of GH
treatment (p<0.0001 and p=0.002) and did no longer signifi cantly differ from 0 SDS after 1
year of treatment.
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Table 2. Anthropometric values during GH treatment.
Start 1 year 2 years 3 years 4 years
To
ta
l g
ro
up
HeightSDS -2.27 ± 1.2 -1.16 ± 1.2a -0.60 ± 1.2a -0.29 ± 1.2a -0.24 ± 1.2a
HeightSDSPWS -0.09 ± 1.0 0.68 ± 1.0
a 1.16 ± 1.0a  1.50 ± 0.9a  1.65 ± 1.0a
Distance to THSDS  2.51 ± 1.2 1.47 ± 1.1a 0.93 ± 1.0a  0.63 ± 1.0a  0.55 ± 1.1a
BMISDS  0.92 ± 1.6 0.85 ± 1.4 1.14 ± 1.2d  1.22 ± 1.2d  1.29 ± 1.1d
BMISDSPWS -0.43 ± 0.9 -0.75 ± 0.9
a -0.70 ± 0.9b -0.71 ± 1.0b -0.69 ± 1.0b
HCSDS -0.79 ± 1.0 -0.18 ± 1.0a 0.06 ± 1.1a  0.03 ± 1.1a  0.07 ± 1.1a
SH/H ratio  0.44 ± 1.4 0.64 ± 1.4 -0.01 ± 1.3c  0.25 ± 1.4 -0.10 ± 1.1c
Hand length SDS -2.26 ± 1.3 -1.59 ± 1.0a -1.84 ± 1.1c -1.78 ± 0.8b -1.92 ± 1.1c
Foot length SDS -2.23 ± 1.6 -1.37 ± 1.6a -1.29 ± 1.6a -1.23 ± 1.3a -1.24 ± 1.4a
Tibia length SDS -1.44 ± 1.5 -0.93 ± 1.3c -0.76 ± 1.4b -0.86 ± 1.1b -0.97 ± 2.2c
Arm span SDS -1.78 ± 1.4 -1.19 ± 1.3a -1.07 ± 1.2a -0.97 ± 0.8a -0.96 ± 1.0a
BA/CA*  0.83 ± 0.3 0.90 ± 0.2b 0.95 ± 0.2b  1.00 ± 0.2c  1.02 ± 0.1d
ΔBA/ΔCA* 1.16 ± 0.4 1.21 ± 0.5  1.21 ± 0.5  1.19 ± 0.4
Pr
ep
ub
er
ta
l g
ro
up
HeightSDS -2.29 ± 1.3 -1.08 ± 1.3a -0.38 ± 1.2a -0.05 ± 1.2a  0.11 ± 1.1a
HeightSDSPWS -0.06 ± 0.9 0.77 ± 0.9
a 1.26 ± 1.0a  1.54 ± 1.0a  1.69 ± 1.0a
Distance to THSDS  2.60 ± 1.2 1.39 ± 1.1a 0.72 ± 1.0a  0.39 ± 1.0a  0.20 ± 0.9a
BMISDS  0.64 ± 1.8 0.78 ± 1.5 1.15 ± 1.3c  1.26 ± 1.3c  1.29 ± 1.2b
BMISDSPWS -0.43 ± 0.8 -0.68 ± 0.9
b -0.65 ± 1.0d -0.68 ± 1.0c -0.70 ± 1.0b
HCSDS -0.87 ± 1.1 -0.11 ± 1.0a 0.22 ± 1.1a  0.24 ± 1.1a  0.25 ± 1.1a
SH/H ratio  0.79 ± 1.5 0.92 ± 1.5 0.14 ± 1.4c  0.48 ± 1.5  0.08 ± 1.1c
Hand length SDS -2.17 ± 1.2 -1.39 ± 1.0b -1.61 ± 1.2d -1.57 ± 0.9c -1.52 ± 0.8b
Foot length SDS -2.25 ± 1.8 -1.26 ± 1.9a -1.18 ± 2.0a -1.17 ± 1.6a -1.22 ± 1.8a
Tibia length SDS -1.44 ± 1.3 -0.89 ± 1.4a -0.60 ± 1.5a -0.76 ± 1.0a -0.53 ± 1.2a
Arm span SDS -1.62 ± 1.5 -0.90 ± 1.4a -0.76 ± 1.4a -0.75 ± 0.8a -0.61 ± 0.8a
BA/CA*  0.73 ± 0.3 0.85 ± 0.2a 0.93 ± 0.2a  1.00 ± 0.2a  1.04 ± 0.2a
ΔBA/ΔCA* 1.28 ± 0.4 1.30 ± 0.5  1.34 ± 0.4  1.30 ± 0.4
Overview of anthropometric results in the total group and prepubertal group. Data expressed as mean ±
SD. SDS, SD score according to age- and sex-matched Dutch reference values41, 42; SDSPWS, standard
deviation score according to age and sex-matched PWS reference values43; THSDS, target heightSDS;
BMISDS, body mass index SDS. BA, bone age; CA, calendar age; ΔBA/ΔCA, ratio of change in bone age
to change in calendar age, also presented for children above 7 yrs at start of study. a p≤0.0001, b p≤0.001,
c p≤0.01, and d p<0.05, all compared to baseline. * Not signifi cant after correction for age.
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BMISDS signifi cantly increased from the second year of study onward (Table 2). However,
this increase is part of the natural development of patients with PWS. When adjusting for this
natural development by using PWS reference values, BMISDSPWS signifi cantly decreased 
during the fi rst year of GH and remained signifi cantly lower than baseline during 4 years of 
GH treatment.
The sitting height to height ratio was signifi cantly lower after 4 years of treatment than at
baseline and did not signifi cantly differ from 0 SDS. Baseline hand, foot, and tibia length
SDS, and arm span SDS signifi cantly increased during GH treatment, but remained
signifi cantly below 0 SDS.
We performed a subgroup analysis in children who remained prepubertal during study and
were less than 11 years (girls) or 12 years (boys) of age after 4 years of study. The mean
± SD age at start of study was 4.1 ± 1.9 years. In general, results in the prepubertal group
were similar, but changes were more pronounced. In this group, heightSDS signifi cantly
increased during each year of treatment (p<0.0001, p<0.0001, p<0.0001, and p=0.0009, for 
each time interval, respectively). Distance to THSDS was signifi cantly greater than 0 after 
3 years (p=0.03), but had completely normalized after 4 years of GH treatment (p=0.23,
Figure 1). Tibia length SDS did no longer signifi cantly differ from 0 after 4 years of GH
treatment (p=0.06).
Bone maturation
The baseline BA/CA ratio was signifi cantly lower than 1 (p<0.0001, Table 2). Age had a
signifi cant effect on the BA/CA and the ΔBA/ΔCA ratio (p=0.0006 and p<0.0001). At start of 
study, bone age was delayed in children under 5 year. Figure 2 shows a shift from a delayed
bone maturation in children under 5 years of age toward a normal bone maturation in those
above 7 years. Thus, bone age caught up with calendar age in children between 5 to 7
years. This is also shown by the lower mean BA/CA ratio in the prepubertal group compared
to the total group. When adjusting for the effect of age, GH treatment had no signifi cant
effect on the ΔBA/ΔCA ratio (p=0.91 and p=0.95 in the total and prepubertal group). 
Long-term effi cacy and safety of GH treatment
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Figure 2. Overview of calendar age and corresponding bone age in the total group of children
at start and during the entire study period. Circles represent individual values. The 45°
line represents perfect bone maturation. Values under the 45° line represent delayed bone
maturation and values above this line an advanced bone maturation. The fi tted line is depicted
in black.
Safety of growth hormone treatment
IGF-I and IGFBP-3
IGF-I SDS signifi cantly increased during the fi rst year of treatment to a mean (95% C.I.)
of 2.45 SDS (2.1-2.8) (Table 3). Thereafter, IGF-I levels did not signifi cantly change, but
levels tended to be lower after 4 years of study than after 1 year with a mean (95% C.I.)
of 2.1 SDS (1.8-2.4) (p=0.06). After 4 years of GH treatment, IGF-I SDS was signifi cantly
higher than at baseline (p<0.0001), but was not signifi cantly higher than 2 SDS (p=0.61).
IGFBP-3 also signifi cantly increased during the fi rst year of GH treatment and was still
signifi cantly higher after 4 years of treatment than at baseline. The IGF-I/IGFBP-3 ratio SDS
signifi cantly increased, which might indicate that more unbound IGF-I was present in the
systemic circulation. 
Glucose homeostasis
Fasting glucose and insulin levels, and HOMA-IR were signifi cantly associated with age
[β (95% C.I.)=0.03 (0.01-0.05), p=0.008; β=0.94 (0.62-1.26), p<0.0001; and β=0.21 (0.14-
0.28), p<0.0001, respectively]. Effects of GH treatment on these variables were therefore
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adjusted for age. GH treatment had no signifi cant effect on glucose and insulin levels and
HOMA-IR (p=0.65, p=0.89, and p=0.92, Table 3), or on HbA1c (p=0.79). IGF-I SDS had also
no signifi cant effect on fasting glucose and insulin levels, HOMA-IR or HbA1c levels (p=0.27,
p=0.16, p=0.18, p=0.56). Fat mass showed a positive association with fasting insulin levels
and HOMA-IR [β=0.28 (0.17-0.38), p<0.0001 and β=0.06 (0.04-0.08), p<0.0001].
Table 3. Safety parameters during 4 years of GH treatment.
Start 1 year 2 years 3 years 4 years
IGF-I SDS -1.97 ± 1.1  2.45 ± 1.3a   2.43 ± 1.0a   2.37 ± 1.2a  2.08 ± 1.1a
IGFBP-3 SDS -2.11 ± 2.9  0.05 ± 1.5a   0.67 ± 0.9a   0.73 ± 1.2a  0.58 ± 1.2a
IGF-I/BP-3 ratio SDS -0.78 ± 1.7  2.68 ± 1.0a   2.56 ± 0.9a   2.66 ± 1.0a  2.32 ± 0.9a
Glucose (mmol/L) 4.53 ± 0.5  4.49 ± 0.5   4.58 ± 0.4   4.64 ± 0.3  4.63 ± 0.4
Insulin (mU/L) 8.75 ± 6.2 10.75 ± 6.5 11.23 ± 8.0 10.96 ± 6.4 12.02 ± 7.7
HOMA-IR 1.83 ± 1.4  2.22 ± 1.4   2.44 ± 1.8   2.29 ± 1.4  2.49 ± 1.7
HbA1c (%) 5.31 ± 0.8  5.37 ± 0.4   5.30 ± 0.4   5.28 ± 0.3  5.21 ± 0.2
Total cholesterol (mmol/L) 4.56 ± 0.8  4.71 ± 1.0   4.57 ± 0.7   4.24 ± 0.6  4.31 ± 0.5
HDL (mmol/L) 1.32 ± 0.8  1.17 ± 0.2   1.20 ± 0.5   1.40 ± 0.3  1.38 ± 0.3
LDL (mmol/L) 2.92 ± 0.7  3.11 ± 0.9   2.95 ± 0.7   2.59 ± 0.6d  2.55 ± 0.4c
Systolic BPSDS 0.59 ± 0.9  0.59 ± 0.7   0.48 ± 0.7   0.46 ± 0.8  0.46 ± 0.9
Diastolic BPSDS 0.28 ± 0.8  0.48 ± 0.9   0.44 ± 0.6   0.47 ± 0.8  0.45 ± 0.6
Overview of IGF-I, IGFBP-3, bioavailability of IGF-I, glucose homeostasis, serum lipids and blood pressure 
in the total study population during 4 years of GH treatment. Data expressed as mean ± SD. SDS, SD score
according to age- and sex-matched Dutch reference values50 or according to height-matched reference 
values [blood pressure45]; IGF-I, insulin-like growth factor type I; IGFBP-3, IGF binding protein type 3. 
HOMA-IR, homeostatic model assessment of insulin resistance; HbA1c, the A1c fraction of hemoglobulin; 
HDL, high density lipoprotein cholesterol; LDL, low density lipoprotein cholesterol; BPSDS, blood pressure 
SDS.
a p≤0.0001, b p≤0.001, c p≤0.01, and d p<0.05, all compared to baseline.
Serum lipids and blood pressure
Serum total cholesterol, HDL, and LDL levels were not signifi cantly associated with age. 
Therefore, effects of GH treatment were not adjusted for age. Total cholesterol and HDL 
cholesterol did not signifi cantly change during GH treatment (Table 3). LDL cholesterol was 
signifi cantly lower after 3 and 4 years of treatment. IGF-I SDS showed a positive association 
with HDL [β (95% C.I.)=0.07 (0.01-0.13), p=0.03], but not with total cholesterol and LDL. Fat 
mass was not signifi cantly associated with any of the serum lipids.
Baseline systolic and diastolic blood pressure SDS were normal and did not change during 
4 years of GH treatment.
Long-term effi cacy and safety of GH treatment
180
Individual cases
One boy deceased after 1 year of study during a mild upper respiratory tract infection.36
As serum cortisol one hour after death was undetectable, central adrenal insuffi ciency was
suspected to be the cause of death. During a polysomnography seven months prior to his
demise, the central apnea index was only 0.9 per hour, which is considered very low for 
children with PWS.51 The death of this boy was considered not GH-related.
There were no cases of non-insulin dependent diabetes mellitus in our study population,
but one girl developed diabetes mellitus type I after 45 months of GH treatment. BMISDS
was normal (0.77) and was decreasing at the time of diagnosis, whereas gain in height
stunted. After induction of insulin therapy, glucose levels and weight normalized, and height
improved.
In one boy, height increased during 1 year of GH treatment from 1.23 SDS to 2.84 SDS with
an increase of serum IGF-I levels to 4.70 SDS. He was not excluded from GH treatment
as baseline body composition was unfavorable with an IGF-I level of -1.49 SDS. GH dose
was fi rst reduced to 0.5 mg/m2·day and later to 0.33 mg/m2·day. Finally, GH treatment was
discontinued after fi ve years. After reduction of the GH dose and discontinuation of GH
treatment, his body composition worsened. An excessive increase in gain in heightSDS
and IGF-I SDS during GH treatment occurred in three more cases. All three boys had a low
heightSDS at start of treatment. They were not included in the current analyses, as they had
not completed 4 years of GH treatment. In all cases a reduction of GH dosage suffi ced to
decrease IGF-I to levels between 2 and 3 SDS and to normalize heightSDS. GH treatment
was therefore not discontinued.
Discussion
Our multicenter prospective follow-up study in children with PWS shows that 4 years of 
continuous GH treatment with a standard dose (1 mg/m2·day) had a signifi cant favorable
effect on body composition, heightSDS, BMISDSPWS, head circumference SDS, without
signifi cant adverse effects on safety parameters. 
Fat%SDS was signifi cantly lower after 4 years of GH treatment than at baseline. LBMSDS
signifi cantly decreased during the fi rst year of GH treatment, but returned to baseline
values the second year and did not signifi cantly change thereafter. Thus, GH resulted in a
signifi cant reduction of fat%SDS and a stabilization of LBMSDS. This is in contrast to the
continuous decrease of LBMSDS in untreated children with PWS.22 Notably, although body
composition markedly improved during treatment, long-term GH did not result in a complete
normalization. This has previously been shown by Carrel et al.,32 but children participating
in that study were not continuously treated with a standard dose. The fact that long-term
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GH treatment did not normalize body composition suggests that the unfavorable fat% and
LBM are not only the result of GH insuffi ciency, but are also the result of the genetic defect
causing the syndrome. Most importantly, our study shows that the benefi cial effects of short-
term GH treatment on body composition11-14,19-26,52 persist during 4 years of treatment.
At start of treatment, heightSDS was low according to Dutch references, but normal according
to PWS references. HeightSDS signifi cantly increased during GH treatment. The distance
to THSDS did, however, not completely normalize in the total group. This effect may be due
to delayed or absent puberty in some children resulting in a lack of pubertal growth spurt.
When height is expressed as SDS, a steady gain in height during the time that healthy
children have a pubertal growth spurt results in a paradoxical decrease of heightSDS in
those with a delayed puberty. We therefore performed a subgroup analysis in a group that
remained prepubertal for 4 years. In this group, distance to THSDS completely normalized
after 4 years of GH treatment. Thus, our results indicate that 4 years of GH treatment result
in a complete normalization of heightSDS and distance to THSDS in prepubertal children.
Bone maturation was not signifi cantly affected by GH treatment. There was a shift from a
delayed bone maturation in children below 5 years of age toward a normal bone maturation
in those above 7 years. This catch-up in bone maturation might be related to adrenarche,
typically occurring early in many children with PWS.34,53 As bone age did not accelerate in 
response to GH treatment, our data suggest that a normal adult height can be reached
when long-term GH treatment is started several years before puberty.
In the general population, a lower head circumference SDS is associated with lower 
intelligence, whereas brain growth during infancy and early childhood is important in
determining cognitive function.54-56 In our study, head circumference SDS improved during
GH treatment. Improvement of mental development and psychosocial functioning during
short-term GH treatment in patients with PWS has previously been described.13,24,25,27 The
improvement of head circumference during long-term continuous GH treatment may have
persistent benefi cial effects on mental development and psychosocial functioning, but this
needs to be investigated in future studies.
It has previously been suggested that when the size of hands and feet normalize during GH
treatment, this would indicate that these features are the result of GH defi ciency rather than
due to the genetic defect.31 Our results, however, show that hand and foot length, as well as
arm span do not completely normalize during GH treatment. Tibia length only normalized
in the prepubertal group, thus when GH treatment was started at a young age. Our results
show that the main catch-up growth of hands and feet occurs during the fi rst year with little
change thereafter. Catch-up in tibia length SDS and arm span SDS may continue in the
second year of treatment reaching a plateau thereafter. These fi ndings suggest that both
GH defi ciency and the genetic defect are responsible for the smaller hands, feet, tibia, and
arm span in children with PWS.
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Mean IGF-I levels rapidly increased during GH treatment, whereas IGFBP-3 increased
more gradually. IGFBP-3 is the major carrier protein of IGF-I and binds 70-95% of IGF-I as
a binary complex or as a ternary complex together with the acid labile subunit (ALS). Only
a minor fraction of IGF-I circulates in its unbound form, which is considered the biologically
active form.57 We found an increase in the IGF-I/IGFBP-3 ratio, suggesting an increase in
free IGF-I levels. Notably, there were a few cases of children with exceptional increases of 
heightSDS and IGF-I SDS during GH treatment. One may consider individualizing the GH
dosage in order to keep IGF-I within reasonable limits. However, Carrel et al.32 reported that
metabolic effects of GH treatment in children with PWS are optimal with a dose of at least
1 mg/m2·day, whereas a dose of 0.3 mg/m2·day had no effect on LBM and fat%. Our limited
data on reduction of GH dosage or discontinuation of treatment also suggest a worsening
of body composition. Thus, GH dosage may be individualized, but caution should be taken
as lower IGF-I levels might result in a less favorable body composition with higher fat%.32
Our results show that IGF-I levels between 2 and 3 SDS result in sustained improvement
of body composition, head circumference, and normalization of heightSDS without adverse
effects.
As insulin levels and HOMA-IR increase with age in untreated prepubertal children with
PWS,58 we adjusted for age in our analysis of glucose homeostasis. GH treatment adjusted
for age had no signifi cant effect on fasting glucose and insulin levels, HOMA-IR, and HbA1c
levels in our group of 55 children. This is in line with Lindgren et al. describing normal
glucose homeostasis during fi ve years of GH treatment in 16 children without rapid weight
gain.29 Furthermore, we had no cases of non-insulin dependent diabetes mellitus. Our 
fi ndings suggest that the high prevalence of non-insulin dependent diabetes mellitus in
adult patients with PWS59 is likely due to increased fat mass. Indeed, our results show that
a signifi cant positive association of fat mass with both fasting insulin levels and HOMA-
IR is already present in childhood. These results underline the importance of achieving
normal BMI and reducing fat mass as part of the primary aims in the comprehensive care
of patients with PWS. In this respect, it is interesting to note that BMISDS according to
PWS reference values signifi cantly decreased during GH treatment. Thus, GH treatment
might have favorable effects on insulin resistance as it decreases fat mass and slows down
weight gain over the years.
GH treatment had no signifi cant effect on total cholesterol and HDL cholesterol, but LDL 
cholesterol was signifi cantly lower after 4 years of GH treatment. We therefore conclude
that GH treatment had no adverse effect on serum lipids. Furthermore, systolic and diastolic
blood pressure SDS did not signifi cantly change during 4 years of GH treatment.
In conclusion, our study shows that long-term GH treatment improves body composition
by decreasing fat%SDS and stabilizing LBMSDS. Furthermore it normalizes heightSDS
and improves head circumference SDS BMISDSPWS. In addition, hand, foot, and tibia
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length SDS, and arm span SDS all improved. Measurements of IGF-I and IGFBP-3 during
treatment are important. Children with an exceptional increase of heightSDS and IGF-I SDS
need adjustment of GH dose to attain an IGF-I level between 2 and 3 SDS. No adverse
effects on blood pressure, glucose homeostasis, and serum lipids were observed. Thus, our 
study shows that long-term continuous standard-dose GH treatment is an effective and safe
therapy for children with PWS.
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and recommendations for future research
Discussion, conclusions, and clinical implications
190
This doctoral dissertation describes studies embedded in the Dutch national growth
hormone trial for children with Prader-Willi syndrome (PWS), coordinated by the Dutch
Growth Research Foundation and performed to improve the knowledge of PWS and care
for patients with PWS. The study population consisted of children with PWS, referred to our 
center by pediatricians and pediatric endocrinologists throughout The Netherlands. Patients
were initially recruited for the multicenter randomized controlled GH trial for the duration of 
one or two years for infants and prepubertal children, respectively. After the randomized
controlled trial, all children continued growth hormone treatment in a multicenter follow-
up study (the Dutch Cohort Study). In this dissertation we present the results of 4 years
continuous GH treatment. This chapter discusses the fi ndings of our studies in view of 
the current literature. Subsequently, clinical implications of our results are presented and
recommendations for future research are provided.
10.1  Sudden death in children with Prader-Willi syndrome
10.1.1  High prevalence of central adrenal insuffi ciency
The annual mortality rate in patients with PWS is very high (3% under 30 years).1 The
sudden deaths in children often share a similar pattern: a sudden deterioration during a mild
or moderate infection, which is often – but not always – an upper respiratory tract infection.
Furthermore, a reduced adrenal size has been found during autopsies in children.2, 3 Adrenal
size may be associated with the cause and duration of the various disease states leading
to adrenal insuffi ciency.4 These fi ndings, coinciding with the presence of hypothalamic
dysregulation in patients with PWS, prompted us to hypothesize that patients with PWS
suffer from central adrenal insuffi ciency during stress. We performed a cross-sectional study,
investigating the ACTH response during a metyrapone test in 25 children. Strikingly, ACTH
levels failed to increase suffi ciently in 60% of patients (15/25), indicating central adrenal
insuffi ciency (CAI). Morning cortisol levels and diurnal cortisol rhythm were assessed on
a different day in all children who underwent a metyrapone test and demonstrated no
abnormalities. We therefore conclude that CAI becomes apparent only during stressful
conditions. The inadequate ACTH response during stress most likely contributes to the
high rate of sudden death in children with PWS. In addition to CAI, the condition of acutely
ill patients with PWS is further compromised by an increase in the number of sleep apneas
during upper respiratory tract infections (URTIs)5 and a vague clinical presentation, as they
often have an increased pain threshold and do not vomit or develop fever. Based on our 
fi ndings, a new guideline advices treatment with a hydrocortison stress dose during illness
or surgery, unless CAI has recently been ruled out with a metyrapone test.
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Four tests are widely used to investigate the integrity of the HPA-axis: the standard-
dose and low-dose ACTH tests, the insulin tolerance test (ITT) and the overnight single
dose metyrapone test (metyrapone test). ACTH tests are the most commonly used tests.
However, the ACTH tests are not be suitable for the diagnosis of partial CAI, which is the
case in patients with PWS. ACTH tests stimulate the adrenal cortex to produce cortisol.
In full-blown CAI, the adrenal cortex is chronically understimulated, resulting in adrenal
atrophy. Therefore, the cortisol response during an ACTH test is blunted. In partial CAI,
however, which occurs only during stress, the diurnal cortisol rhythms are normal, thereby
preventing adrenal atrophy. ACTH stimulation, even low-dose ACTH (1 μg, which is still
supraphysiological), may stimulate the adrenal cortex enough to produce cortisol levels
above the cut-off level for this test. Thus, ACTH tests are appropriate for general screening,
but are unsatisfactory for diagnosing CAI, because partial ACTH defi ciency may not always
result in atrophy of the adrenal cortex.6-10 Sensitivity and specifi city have been reported to
be 60-80% compared to the ITT and metyrapone test.11,12 The ITT, although highly sensitive
and specifi c, requires close medical supervision and can cause life threatening shock.9,10,13-
18 The metyrapone test is of similar or even superior quality in assessing CAI compared
to the ITT and the risk for an Addisonian crisis is much lower than with the ITT.9,13,17,19-
21 The metyrapone test is considered a safe and reliable procedure for the assessment
of CAI.14,17,19,20 Due to the suspicion of partial central adrenal insuffi ciency and the high
sensitivity and specifi city of this test, we chose to perform metyrapone tests in our patients
with PWS. Such tests should be performed in the pediatric intensive care unit, under 
continuous monitoring. Our study demonstrated low blood pressures in the early morning
hours, which supports the need for admission during the metyrapone test. Notably, no
metyrapone test had to be discontinued.
In line with literature, patients with CAI had slightly higher cortisol levels after the metyrapone
test than those without CAI.22,23 These differences could be interpreted as a reduced cortisol
inhibition and consequent ACTH response. However, there was no signifi cant difference
between the two groups in the decline of cortisol levels from 2330 h to 0400 h, in the maximally
suppressed cortisol levels (0400 h), nor in the rise of cortisol levels thereafter. Thus, cortisol
production was equally inhibited by metyrapone in both groups. A signifi cant difference in
ACTH levels was already present at 0400 h and lasted throughout the metyrapone test. The
interpretation of our results are therefore considered valid, demonstrating a high prevalence
of CAI in patients with PWS.
During the metyrapone test, blood pressure was low during early morning hours. Notably,
most sudden deaths in children with PWS occur during early morning hours.24 The decrease 
in blood pressure was demonstrated despite the absence of illness or shock, as all
metyrapone tests were performed during healthy condition. The low blood pressures during
the metyrapone test occurred in all children and correlated signifi cantly with serum cortisol
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levels. Thus, the early morning hours might be the critical period during which PWS patients
with CAI are at risk of sudden demise.
Our study showed no abnormalities in morning cortisol levels and normal cortisol diurnal
rhythm. In an invited comment, Butler et al. recently reported morning cortisol levels of 
63 patients with PWS between 0800 h and 1100 h.25 In contrast to our study, low morning
cortisol levels were found in 4 children, all ≤3 years of age. In our metyrapone study we
additionally investigated the diurnal salivary cortisol rhythm, but the youngest child included
in our study was 3.7 years old. Therefore, we have no data available on morning cortisol
levels in children with PWS ≤3 years of age. Butler et al. suggested that the transition
from the infant phase to the hyperphagic obese phase in PWS coincides with hypothalamic
changes, possibly explaining the difference in morning cortisol secretion between patients
≤3 years and those >3 years of age. Off note, the peak morning cortisol level usually occurs
within 30 minutes after wake-up, but morning cortisol levels rapidly decrease after 0800 h.
Perhaps, the low morning cortisol levels demonstrated in the study of Butler et al. refl ect the
time of measurement rather than a hypoadrenal state. Nonetheless, Butler et al. concluded
that cortisol levels in patients with PWS support changes in routine care, as advised in the
new guideline based on our fi ndings.
All of our patients who underwent a metyrapone test were treated with GH. We do not
believe that this infl uenced the outcomes of our studies. Data on relationships between
the GH-IGF-I system and the HPA-axis are contradictory.26,27 The prevalence of CAI is
not increased in GH-treated children with isolated GH defi ciency, Turner syndrome, or 
other disorders.26 Moreover, the similar death rate of PWS patients with and without GH
treatment,24,28 suggests an intrinsic rather than an extrinsic cause of CAI. Tauber et al.28
presented an interesting review of 64 cases of sudden death. In this report, a clustering
of sudden deaths was found during the fi rst 9 months of GH treatment. However, this
fi nding may be biased due to selection: one would earlier consider GH treatment of patients
in less healthy condition, aiming to support them by improving body composition and
endurance. Importantly, when patients are followed three-monthly in clinical trials, sudden
deaths are earlier noticed and better reported than of patients not participating in studies.
This increases the a priori chance of noticing sudden death during the initial phase of GH
treatment. Nonetheless, patients on GH treatment should be regularly evaluated for fl uid
retention and enlarged tonsils. In order to prevent fl uid retention, children participating in
our studies received a GH dose of 0.5 mg/m2·day, which was increased after 4 weeks to
1.0 mg/m2·day. 
In conclusion, there is a high prevalence of central adrenal insuffi ciency during stress,
which may contribute to the high mortality rate in patients with PWS. Based on our fi ndings,
a hydrocortisone stress dose should be administered to patients with PWS during stress,
unless CAI has recently been ruled out with a metyrapone test. Appendix A provides an
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example of a cortisone treatment regimen that could be applied for patients with PWS
during stress, in particular during illness or surgery.
10.1.2  Central adrenal insuffi ciency is associated with sleep-related
 breathing disorders in children with Prader-Willi syndrome
Patients with PWS often have sleep-related breathing disorders (SRBDs), consisting
of obstructive and central sleep apneas. Sleep apneas are the result of a reduction in
upper airway diameter, hypoventilation, decreased pulmonary function, and a decreased
ventilatory and arousal response during hypercapnia.5,29-33 The number of central and
obstructive sleep apneas increase during illness.5,29 Sleep apneas have been suggested to
play a role in the sudden death of patients with PWS.5,24,28,29,34 We therefore investigated the
relationship between central adrenal insuffi ciency and sleep apneas. We evaluated sleep-
related breathing during a metyrapone test and studied the difference in change of sleep-
related breathing in response to metyrapone between children later diagnosed with CAI and 
those not. Sleep-related breathing deteriorated in response to metyrapone-induced stress 
in all children, both with and without CAI. Interestingly, the deterioration was signifi cantly 
worse in children with CAI. In addition, children with CAI already had a signifi cantly higher 
central apnea index compared to those without, several months prior to the metyrapone 
test.
As patients with PWS suffer from hypothalamic dysregulations34-37, CAI is likely to result 
from an inappropriate CRH secretion by the hypothalamus. Low CRH levels have been
demonstrated to decrease EEG frequency, causing deeper sleep and less wakefulness.38
A deeper stage of sleep is associated with a higher arousal threshold.39 Possibly, children
with CAI may be more prone to have central sleep apneas due to lower CRH levels resulting
in deeper sleep and an increased arousal threshold. This may also account for the higher 
increase in oxygen-desaturation-index in response to metyrapone in children with CAI. On
the other hand, CAI during stress and a high central apnea index during health may also
be considered two independent symptoms, both resulting from a more severe degree of 
hypothalamic dysfunction.
Our group investigated sleep-related breathing in a cohort of 53 children with PWS, before
and 6 months after initiation of GH treatment.5 GH treatment had no signifi cant effect on
sleep-related breathing. Miller et al.29 investigated sleep-related breathing before and 6 
weeks after initiation of GH. In 20 children, 6 had worsening of sleep-related breathing.
However, all noteworthy changes occurred in those with an URTI. In contrast to Miller et
al.29, we interpret these as demonstrating that GH treatment has no effect on sleep-related
breathing, similar to results from our study.5 Notably, Lindgren et al.32 reported an increase in 
inspiratory drive in 9 children 6-9 months after start of GH treatment compared to baseline,
which was demonstrated by an improved ventilatory response to low pCO2 levels. Thus, we
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conclude that GH has no adverse effect on sleep-related breathing in children with PWS.
In conclusion, children with PWS and CAI during stress have a signifi cantly higher central
apnea index during healthy condition and a higher increase in central apnea index during
stress. The combination of CAI and compromised sleep-related breathing will aggravate the
deterioration of the condition of an acutely ill patient with PWS. This combination might well
be the prelude of a fatal cascade during illness.
10.1.3  A new hypothesis on sudden death in Prader-Willi syndrome
Based on our fi ndings, we present a new hypothesis on sudden death in children with PWS,
depicted in Figure 1.
Figure 1. New hypothesis on the mechanism of sudden death in patients with PWS. CAI,
central adrenal insuffi ciency; SRBD, sleep-related breathing disorder; URTI, upper respiratory
tract infection
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We postulate the following pathway leading to sudden death in patients with PWS (Figure
1): 
Due to a dysregulated hypothalamus, children are at risk for developing CAI during−
stress. In addition, this may coincide with sleep-apneas. Children at risk of CAI during
stress have a higher number of central sleep apneas, as shown in our study.
During stress, CAI occurs and sleep-related breathing may worsen, resulting in−
a deterioration of the patient’s condition. The worsening of sleep-related breathing
in response to stress is more severe in children with CAI than in those without, as
demonstrated in our study. Importantly, the deterioration of the condition of a patient
with PWS may be masked due to absence of fever and vomiting, and a decreased
pain threshold.
In children with an upper respiratory tract infection (URTI), sleep-related breathing−
can be further compromised by enlarged tonsils, causing an increase in the number 
and severity of obstructive sleep apneas. Children suffering an upper respiratory tract
infection are therefore at higher risk of sudden death than those with other infections,
which would explain why most - but not all - sudden deaths occur during URTI. 
As CAI during stress and sleep-related breathing disorders (SRBD) could be considered−
two distinct features, they may also result in sudden death independently from each
other. However, it seems logical to assume that a combination of CAI and SRBD yields
a higher risk of mortality.
10.2  Scoliosis and effects of growth hormone treatment in
children with Prader-Willi syndrome
10.2.1  Scoliosis
Information on scoliosis in PWS was limited and varied greatly.40-44 The prevalence was
estimated to be between 15% and 86%.40-44 As prospective data concerning prevalence of 
scoliosis in a large group of children with PWS not treated with GH were not available, we
investigated the prevalence of scoliosis and the effects of age, gender, body mass index
and lean body mass before start of GH treatment. Our study demonstrated a prevalence
of 30% in children under 10 years, increasing to 80% in children above 10 years of age.
Notably, in the total group, 50% of children had a Cobb’s angle above 20° and therefore
required referral to an orthopedic surgeon. We found two types of scoliosis, long C-curve
type scoliosis (LCS) and one type resembling idiopathic scoliosis (IS). LCS was mainly found
in young children, whereas children above 10 years only showed IS-type. Children with LCS
had a signifi cantly lower truncal lean body mass to body surface area ratio, compared to
those with IS, suggestive of a relationship between truncal hypotonia and LCS. Thus, the
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decreasing prevalence of LCS with increasing age, may be associated with an increase in
truncal lean body mass. This suggests that the change in predominance is partly caused by
regression of LCS-type, resulting from an increase in truncal muscle strength.
Odent et al.45 assessed the prevalence of scoliosis in a group of 145 children with PWS. That
study found an overall prevalence of about 40%, which is in line with our fi ndings. Moreover,
they had a larger adolescent population, demonstrating that nearly 70% of adolescents had
scoliosis at skeletal maturity. 
In our study, nearly 50% of adolescents diagnosed with scoliosis required conventional or 
surgical intervention. Accadbled et al.46 reported the outcome of surgical intervention in 16
patients demonstrating major complications in 9 and minor complications in 6 patients. Thus,
surgical intervention was uncomplicated in only one patient. Four of the major complications
consisted of progressing kyphosis requiring reoperation, complicated with permanent spinal
cord injury in three patients. In addition, skin picking and autism-like repetitive upper body
movements may further complicate recovery. This underlines the importance of scoliosis
surgery being performed by a skilled orthopedic surgeon experienced in spinal surgery in
patients with PWS. Comprehensive multidisciplinary care becomes even more important
during times of invasive treatment. For example, physicians, parents, and patients should
take into account the need for change of diet during a prolonged period of immobilization,
such as during recovery of spinal surgery.
In conclusion, the prevalence of scoliosis in children with PWS without GH treatment is 30%
under 10 years and 70-80% above 10 years. Young children mainly have LCS, whereas
adolescents only have IS. There is a strong association between the types of scoliosis
and age and truncal hypotonia. The number of children with PWS with moderate or severe
scoliosis is alarmingly high, resulting in many children requiring treatment.
10.2.2 Effects of growth hormone treatment on scoliosis
Accelerated growth, either spontaneous or during GH treatment, has been associated
with the onset of scoliosis and scoliotic curve progression.47-52 Scoliosis was therefore
often considered a contraindication for GH treatment. However, benefi cial effects of GH
treatment, such as increasing lean body mass, may counteract potential adverse effects
on spinal growth. It was therefore unknown whether abstinence or withdrawal of GH
treatment in children with scoliosis should also be advised for those with PWS and the
need for controlled data was emphasized.34,45,53 In the randomized controlled GH trial we
investigated the effects of GH treatment on onset and progression of scoliosis in 91 children
with PWS. Our study demonstrated no signifi cant difference between GH-treated children
and randomized controls with regard to onset of scoliosis, curve progression, and start of 
treatment of scoliosis. GH treatment, gain in heightSDS, gain in truncal LBM (used as a
proxy for gain in height), and IGF-I SDS were not associated with an increased risk of onset
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of scoliosis or curve progression, both before and after correction for confounders.
Some authors have described an association between increased GH levels and a higher 
rate of curve progression in children without PWS.50-52 In contrast to these reports, our data
show that a higher baseline IGF-I SDS was associated with a lower severity of scoliosis,
suggesting a protective effect of higher IGF-I SDS in children with PWS. Because IGF-I
SDS was also positively associated with the trunkLBM:BSA ratio, the protective effect may
be due to a higher trunkLBM.
In conclusion, GH treatment has no adverse effect on onset of scoliosis and curve
progression in children with PWS. Because of the high prevalence of scoliosis and the
potential associated morbidities in patients with PWS, it is recommended to perform
frequent physical examinations and yearly radiographic examination, independently from
GH treatment.
10.3 Bone mineral density and effects of growth hormone
treatment in children with Prader-Willi syndrome
10.3.1 Bone mineral density
Although childhood is the critical period for bone accumulation, reports on BMD in children
with PWS were very scarce.54-56 Moreover, corrections for short stature in the analysis of 
BMD were never performed. We evaluated total body and lumbar spine BMD (BMDTB and
BMDLS), and lumbar spine bone mineral apparent density (BMADLS), thereby adjusting
for height. Our results show that BMDTB, BMDLS, and BMADLS are normal in prepubertal
children with PWS. BMADLS SDS was even signifi cantly above zero SDS, indicating that
BMD, corrected for short stature, is not decreased in prepubertal children with PWS. The
normal BMADLS SDS is in contrast to results from cross-sectional studies in adults, showing
osteoporosis in a high percentage of them.57-59 These studies, however, did not correct for 
the short stature of persons with PWS. It is, on the other hand, likely that adults with PWS
do have a decreased BMADLS as the prevalence of osteoporosis in older subjects with 
PWS is up to 90% and associated complications are frequently reported.57-59 Presumably,
there is a change from a normal BMADLS SDS in prepubertal children toward a low BMADLS
SDS in adults. We postulate that this decrease results from delayed and abnormal pubertal
development due to hypogonadotropic hypogonadism in many patients with PWS, which
will lead to a lack of increase in BMD and a lower peak bone mass. 
In our study BMI was signifi cantly higher than 0 SDS, although still within the normal range.
As BMISDS was signifi cantly associated with all BMD parameters, the high-normal BMISDS
could contribute to the normal BMD found in our study. However, only 1 of 13 patients with a
BMI below 1 SDS had a reduced BMADLS, indicating that BMD is normal in most prepubertal
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children with PWS, independently from BMISDS. We have not measured DHEAS levels in
our patients. Other studies have demonstrated high levels of DHEAS in children with PWS60,
61, which may contribute to the normal BMD demonstrated in our patients.62
Thus, BMD is normal in prepubertal children with PWS and the low BMD in adult patients is
most likely the result from hypogonadal hypogonadism, preventing the attainment of normal
peak bone mass during normal pubertal development.
10.3.2  Effects of growth hormone treatment on bone mineral density
In patients with GH defi ciency, BMD is decreased but normalizes during GH treatment.63,64
However, GH and IGF-I secretion are usually more affected in GH-defi cient children than
in those with PWS.65 The effects of GH treatment on BMD in children with PWS were
unknown. We therefore investigated the effects of GH treatment on bone mineral density in
the randomized controlled GH trial.
After start of GH treatment, BMDTB SDS decreased during the fi rst 6 months, did not change
during the second 6 months, and increased thereafter. The decrease during the initial phase
of GH treatment is most likely due to a higher rate of bone expansion compared to mineral
acquisition and is also found in other study populations.63,64 In contrast to bones in the total
body which consist for 80% of cortical bone, the lumbar spine mainly consists of trabecular 
bone which has a higher rate of bone turnover.66 Therefore, the equilibrium between bone
expansion and mineral acquisition is earlier restored, and this most likely explains why no
signifi cant decrease in BMDLS SDS was found during the initial phase of GH treatment.
The fl uctuation in BMDTB SDS during the fi rst 6 months of GH treatment was not previously
described, as measurements in other studies were only performed annually.54,55 These studies
suggested no effect of GH treatment on BMDTB, which is in line with our results. However,
our results also show a signifi cant positive association of BMDTB and BMDLS SDS with IGF-I
SDS at 24 months of study, suggesting that long-term GH treatment might increase BMDTB
and BMDLS SDS. However, our study showed that BMADLS did not signifi cantly change
during GH treatment and was not signifi cantly associated with IGF-I SDS. Unlike children
with GH defi ciency, baseline BMD is not decreased in children with PWS. Therefore, it is
not unexpected to fi nd no effect of GH treatment on BMD in children with PWS, in contrast
to results in patients with GH defi ciency showing normalization of BMD.63,64 As BMADLS
SDS, which is considered the best presentation of BMD in children with short stature,67 did
not signifi cantly change during our study, we conclude that GH treatment has no signifi cant
effect on BMD in prepubertal children with PWS.
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10.4  Cardiovascular and metabolic risk profi le and ASP levels in
children with Prader-Willi syndrome and effects of growth
hormone treatment
10.4.1  Cardiovascular and metabolic risk profi le and effects of growth
 hormone treatment
There was a paucity of knowledge regarding the cardiovascular and metabolic risk profi le
in young children with PWS. Also, reports about effects of GH treatment on cardiovascular 
and metabolic risk factors were scarce.68,69
Our study shows that 95% of children in the prepubertal group had a baseline fat% above
2 SDS. Notably, fat mass corrected for age and gender was signifi cantly correlated with
systolic and diastolic blood pressure, even in our young group of children with PWS. In
63% of infants and 73% of prepubertal children, at least one of the following factors was
present: systolic or diastolic blood pressure >2 SDS; elevated serum total cholesterol,
LDLc, triglyceride, or Lp(a) levels; or reduced HDLc levels; indicating an unfavorable
cardiovascular profi le in addition to the high fat%.
In the prepubertal group, 7% of children were diagnosed with the metabolic syndrome,
defi ned as the presence of at least three of the following components: BMI or systolic or 
diastolic blood pressure >2 SDS; triglyceride level ≥1.7 mmol/l; HDLc level <1.03 mmol/l;
glucose level ≥5.6 mmol/l. Notably, about 40% of infants and prepubertal children
demonstrated at least one component of the metabolic syndrome. The elevated glucose
and insulin levels were found in children with a high fat%SDS or BMISDS. Systolic and
diastolic blood pressure were normal in nearly all children.
GH treatment improved the HDLc to LDLc ratio, which is in line with Carrel et al.68 However,
in contrast to literature,68,69 our results do not show a benefi cial effect of GH treatment on
serum lipids. Furthermore, our study demonstrated no effect of GH on systolic and diastolic
blood pressure, serum lipids, and glucose homeostasis.
Importantly, our results show that serum lipids did not signifi cantly differ between the infant
and prepubertal group, indicating that the unfavorable lipid profi les are most likely present
from infancy onwards, although this should be confi rmed in studies investigating neonates
with PWS.
Although about 40% of children demonstrated at least one component of the metabolic
syndrome, nearly all children had normal glucose and insulin levels, despite the severely
elevated fat%. Increased adiponectin has been suggested to play a role in preventing insulin
resistance, also by our group.70-72
In conclusion, our study demonstrates a high fat% and dyslipidemia in many young
children with PWS, indicating an unfavorable cardiovascular and metabolic risk profi le. GH
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treatment signifi cantly reduced fat% and improved the HDLc to LDLc ratio during 24 months
of study.
10.4.2  Acylation stimulating protein and effects of growth hormone 
  treatment
ASP stimulates free fatty acid incorporation into adipose tissue by increasing triglyceride
synthesis and storage and increases glucose uptake through enhanced translocation of 
glucose transporters to the plasma membrane surface.73-79 Furthermore, ASP reduces
triglyceride lipolysis in adipocytes by inhibiting hormone-sensitive lipase.78,79 By controlling
the storage of triglycerides, ASP is an important factor in keeping lipid levels within normal
range. The high fat% in children with PWS, even in underweight infants, and the role of ASP
levels in triglyceride storage prompted us to assess ASP levels in children with PWS and to
investigate the effects of GH treatment.
Our study demonstrated high ASP levels in young children with PWS, coinciding with
an increased fat mass, but normal triglyceride levels. High ASP levels are suggestive of 
ASP resistance, also shown in subjects with obesity, insulin resistance, dyslipidemia and
cardiovascular disease.79-84 In subjects with ASP resistance, however, high ASP levels
coincide with high triglyceride levels and may show a positive correlation with triglyceride
levels. In contrast, most of our children with PWS had normal triglyceride levels, which
correlated inversely with ASP, indicating an effective function of ASP in triglyceride storage.
Thus, high ASP levels in PWS seem to contribute in keeping triglyceride levels within
normal range. Furthermore, ASP increases glucose uptake through enhanced translocation
of glucose transporters to the plasma membrane surface.73-77 We found normal glucose
and insulin levels in nearly all children, despite high fat%. High ASP levels without ASP
resistance results in increased triglyceride storage as well as in increased glucose uptake.
The high ASP levels in PWS may therefore not only contribute to the high fat%, but may
also keep glucose and insulin levels within normal range, as has also been suggested for 
adiponectin.70-72
GH treatment does not result in complete normalization of fat mass in children with PWS,85-89
which suggest that GH insuffi ciency is not the only factor involved in the mechanism leading
to abnormal body composition in PWS. ASP levels were high in most children with PWS
and were not signifi cantly different between GH-treated children and randomized controls.
Furthermore, ASP levels correlated positively with fat mass and inversely with triglyceride
levels. This indicates that high ASP levels may contribute to the sustainment of high fat%,
even during GH treatment. Thus, the high ASP levels do not change in response GH
treatment and may play a role in preventing complete normalization of fat mass during GH
in children with PWS.
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In conclusion, ASP levels are high in children with PWS. As ASP stimulates triglyceride
synthesis and storage into adipose tissue and does not decline in response to GH, elevated
ASP levels may contribute to the high fat% and may possibly play a role in the lack of 
complete normalization of body composition during GH treatment in children with PWS. As
ASP also stimulates glucose uptake, high ASP levels may play a role in keeping glucose
and insulin levels within normal range.
10.5  Genetics
Previously reported prevalences of chromosomal abnormalities were 70-75% for deletion,
20-25% for UPD, 2-5% for ICD and less than 1% for chromosomal translocation.34,90-97 These
prevalences were based on studies which included patients diagnosed according to clinical
criteria and may therefore be subject to selection bias. To date, recommendations advice
to exclude the diagnosis of PWS in any neonate with hypotonia, feeding diffi culties, low
refl exes, and/or hypoplasia of the external genitalia.34,98-100 Our large cohort of children with 
PWS show a much higher prevalence of UPD and therefore a lower prevalence of deletions
(both about 45%). The higher prevalence of UPD may be due to a trend of increased
maternal age at time of conception and enhanced diagnostic methods.101-103 In earlier years,
the use of clinical criteria for diagnosing PWS may have led to a lower prevalence of UPD,
as this diagnosis is more easily missed due to the more discrete phenotypic appearance.34,91
We found a slightly higher prevalence of ICD (9%), but the prevalence of chromosomal
translocation (1%) was similar to previous reports.91,96,97 The changed prevalence of 
genetic subtypes has also been demonstrated in the United Kingdom.104 Thus, the current
prevalences of genetic subtypes are 45% for deletion, 45% for UPD, 9% for ICD and 1% for 
Robertsonian translocation.
10.6  Effi cacy and safety of long-term growth hormone treatment 
in children with Prader-Willi syndrome
Data of the randomized controlled GH trial demonstrated that body composition, height, and
anthropometric outcomes improved in children with short-term GH treatment, compared to
randomized controls. This is in line with other studies demonstrating benefi cial effects during
1 or 2 years of treatment.54,68,88,105-113 Although short-term GH has been proven benefi cial, 
reports on effects of long-term GH treatment in children with PWS were scarce.89,114-116 We
therefore performed a 4-year multicenter prospective follow-up study (the Dutch Cohort
Study) to evaluate effi cacy and safety of long-term continuous GH treatment in a large
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group of children with PWS, with onset of treatment before puberty. The various outcomes
of this study are described below. 
10.6.1 Body composition
Our randomized controlled study showed a signifi cant benefi cial effect of GH treatment on
fat%, compared to controls. The Dutch Cohort Study demonstrated that fat%SDS was still
signifi cantly lower after 4 years of GH treatment than at baseline. LBMSDS signifi cantly
decreased during the fi rst year of GH treatment, but returned to baseline values during the
second year and did not signifi cantly change during the two years thereafter. In contrast, the
results from our randomized controlled study showed that LBMSDS continuously decreased
in untreated children with PWS. We therefore conclude that 4 years of continuous GH
treatment with a standard dose (1 mg/m2·day) has a signifi cant favorable effect on body
composition, with a signifi cant reduction of fat%SDS and a stabilization of LBMSDS.
Figures 2 and 3 depict the effects of GH treatment on body composition and height in two
patients with PWS. The remarkable changes during GH treatment, as well as the striking
difference between the untreated 3-year old boy in Figure 2 (left) and the GH-treated boy
of the same age in Figure 3 (right), endorse the view that GH treatment should be initiated
at an early age in children with PWS. This is also supported by studies showing signifi cant
benefi cial effects on psychomotor development in young children with PWS.54,110,117
Although body composition markedly improved during treatment, long-term GH did not result
in a complete normalization. This has previously been shown by Carrel et al.,89 but children
participating in that study were not continuously treated with a standard dose. The fact that
long-term GH treatment did not completely normalize body composition suggests that the
unfavorable fat% and LBM are not only the result of GH insuffi ciency. Other factors, such as
genetic programming and elevated ASP levels, most likely contribute to the abnormal body
composition, as well.
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Figure 2. Changes during growth hormone treatment in a boy with PWS.
Left, without GH treatment (3 years of age); middle, after 1 year of GH treatment (5 years
of age); right, after 5.4 years of GH treatment (age 9.4 years). Photos are depicted with
permission of parents and the child.
Figure 3. Changes during growth hormone treatment in a boy with PWS.
Left, without GH treatment (6 weeks of age); middle, without GH treatment (10 months of age);
right, after 1.6 years of GH treatment (age 3.2 years). Photos are depicted with permission of 
parents and the child.
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10.6.2  Height and bone maturation
Our randomized controlled trial showed that GH treatment has a signifi cant benefi cial
effect on heightSDS, which is in line with previous studies.54,86,88,105-113 Our data from the
Dutch Cohort study show that the benefi cial effect of GH on height persists during long-
term treatment. In our study, heightSDS had completely normalized after 4 years of GH
treatment, indicating that a normal heightSDS can be attained when GH treatment is started
several years before onset of puberty (Figure 4). This is in line with two previous reports in
a small group of patients with PWS, suggesting that a normal adult height may be obtained
in patients with PWS if GH treatment is initiated before puberty.114,116
Bone maturation was not signifi cantly affected by GH treatment. There was a shift from a
delayed bone maturation in children below 5 years of age toward a normal bone maturation
in those above 7 years. This catch-up in bone maturation might be related to adrenarche,
typically occurring early in many children with PWS.61,118 As bone age did not accelerate
in response to GH treatment, our data suggest that a normal adult height can be reached
when long-term GH treatment is started several years before puberty.
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Figure 4. Growth charts depicting the change in heightSDS in boys and girls after 4 years
of GH treatment. Lines represent -2, 0, and 2 SDS for Dutch and PWS (dotted) reference
values. Open and closed symbols represent values at start and after 4 years of GH treatment,
respectively. Height in boys is depicted in circles, whereas height in girls is depicted in
triangles.
205
C
ha
pt
er
 1
0
10.6.3  Head circumference
Head circumference SDS improved signifi cantly during short-term GH treatment. This
effect persisted during long-term GH treatment. In the general population, a lower head
circumference SDS is associated with lower intelligence, whereas brain growth during
infancy and early childhood is important in determining cognitive function.119-121 Improvement
of mental development and psychosocial functioning during short-term GH treatment in
patients with PWS has previously been described.105,122 Our group reported a median (iqr)
increase in mental development quotient of 9.3% (-5.3 to 13.3) in infants after 12 months
of GH treatment versus -2.9% (-8.1 to 4.9) in controls (p<0.05).122 There are no studies
available regarding long-term effects of GH on psychomotor development, intelligence,
or psychosocial functioning, but we hypothesize that GH may have a favorable effect on
these outcomes, resulting from sustained improvement of head circumference SDS as
demonstrated by our study.
10.6.4  Hands, feet, tibiae, and arm span
Long-term GH treatment improved, but did not completely normalize SDS of the hand and
foot length and arm span. Tibia length only normalized in the prepubertal group, thus when
GH treatment was started at an early age. The main catch-up growth of hands and feet
occurred during the fi rst year with little change thereafter. Catch-up in tibia length SDS and
arm span SDS continued in the second year of treatment and reached a plateau thereafter.
It has previously been suggested that when these outcomes normalize during GH treatment,
this would indicate that these features are the result of GH defi ciency rather than due to the
genetic defect.116 Our fi ndings suggest that both GH defi ciency and the genetic defect might 
explain the shorter hands, feet, tibiae, and arm span in children with PWS.
10.6.5  IGF-I and IGFBP-3 levels, glucose homeostasis, blood pressure, 
 and serum lipids
In the Dutch Cohort Study, mean IGF-I levels rapidly increased during GH treatment, whereas
IGFBP-3 levels increased more gradually. IGFBP-3 is the major carrier protein of IGF-I and
binds 70-95% of IGF-I as a binary complex or as a ternary complex together with the acid
labile subunit (ALS). Only a minor fraction of IGF-I circulates in its unbound form, which is
considered the biologically active form.123 We found an increase in the IGF-I/IGFBP-3 ratio 
during GH treatment, suggesting an increase in free IGF-I levels. Carrel et al.89 reported that
metabolic effects of GH treatment in children with PWS are optimal with a dose of at least
1 mg/m2·day, whereas a dose of 0.3 mg/m2·day had no effect on LBM and fat%. Our results
show that the improvement of body composition and head circumference and normalization
of heightSDS is sustained with IGF-I levels between 2 and 3 SDS, without adverse effects
during 4 years of GH treatment. Thus, it is reassuring that the benefi cial effects of high IGF-I
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levels outweigh the potential unfavorable effects during at least 4 years of study. However,
research of longer-term effects of high IGF-I levels is required for defi nite conclusions.
Notably, there were a few children with exceptional increases of heightSDS and IGF-I SDS
during GH treatment. One may consider individualizing the GH dosage in order to attain
IGF-I levels between 2 and 3 SDS. However, the limited data on reduction of GH dosage
or discontinuation of treatment also suggest a worsening of body composition.89 Thus, GH
dosage may be individualized, but caution should be taken as lower IGF-I levels might
result in a less favorable body composition with higher fat%.89
One major concern with high IGF-I levels is insulin resistance. Our study showed an
increase in insulin resistance with age, but demonstrated that GH treatment had no effect on
fasting glucose and insulin levels, HOMA-IR, and HbA1c levels in our group of 55 children,
when adjusted for age and gender. This is in line with Lindgren et al. describing normal
glucose homeostasis during fi ve years of GH treatment in 16 children without rapid weight
gain.114 We had no patients with non-insulin dependent diabetes mellitus. The outcomes
of our study suggest that the high prevalence of non-insulin dependent diabetes mellitus
in adult patients with PWS40 is most likely due to increased fat mass. Our data show that
a signifi cant positive association of fat mass with both fasting insulin levels and HOMA-
IR is already present in childhood. These results underline the importance of achieving
normal BMI and reducing fat mass as part of the primary aims in the comprehensive care
of patients with PWS. In this respect, it is interesting to note that BMISDS according to
PWS reference values signifi cantly decreased during GH treatment. Thus, GH treatment
might have favorable effects on insulin resistance as it decreases fat mass and slows down
weight gain over the years. In addition, our research group found high adiponectin levels
in prepubertal children with PWS, which further increased during GH treatment. This is
reassuring with regard to the development of insulin resistance.
Blood pressure SDS did not signifi cantly differ between GH-treated children and randomized
controls. Furthermore, blood pressure SDS did not signifi cantly change during long-term GH
treatment. GH treatment had no signifi cant effect on total cholesterol and HDL cholesterol,
but LDL cholesterol was signifi cantly lower after 4 years of GH treatment. We therefore
conclude that GH treatment had no adverse effect on serum lipids.
In conclusion, GH treatment with 1.0 mg/m2·day results in IGF-I levels between 2 and 3
SDS, leading to sustained improvement of body composition, head circumference, and
normalization of heightSDS without adverse effects on glucose homeostasis, blood
pressure, and serum lipids during 4 years of study.
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10.7  Main conclusions of the thesis and clinical implications
10.7.1  Central adrenal insuffi ciency and sleep-related breathing disorders
There is a high prevalence of central adrenal insuffi ciency during stress, which may
contribute to the high mortality rate in patients with PWS. Based on our fi ndings, a new
guideline was made advicing treatment with a hydrocortison stress dose during illness or 
surgery, unless CAI has recently been ruled out with a metyrapone test.
Children with CAI during stress have a signifi cantly higher central apnea index during healthy
condition and a higher increase in central apnea index in response to metyrapone-induced
stress. The combination of CAI and compromised sleep-related breathing may aggravate
the deterioration of the condition of an acutely ill patient with PWS. This combination might
well be the prelude of a fatal cascade during illness. A new hypothesis regarding the pathway
leading to sudden death is presented.
10.7.2  Scoliosis and effects of growth hormone treatment
The prevalence of scoliosis in children with PWS without GH treatment is 30% under 10
years and 70-80% above 10 years. Two types of scoliosis are distinguished: long C-curve
type scoliosis (LCS) and scoliosis resembling idiopathic scoliosis (IS). There is a strong
association between the types of scoliosis and age and truncal hypotonia. The number of 
children with PWS with moderate or severe scoliosis is alarmingly high, resulting in many
children requiring treatment. Surgical intervention for scoliosis should be performed by a
skilled orthopedic surgeon experienced in spinal surgery in patients with PWS and familiar 
with the clinical manifestations of the syndrome affecting post-operative recovery.
GH has no adverse effects on onset and progression of scoliosis in children with PWS.
Scoliosis should therefore no longer be considered a contraindication for GH treatment in
these children. Because of the high prevalence of scoliosis and the potential associated
morbidities in patients with PWS, it is recommended to perform frequent physical
examinations and yearly radiographic examination, independently from GH treatment.
10.7.3  Bone mineral density and effects of growth hormone treatment
Bone mineral density is normal in prepubertal children with PWS. The transition of normal
bone mineral density in prepubertal children toward low bone mineral density in adults may
be related to hypogonadal hypogonadism, preventing the attainment of normal peak bone
mass during normal pubertal development. GH treatment had no effect on BMD, except for 
a temporary decrease of total body BMDSDS during the fi rst 6 months of treatment.
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10.7.4  Cardiovascular and metabolic risk profi le, ASP levels, and effects 
  of GH treatment
The majority of prepubertal children with PWS have a high fat% and abnormal serum lipids,
indicating an unfavorable cardiovascular and metabolic profi le. Systolic and diastolic blood
pressure were normal in most children, as well as insulin and glucose levels. ASP stimulates
glucose uptake and triglyceride synthesis and storage into adipose tissue. ASP levels are
elevated in prepubertal children with PWS, possibly contributing to the high fat%. The high
ASP levels may also keep glucose and insulin levels within normal range. 
GH improved fat% and the HDLc to LDLc ratio, but had no effect on blood pressure, serum
lipids, and glucose homeostasis. The high ASP levels did not change in response to GH
and may therefore contribute to the lack of normalization of fat% during GH treatment in
patients with PWS.
10.7.5  Safety and effi cacy of long-term GH treatment
Four years of GH treatment with a dose of 1 mg/m2·day results in a sustained improvement
of body composition and head circumference and a normalization of heightSDS, when
started several years before puberty. Long-term GH treatment reduced fat% and stabilized
LBMSDS, but body composition did not completely normalize. GH increased the SDS of 
hand, foot, and tibia length, as well as arm span.
IGF-I levels rapidly increased during GH treatment, whereas IGFBP-3 increased more
gradually. IGF-I levels between 2 and 3 SDS were attained, without adverse effects on
glucose homeostasis, blood pressure, and serum lipids during 4 years of study.
10.8  Recommendations for future research
Based on our research, new insights and recommendations have been provided. But
in concordance with this growing knowledge, new questions and dilemmas appeared,
revealing possible directions for future research.
We have demonstrated a high prevalence of central adrenal insuffi ciency in children with
PWS, apparent only during stressful conditions, and found an association between CAI and
sleep-related breathing. Future research should focus on confi rming the high prevalence of 
CAI, in children as well as in adults. In addition, it would be interesting to investigate if CAI
is caused by pituitary or, more likely, hypothalamic insuffi ciency. Also, the possibility of using
other screening methods, such as ACTH tests, should be explored. Based on our fi ndings,
it would be interesting to investigate whether correct implementation of hydrocortisone
treatment during illness reduces the annual mortality rate. Also, more research needs to be
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performed studying the relationship between central adrenal insuffi ciency and sleep-related
breathing in larger numbers of patients.
We assessed prevalences of scoliosis in children with PWS and evaluated the effects
of GH treatment on onset and progression of scoliosis. Future research should focus on
optimizing scoliosis treatment regimens, divided by type of scoliosis. For non-severely
progressing LCS type scoliosis, one may focus on increasing truncal lean body mass rather 
than applying orthopedic treatments. IS type scoliosis probably warrant earlier treatment,
but the complication rate of spinal surgery in patients with PWS is high. In this respect,
the option of upper body immobilization during post-operative recovery should be explored
in order to prevent skin-picking and instrument-related complications and to minimize the
need for reoperation. 
Our study demonstrated normal bone mineral density in prepubertal children with PWS,
which was not affected by GH treatment. We hypothesized that the decreased BMD in adult
patients with PWS is the result of hypogonadotropic hypogonadism. Future research should
aim to investigate this hypothesis.
The elevated ASP levels may be confi rmed, not only in children, but also in adults. Perhaps
future research could render a means to decrease ASP levels, thereby possibly providing
new treatment options for the obesity of patients with PWS. Furthermore, we found a
high prevalence of cardiovascular and metabolic risk factors in children with PWS. Future
research may explore the effi cacy of treatment of these risk factors at an early age.
We concluded that the improvement of body composition and head circumference and
normalization of heightSDS is sustained with IGF-I levels between 2 and 3 SDS, without
adverse effects during 4 years of GH treatment. Future research may focus on individualizing
the GH dose and assessing the effi cacy and particularly the safety of high IGF-I levels during
a prolonged follow-up period. Also, long-term effects of GH on psychosocial functioning
and intelligence warrant investigation. Thus, it is important to carefully follow GH-treated
children with PWS until adult height.
Currently, GH treatment is discontinued when adult height is attained. Studies investigating
the effects of GH treatment during several years after attainment of adult height and during
adulthood are warranted.
Children with PWS present as a heterogeneous group of patients, in part due to the
genotype-phenotype correlations. Our study demonstrated new prevalences of the different
chromosomal defects causing PWS. More research investigating the genotype-phenotype
correlations is warranted and could possibly provide distinct means of treatment and care.
Children with PWS require comprehensive multidisciplinary care. GH treatment alone is not
enough to relieve symptoms of PWS, but should be combined with a strict diet and physical
therapy and/or training. The effectiveness of different physical therapeutic programs
should be investigated. We have conducted research in a group of mainly young children
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with PWS, belonging to a new generation with an early diagnosis allowing early treatment.
From clinical practice, it is evident that this new generation thrives much better, through
the early implementation of the combined efforts of physicians, allied health professionals,
parents, and patients. These children need to be carefully followed in order to optimize
treatment abilities specifi c to this new patient population, with the ultimate goal of promoting
health and increasing quality of life.
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Chapter 11
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This doctoral dissertation provides a detailed account of the various studies performed to
improve the knowledge of PWS and care for patients with PWS. Studies were embedded
in the Dutch national randomized controlled GH trial. General aspects of children with PWS
were studied, such as the prevalence of central adrenal insuffi ciency, sleep-related breathing
disorders, scoliosis, bone mineral density, and cardiovascular risk factors including ASP
levels. Furthermore, we evaluated the effi cacy and safety of short- and long-term growth
hormone treatment by investigating the effects of GH on body composition, height, head
circumference and other anthropometric outcomes, bone maturation, scoliosis, bone mineral
density, blood pressure, glucose homeostasis, and serum lipids. This chapter summarizes
these studies and their most important outcomes.
Chapter 2
High prevalence of central adrenal insuffi ciency in patients with Prader-
Willi syndrome
The annual death rate in patients with PWS is very high (3% under 30 years). The sudden
deaths in children often share a similar pattern: a sudden deterioration during a mild or 
moderate infection, which is often – but not always – an upper respiratory tract infection.
Furthermore, a reduced adrenal size has been found during autopsies in children. These
fi ndings, coinciding with the presence of hypothalamic dysregulation in PWS, prompted us
to investigate the prevalence of central adrenal insuffi ciency during stress. We admitted
25 randomly selected patients, with a median (iqr) age of 9.7 years (6.8-13.6), in a
Pediatric Intensive Care Unit to undergo a metyrapone test. At 2330 h, metyrapone was
administered. At 0400, 0600, and 0730 h, ACTH, 11-deoxycortisol, cortisol, and glucose
levels were measured. The cut-off level for an adequate ACTH response is >33 pmol/l at
0730 h. Diurnal salivary cortisol profi les were assessed on a different day at wake-up, 30
min after wake-up, at 1400 h, and at 2000 h. All patients received GH treatment and were
naïve to glucocorticoid therapy. All tests were performed during healthy condition.
Strikingly, 15 patients (60%) had CAI, defi ned as ACTH levels failing to increase suffi ciently
during a metyrapone test. The difference in ACTH response between children later 
diagnosed with CAI and those not was already signifi cant at 0400 h and 0600 h. Age, gender,
genotype, and BMISDS did not signifi cantly differ between patients with and without CAI.
Morning salivary cortisol levels and diurnal profi les were normal in all children, suggesting
that CAI becomes apparent only during stressful conditions. The high percentage of CAI
in PWS patients might explain the high rate of sudden death in these patients, particularly
during infection-related stress. Based on our data, one should consider treatment with
hydrocortisone during acute illness in PWS patients unless CAI has recently been ruled out
with a metyrapone test.
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Chapter 3
The relationship between central adrenal insuffi ciency and sleep-related
breathing disorders in children with Prader-Willi syndrome
Next to the high prevalence of CAI in children with PWS (Chapter 2), sleep apneas
have also been suggested to play a role in sudden deaths. We therefore investigated
the relationship between CAI and sleep-related breathing disorders. In 20 children who
underwent a metyrapone test, sleep-related breathing was evaluated by polysomnography
prior to the metyrapone test, as part of the protocol of the randomized controlled GH trial.
In addition, we could record sleep-related breathing in 10 children with PWS during their 
metyrapone test. The median (iqr) age was 8.4 years (6.5-10.2) at time of the metyrapone
test. After metyrapone administration, the median (iqr) central apnea index (number/hour)
increased signifi cantly, from 2.2 (0.4-4.7) to 5.2 (1.5-7.9). The increase tended to be higher 
in children with CAI [2.8 (2.0-3.9) vs. 1.0 (-0.2 to 2.6), p=0.09]. During polysomnography
prior to the metyrapone test, sleep-related breathing was worse in children with CAI, as they
had a signifi cantly higher central apnea index and tended to have a lower minimum oxygen
saturation compared to those without CAI (p=0.03 and p=0.07).
In conclusion, our study showed that the central apnea index increased signifi cantly after 
metyrapone administration, particularly in children diagnosed with CAI during stress. In
addition, children with CAI had a higher central apnea index compared to those without,
several months prior to the metyrapone test. Based on our fi ndings described in Chapter 
3, we launched a new hypothesis on the most common mechanism of sudden death in
children with PWS in the General Discussion in Chapter 10.
Chapter 4
Scoliosis in Prader-Willi syndrome: Effects of age, gender, body mass
index, lean body mass, and genotype
The reported prevalence of scoliosis varied greatly. We therefore assessed the prevalence
of scoliosis in a group of 96 children with PWS in a cross-sectional study design. None
of the children had been treated with growth hormone. Radiographs were taken, length
and weight were measured, BMI standard deviation scores and body surface areas were
calculated, and dual energy x-ray absorptiometry (DXA) was performed, measuring lean
body mass and truncal lean body mass. The median (iqr) age was 4.8 (2.1-7.5) years.
The prevalence of scoliosis was 30% in children under 10 years to 80% in children above
10 years. Fifty percent of children had a Cobb’s angle above 20°, requiring referral to an
orthopedic surgeon, whereas 13% had undergone treatment for scoliosis (brace or surgery).
Two types of scoliosis were identifi ed: 1) Long C-curve type scoliosis, mainly occurring
in young children with a low truncal lean body mass to body surface area ratio; and 2)
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Scoliosis resembling idiopathic scoliosis (IS), mainly occurring in older children with less
hypotonia of the truncal musculature.
Based on our fi ndings, we recommend frequent physical examination for signs of scoliosis
and yearly radiographic evaluation of the spine in children with PWS.
Chapter 5
Randomized controlled trial to investigate the effects of growth hormone
treatment on scoliosis in children with Prader-Willi syndrome
We have earlier demonstrated a high prevalence of scoliosis in children with PWS, ranging
from 30-80%, depending on age. Based on uncontrolled data from the general population,
indicating a possible effect of accelerated growth on spinal deformity, scoliosis was often
considered a contraindication for GH treatment in children with PWS. However, there were
no reports on the effects of GH treatment on scoliosis in children with PWS. We therefore
conducted a randomized controlled trial, investigating the effects of GH treatment on onset
of scoliosis and curve progression. Thirty-eight infants and 44 prepubertal children were
randomized into a GH-treated group (1 mg/m2·day) or a control group, for one and two years,
respectively. Pubertal children were randomized to receive somatropin 1 or 1.5 mg/m2·day.
Annually, x-rays of the spine were taken, and height, weight, truncal lean body mass (with
dual energy x-ray absorptiometry), and IGF-I levels were measured. GH-treated children
had similar onset of scoliosis and curve progression as randomized controls (p=0.27-0.79
and p=0.18-0.98, respectively). GH treatment, IGF-I SDS, and catch-up growth had no
adverse effect on the onset of scoliosis or curve progression, even after adjustment for 
confounders. HeightSDS, truncal lean body mass, and IGF-I SDS were signifi cantly higher 
in GH-treated children than in randomized controls. At baseline, a higher IGF-I SDS was
associated with a lower severity of scoliosis. Thus, we conclude that scoliosis should no
longer be considered a contraindication for GH treatment in children with PWS.
Chapter 6
Randomized controlled GH trial: Effects on anthropometry, body
composition, and body proportions in a large group of children with
Prader-Willi syndrome
Children with PWS have impaired growth and an abnormal body composition, with high
fat% and low lean body mass. Previous one-year controlled studies demonstrated that
GH treatment resulted in improved growth and body composition in PWS. These studies,
however, described relatively small patient groups of mostly overweight PWS patients.
We performed a randomized controlled GH trial in 91 pre-pubertal children with PWS (42
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infants, 49 prepubertal children aged 3-14 years), evaluating growth, body composition, and
anthropometric outcomes. Infants and prepubertal children were randomly allocated to a
GH-treated group (1 mg/m2·day) or a control group for 1 and 2 years, respectively. Annually,
anthropometric assessments were performed and body composition was measured by dual
energy x-ray absorptiometry (DXA). Median (iqr) heightSDS increased during GH treatment
in infants from -2.3 (-2.8 to -0.7) to -0.4 (-1.1 to 0.0) and in prepubertal children from -2.0
(-3.1 to -1.7) to -0.6 (-1.1 to -0.1). In non-GH-treated children height SDS did not increase.
Head circumference improved in response to GH. Body fat percentage and anthropometric
outcomes improved in GH-treated children, but did not completely normalize. Lean body
mass SDS stabilized in contrast to a persistent decrease in controls.
In conclusion, GH in children with PWS improves height, body composition, head
circumference and anthropometric outcomes. Children with PWS are highly sensitive to
GH, indicating that monitoring of serum IGF-I levels during GH treatment is indicated.
Chapter 7
Randomized controlled trial investigating bone mineral density and effects
of growth hormone treatment in prepubertal children with Prader-Willi
syndrome
Bone mineral density is decreased in adults with PWS. Although childhood is the critical period
for bone accumulation, reports on BMD in children with PWS are very limited. Patients with
PWS have many symptoms resembling GH defi ciency. In children with GH defi ciency, BMD
is decreased and normalizes during GH treatment. We conducted a national multicenter 
randomized controlled trial evaluating BMD and BMADLS, which corrects for short stature,
and investigating the effects GH treatment. Children were randomly assigned to a GH-
treated group (1 mg/m2·day) or a control group for the duration of 2 years. We included 46
prepubertal children with PWS, with a mean ± SD age of 7.1 ± 2.2 years. At start, 6, 12, and
24 months of study, total body and lumbar spine BMD (BMDTB and BMDLS) were measured
by dual energy x-ray absorptiometry (DXA) and bone mineral apparent density (BMADLS) 
was calculated. Baseline BMDTBSDS, BMDLSSDS, and BMADLSSDS were all normal (mean
± SD: -0.2 ± 1.1 SDS; -0.4 ± 1.2 SDS; and 0.40 ± 1.1 SDS, respectively). After start of 
GH treatment, BMDTB SDS decreased during the fi rst six months, did not change during
the second six months, and increased thereafter. The decrease during the initial phase of 
GH treatment is most likely due to a higher rate of bone expansion compared to mineral
acquisition and is also found in other study populations. In contrast to bones in the total
body which consist for 80% of cortical bone, the lumbar spine mainly consists of trabecular 
bone which has a higher rate of bone turnover. Therefore, the equilibrium between bone
expansion and mineral acquisition is earlier restored, and this most likely explains why no
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signifi cant decrease in BMDLS SDS was found during the initial phase of GH treatment.
After 24 months of study, BMDTBSDS, BMDLSSDS, and BMADLSSDS did not signifi cantly
differ between GH-treated children and randomized controls (p=0.30, p=0.44, and p=0.47,
respectively). Repeated measurements analysis showed a signifi cant positive association
between IGF-I SDS and BMDTBSDS and BMDLSSDS, but not with BMADLS.
In conclusion, our results show that prepubertal children with PWS have a normal BMD.
GH treatment had no effect on BMD, except for a temporary decrease of BMDTBSDS in the
fi rst 6 months.
Chapter 8
Cardiovascular and metabolic risk profi le and acylation stimulating
protein levels in children with Prader-Willi syndrome and effects of growth
hormone treatment
Children with PWS have an unfavourable body composition with a high fat%. However,
reports on the cardiovascular and metabolic risk profi le in children with PWS and the effects
of GH treatment were scarce. Acylation stimulating protein (ASP) stimulates glucose uptake
and triglyceride storage in adipose tissue. Acylation stimulating protein (ASP) stimulates
glucose uptake and triglyceride storage in adipose tissue and is an important marker for 
fat accumulation and dyslipidemia. However, ASP levels of children with PWS have never 
been reported.
We conducted a randomized controlled trial in 85 young children with PWS to assess the
baseline cardiovascular and metabolic risk profi le and ASP levels and to investigate the
effects of GH treatment. Thirty-fi ve infants and 50 prepubertal children were randomly
allocated to either a GH-treated group (1 mg/m2·day) or a control group, for one and two
years, respectively. The mean ± SD age was 4.9 ± 3.0 years. The mean ± SD fat% was 28.4
± 6.2 in infants and 36.9 ± 8.5 in prepubertal children. Fat%SDS was elevated in 95% of 
prepubertal children. In addition to high fat%, 63% of infants and 73% of prepubertal children
had dyslipidemia, indicating an unfavourable cardiovascular profi le. Systolic and diastolic
blood pressure were normal in nearly all children. Forty percent of infants and prepubertal
children demonstrated at least one component of the metabolic syndrome, whereas 5%
demonstrated at least three and could therefore be diagnosed with the metabolic syndrome.
Glucose and insulin levels were normal in nearly all children. The mean ± SD baseline ASP
level was 107 ± 45 nmol/l (normal<58 nmol/l) and correlated positively with fat mass and
inversely with serum triglyceride levels. GH improved fat%SDS and the HDLc to LDLc ratio
(p<0.0001 and p=0.04). GH had no signifi cant effect on ASP levels.
In conclusion, the majority of young children with PWS have a high fat% and dyslipidemia,
indicating an unfavorable cardiovascular and metabolic profi le. Systolic and diastolic blood
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pressure were normal in most children, as well as insulin and glucose levels. As ASP
stimulates glucose uptake and triglyceride synthesis and storage into adipose tissue, the
high ASP levels in children with PWS may contribute to the high fat% and may also keep
glucose and insulin levels within normal range. GH improved fat% and the HDLc to LDLc
ratio, but had no effect on blood pressure, glucose homeostasis, and serum lipids. The high
ASP levels did not change in response to GH and may therefore contribute to the lack of 
normalization of fat% during GH treatment in patients with PWS.
Chapter 9
Effi cacy and safety of long-term continuous growth hormone treatment in
children with Prader-Willi syndrome
Patients with PWS have an abnormal body composition with increased fat mass and
decreased lean body mass, and short stature. Some studies showed normalization of adult
height when GH treatment was started before onset of puberty. Although improvement of 
body composition is considered the most important effect of GH in children with PWS,
there are no reports regarding effects of long-term GH treatment on body composition in
a large group of patients. We investigated long-term effi cacy and safety of GH treatment
on body composition, growth, bone maturation, and safety parameters, in 55 children with
PWS included in a 4-year national multicenter prospective follow-up study. The mean ± SD
age at start of study was 5.9 ± 3.2 years. All children received somatropin 1 mg/m2·day.
The following data were annually obtained in one center: fat% and lean body mass (LBM)
by dual-energy x-ray absorptiometry, height, weight, head circumference, bone age, blood
pressure, and fasting IGF-I, IGFBP-3, glucose, insulin, HbA1c, total cholesterol, HDL, and
LDL. SD-scores were calculated according to Dutch and PWS reference values (SDS and
SDSPWS).
Fat%SDS was signifi cantly lower after 4 years of GH treatment (p<0.0001). LBMSDS
signifi cantly increased during the fi rst year (p=0.02), but returned to baseline values the
second year and remained unchanged thereafter. Thus, LBM stabilized during long-term
continuous GH treatment, which is in contrast to the persistent decrease of LBMSDS
commonly observed in untreated children with PWS. Mean ± SD height normalized from
–2.27 ± 1.2 SDS to –0.24 ± 1.2 SDS (p<0.0001). Head circumference SDS increased from
–0.79 ± 1.0 at start to 0.07 ± 1.1 SDS after 4 years. BMISDSPWS signifi cantly decreased.
Mean ± SD IGF-I and the IGF-I/IGFBP-3 ratio signifi cantly increased to 2.08 ± 1.1 and 2.32 
± 0.9 SDS, respectively. GH treatment had no adverse effects on bone maturation, blood 
pressure, glucose homeostasis, and serum lipids.
Our study shows that 4 years of continuous GH treatment with a standard dose (1 mg/
m2·day) had a signifi cant favorable effect on body composition, heightSDS, BMISDSPWS, and
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head circumference SDS, without adverse effects on blood pressure, glucose homeostasis,
and serum lipids. Importantly, the favorable effect on body composition persisted during the
4 years of study. Based on our fi ndings, it is recommended to keep IGF-I levels between 2
and 3 SDS for optimal effects in children with PWS, without adverse effects. In conclusion,
long-term continuous GH treatment is an effective and safe therapy for children with PWS.
Chapter 12
Samenvatting
Samenvatting
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Dit proefschrift beschrijft verschillende studies die zijn verricht om de kennis van PWS te
vergroten en de zorg voor patiënten met PWS te verbeteren. Studies zijn uitgevoerd binnen
het kader van de landelijke groeihormoonstudie voor kinderen met PWS. Algemene aspecten
van PWS werden onderzocht, zoals de prevalentie van bijnierinsuffi ciëntie, alsmede
slaapgerelateerde ademhalingsstoornissen, scoliose, botdichtheid en cardiovasculaire
risicofactoren. Ook werd onderzoek verricht naar de effectiviteit en veiligheid van
groeihormoonbehandeling op korte en lange termijn. In het bijzonder werden bestudeerd
of de volgende factoren beïnvloed werden door GH: lichaamssamenstelling, lengte,
hoofdomtrek en overige antropometrische uitkomsten, botrijping, scoliose, botdichtheid,
bloeddruk, glucosehuishouding en lipiden. Dit hoofdstuk geeft een samenvatting van deze
studies en de belangrijkste uitkomsten.
Hoofdstuk 2
Hoge prevalentie van bijnierinsuffi ciëntie bij patiënten met 
Prader-Willi syndroom
Patiënten met PWS hebben een hoog overlijdensrisico. Het sterftecijfer wordt geschat op 3%
onder de 30 jaar. Bij kinderen is met name sprake van plotselinge sterfte. Deze overlijdens
geschieden grotendeels volgens een bepaald patroon, namelijk een plotselinge verergering
tijdens een milde of matige infectie (meestal een bovenste luchtweginfectie). Daarbij hebben
enkele studies aangetoond dat overleden kinderen met PWS verkleinde bijnieren hadden
bij obductie. In ogenschouw nemend dat patiënten met PWS een disregulatie van de
hypothalamus hebben, wijzen deze factoren op het mogelijk bestaan van bijnierinsuffi ciëntie
binnen deze patiëntengroep. Daarom hebben wij middels metyrapontesten de functie van
de bijnier onderzocht in 25 at random geselecteerde patiënten met een mediane (25e-75e
percentiel) leeftijd van 9,7 jaar (6,8-13,6). Deze testen werden verricht op de Intensive Care
Pediatrie van het Sophia Kinderziekenhuis te Rotterdam. Om 23.30 uur werd metyrapon
toegediend. Op 23.30, 4.00, 6.00 en 7.30 uur werd bloed afgenomen voor de bepaling van
ACTH, 11-desoxycortisol, cortisol en glucose. De afkapgrens voor een correcte oploop van
ACTH is >33 pmol/l om 7.30 uur. Dagritmes speekselcortisol werden afgenomen op een
andere dag op de volgende tijdstippen: ontwaken, een half uur na het ontwaken, 14.00 uur 
en 20.00 uur. Alle patiënten waren anderszins gezond tijdens beide testen. Allen werden
behandeld met GH en werden vóór de test niet behandeld met glucocorticoïden.
Vijftien patiënten (60%) hadden centrale bijnierinsuffi ciëntie (CAI), gedefi nieerd als
onvoldoende ACTH oploop tijdens een metyrapontest. Om 04.00 uur en 06.00 uur was
al een duidelijk signifi cant verschil aanwezig in ACTH oploop tussen kinderen die later 
gediagnosticeerd werden met CAI en de groep zonder CAI. Er was geen signifi cant verschil
in leeftijd, geslacht, genotype en BMISDS tussen kinderen met en zonder bijnierinsuffi ciëntie.
229
C
ha
pt
er
 1
2
Geen van de kinderen had een afwijkende cortisolspiegel in de ochtend of een afwijkend
cortisoldagritme. Dit duidt erop dat CAI alleen aanwezig is tijdens stress (bijvoorbeeld
ziekte). De hoge prevalentie van CAI bij patiënten met PWS zou kunnen bijdragen aan
het hoge sterftecijfer, met name tijdens infectiegerelateerde stress. Op basis van ons
onderzoek wordt geadviseerd om patiënten met PWS een stressdosering hydrocortison
toe te dienen in geval van stress, tenzij CAI recent werd uitgesloten door middel van een
metyrapontest.
Hoofdstuk 3
De relatie tussen centrale bijnierinsuffi ciëntie en slaapgerelateerde 
ademhalingsstoornissen bij patiënten met Prader-Willi syndroom
In het voorgaande hoofdstuk werd een hoge prevalentie van CAI bij kinderen met PWS
aangetoond. Echter, in het verleden werd ook gesuggereerd dat slaap-apneus een
belangrijke rol zouden hebben in het plotseling overlijden van patiënten met PWS. Daarom
werd de relatie tussen CAI en slaapgerelateerde ademhalingsstoornissen onderzocht.
Van 20 kinderen die in de studie beschreven in hoofdstuk 2 werden onderzocht, waren
polysomnografi sche gegevens beschikbaar, die verkregen waren in het kader van de
landelijke groeihormoonstudie voor kinderen met PWS. Daarnaast werd van 10 kinderen
de slaap gemeten tijdens de metyrapontest. 
De mediane (25e-75e percentiel) leeftijd bij de metyrapontest was 8,4 jaar (6,5-10,2). Na
toediening van metyrapon werd een signifi cante stijging van de centrale apneu index
(aantal/uur) waargenomen, van 2,2 (0,4-4,7) naar 5,2 (1,5-7,9). De toename in centrale
apneu index leek hoger bij de kinderen met CAI t.o.v. kinderen zonder CAI [2,8 (2,0 tot 3,9)
t.o.v. 1,0 (-0,2 tot 2,6), p=0,09]. Uit polysomnografi sche data, die enige maanden voor de
metyrapontest verkregen werden, bleek dat de slaapgerelateerde ademhaling signifi cant
ernstiger verstoord was bij kinderen die later met CAI gediagnosticeerd werden (p=0,03).
Ook leek deze groep kinderen een lagere minimale zuurstofsaturatie te hebben (p=0,07).
Samenvattend laat onze studie zien dat de centrale apneu index signifi cant stijgt na
toediening van metyrapon, met name bij kinderen die gediagnosticeerd werden met
CAI tijdens stress. Daarnaast hadden kinderen met CAI al enige maanden voor de
metyrapontest een signifi cant hogere centrale apneu index dan kinderen zonder CAI. Op
basis van ons onderzoek werd een nieuwe hypothese opgesteld met betrekking tot de
meest voorkomende oorzaak van plotselinge sterfte in patiënten met PWS (zie Hoofdstuk
10 van dit proefschrift).
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Hoofdstuk 4
Scoliose in Prader-Willi syndroom: Effecten van leeftijd, geslacht,
body mass index, spiermassa en genotype
Aangezien er slechts weinig kennis was van het vóórkomen van scoliose bij kinderen met
PWS, werd een cross-sectioneel onderzoek verricht naar de prevalentie van scoliose bij
een groep van 96 kinderen met PWS. Jaarlijks werden röntgenfoto’s genomen van de
wervelkolom. Ook werden de lengte, het gewicht, de totale spiermassa en de spiermassa
van de romp (middels een DXA-scan) gemeten. De mediane (25e-75e percentiel) leeftijd was
4,8 (2,1-7,5) jaar. De prevalentie van scoliose was 30% bij kinderen onder de 10 jaar tot
80% bij kinderen van 10 jaar en ouder. Vijftig procent van de kinderen had een Cobbse hoek
die groter was dan 20°, waarvoor verwijzing naar een orthopedisch chirurg noodzakelijk is.
Daarnaast had 13% van de kinderen een behandeling voor scoliose ondergaan, bestaande
uit een korset of een operatie. Bij kinderen met PWS komen twee typen scoliose voor: 1) de
“long C-curve type” scoliose, die met name vóórkomt in jonge kinderen met een lage ratio
van de spiermassa van de romp t.o.v. het lichaamsoppervlak (trunkLBM:BSA); en 2) een
vorm die lijkt op idiopathische scoliose (IS), die met name voorkomt in oudere kinderen met
minder hypotonie van de rompmusculatuur.
Op basis van ons onderzoek wordt aangeraden om kinderen met PWS regelmatig te
controleren op tekenen van scoliose middels lichamelijk onderzoek en om jaarlijks
röntgenfoto’s te laten maken van de wervelkolom.
Hoofdstuk 5
Gerandomiseerde gecontroleerde studie: effect van groeihormoon-
behandeling op scoliose bij kinderen met Prader-Willi syndroom
Eerder toonden wij een hoge prevalentie van scoliose aan bij kinderen met PWS. De
prevalentie was 30% bij kinderen onder de 10 jaar tot 80% bij kinderen van 10 jaar of 
ouder. In de algemene populatie is een snelle groei geassocieerd met het ontstaan en
de progressie van scoliose. Daarom werd scoliose vaak gezien als contra-indicatie
voor groeihormoonbehandeling, ook voor kinderen met PWS. Echter, de effecten van
groeihormoonbehandeling op scoliose bij kinderen met PWS was helemaal niet bekend.
Daarom hebben wij binnen de landelijke groeihormoonstudie gekeken naar de effecten
van groeihormoon op het ontstaan en de progressie van scoliose bij 91 kinderen met PWS.
Achtendertig kinderen <3 jaar en 44 prepubertaire kinderen >3 jaar werden verdeeld over een
groeihormoonbehandelde groep (1 mg/m2·dag) en een controlegroep, respectievelijk voor 
de duur van 1 en 2 jaar. Pubers werden verdeeld over twee groepen met een verschillende
dosis groeihormoon, namelijk 1 mg/m2·dag en 1,5 mg/m2·dag. Jaarlijks werden röntgenfoto’s
231
C
ha
pt
er
 1
2
gemaakt van de wervelkolom en werd de lengte, het gewicht, de spiermassa van de romp
(middels een DXA-scan) en IGF-I spiegels gemeten. Er was geen verschil in het ontstaan
en de progressie van scoliose tussen groeihormoonbehandelde kinderen en kinderen in
de controlegroep (respectievelijk p=0,27-0,79 en p=0,18-0,98). Groeihormoonbehandeling,
IGF-ISDS en inhaalgroei hadden geen invloed op het ontstaan en de progressie van
scoliose, ook niet na correctie voor mogelijke confounders. De lengte en spiermassa van
de romp werden gunstig beïnvloed door groeihormoonbehandeling. Bij start van de studie
werd een associatie gevonden tussen hogere IGF-I spiegels en minder ernstige scoliose.
Samenvattend tonen onze resultaten aan dat scoliose niet meer als contra-indicatie gezien
moet worden voor groeihormoonbehandeling bij kinderen met PWS.
Hoofdstuk 6
Effecten van groeihormoon op antropometrie, lichaamssamenstelling en
-proporties bij een grote groep kinderen met Prader-Willi syndroom
tijdens de gerandomiseerde gecontroleerde groeihormoonstudie
Kinderen met PWS hebben een verminderde lengtegroei en een afwijkende
lichaamssamenstelling met een hoog vetpercentage en een lage spiermassa. Uit eerdere
studies is gebleken dat groeihormoonbehandeling de lengtegroei bevordert en de
lichaamssamenstelling verbetert. Echter, de gecontroleerde studies hadden een maximale
duur van 1 jaar en onderzochten relatief kleine groepen kinderen met PWS. Bovendien
hadden de meeste kinderen in deze studies ernstig overgewicht. Wij hebben daarom een
gerandomiseerde gecontroleerde studie uitgevoerd, waarin 91 prepubertaire kinderen
met PWS werden geïncludeerd, waarvan 42 kinderen <3 jaar en 49 kinderen tussen 3
en 14 jaar. Wij onderzochten de effecten van groeihormoonbehandeling op lengtegroei,
lichaamssamenstelling en –proporties. De kinderen werden onafhankelijk verdeeld in 2
groepen: een groeihormoonbehandelde groep (1 mg/m2·dag) en een controlegroep. De
duur van de studie was 1 jaar voor kinderen <3 jaar en 2 jaar voor kinderen tussen 3 en 14
jaar. Jaarlijks werd antropometrie verricht en werd de lichaamssamenstelling gemeten met
behulp van een DXA-scan. De mediane (25e-75e percentiel) lengteSDS steeg in kinderen
<3 jaar van -2,3 (-2,8 tot 0,7) naar -0,4 (-1,1 tot 0,0) en in prepubertaire kinderen van -2,0
(-3,1 tot -1,7) naar -0,6 (-1,1 tot -0,1). In de controlegroep steeg de lengteSDS niet. Tijdens
groeihormoonbehandeling werd ook een verbetering van de hoofdomtrek waargenomen.
Het lichaamsvetpercentage en lichaamsproporties verbeterden, maar normaliseerden niet
volledig. In tegenstelling tot de controlegroep waarin de spiermassa daalde, werd een
stabilisatie van de spiermassa in de behandelgroep waargenomen.
Samenvatting
232
Samenvattend bevordert groeihormoonbehandeling de lengte, lichaamssamenstelling,
hoofdomtrek en lichaamsproporties van kinderen met PWS. Omdat de IGF-I spiegels fors
stijgen bij een aantal kinden met PWS, wordt regelmatige controle van IGF-I spiegels tijdens
groeihormoonbehandeling aangeraden.
Hoofdstuk 7
Gerandomiseerde gecontroleerde studie: botdichtheid en de effecten
van groeihormoonbehandeling bij prepubertaire kinderen met
Prader-Willi syndroom
Volwassenen met PWS hebben een lage botdichtheid. Ondanks dat de kinderperiode
de belangrijkste periode is voor de accumulatie van bot, was zeer weinig bekend over 
de botdichtheid van patiënten met PWS in de kinderleeftijd. Daarnaast hebben patiënten
met PWS veel symptomen die ook voorkomen bij kinderen met groeihormoondefi ciëntie.
Deze groep kinderen heeft een verlaagde botdichtheid, die normaliseert tijdens
groeihormoonbehandeling. Binnen de landelijke groeihormoonstudie voor kinderen met
PWS hebben wij de botdichtheid (BMD) en de botdichtheid gecorrigeerd voor de lengte
(BMADLS) bestudeerd en hebben wij de effecten van groeihormoon hierop gemeten.
Zesenveertig prepubertaire kinderen werden voor de duur van 2 jaar onafhankelijk verdeeld
over twee groepen: een groeihormoonbehandelde groep (1 mg/m2·dag) en een controle
groep. De gemiddelde ± SD leeftijd was 7,1 ± 2,2 jaar. Bij start, 6, 12 en 24 maanden,
werden middels een DXA-scan de BMD van het gehele lichaam en van de lumbale
wervelkolom (BMDTB en BMDLS) gemeten en werd de BMADLS gecalculeerd. Bij start waren
de BMDTBSDS, BMDLSSDS en de BMADLSSDS normaal (gemiddelde ± SD respectievelijk:
-0,2 ± 1,1 SDS; -0,4 ± 1,2 SDS; en 0,40 ± 1,1 SDS). Gedurende de eerste 6 maanden
van groeihormoonbehandeling daalde de BMDTBSDS. De BMDTBSDS veranderderde
vervolgens niet gedurende de tweede 6 maanden, maar vertoonde daarna wel een stijging.
Deze tijdelijke daling van de BMDTBSDS werd waarschijnlijk veroorzaakt door een disbalans
tussen botgroei en mineraalopstapeling en is ook in andere studies beschreven. Botten in het
gehele lichaam (TB) bestaan voor 80% uit corticaal bot. Botten van de lumbale wervelkolom
(LS) bestaan met name uit trabeculair bot. Trabeculair bot heeft een sneller botmetabolisme
dan corticaal bot. Daarom is de balans tussen botgroei en mineraalopstapeling sneller 
hersteld in trabeculair bot, waardoor er tijdens de eerste fase van groeihormoonbehandeling
geen daling plaatsvindt van de BMDLS. Na 24 maanden was er geen signifi cant verschil in
BMDTBSDS, BMDLSSDS en BMADLSSDS tussen de groeihormoonbehandelde kinderen en
de kinderen in de controlegroep (respectievelijk p=0,30, p=0,44 en p=0,47). IGF-I SDS
toonde een signifi cante positieve associatie met BMDTBSDS en BMDLSSDS, maar niet met
BMADLSSDS.
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Samenvattend toont onze studie aan dat de botdichtheid van prepubertaire kinderen met
PWS normaal is en dat groeihormoonbehandeling geen effect had op de botdichtheid,
behoudens een tijdelijke daling van de BMDTB tijdens de eerste zes maanden.
Hoofdstuk 8
Het cardiovasculaire en metabole risicoprofi el en acylation 
stimulating protein bij kinderen met PWS en de effecten van
groeihormoonbehandeling
Kinderen met PWS hebben een ongunstige lichaamssamenstelling met een hoog
vetpercentage. Desondanks was er weinig informatie over het cardiovasculaire en
metabole risicoprofi el van kinderen met PWS. Ook waren de effecten van groeihormoon
op cardiovasculaire en metabole risicofactoren nog niet goed in kaart gebracht. Acylation
stimulating protein (ASP) stimuleert de opname van glucose en de opslag van triglyceriden
in vetweefsel. Daarmee is een hoog ASP een belangrijke aanwijzing voor dyslipidemie en
vetophoping. Er was nog geen onderzoek verricht naar de ASP waarden in kinderen met
PWS of de effecten van groeihormoon hierop.
Binnen de landelijke groeihormoonstudie hebben wij gekeken naar het cardiovasculaire
en metabole risicoprofi el en de ASP spiegels van kinderen met PWS. Daarnaast hebben
wij het effect van groeihormoonbehandeling op deze parameters onderzocht. Vijfendertig
kinderen <3 jaar en 50 prepubertaire kinderen >3 jaar werden verdeeld over een
groeihormoonbehandelde groep (1 mg/m2·dag) en een controlegroep, respectievelijk voor 
de duur van 1 en 2 jaar. De gemiddelde ± SD leeftijd was 4,9 ± 3,0 jaar. Het gemiddelde
± SD vetpercentage was 28,4 ± 6,2 in kinderen < 3 jaar en 36,9 ± 8,5 in de prepubertaire
groep. Het vetpercentage uitgedrukt in SDS was verhoogd in 95% van de prepubertaire
kinderen. Naast een verhoogd vetpercentage hadden 63% van de kinderen < 3 jaar en
73% van de prepubertaire kinderen dyslipidemie. Deze kinderen hadden dus een ongunstig
cardiovaculair risicoprofi el. Daarentegen hadden bijna alle kinderen een normale systolische
en diastolische bloeddruk. In 40% van alle kinderen werd tenminste één component van het
metabool syndroom gevonden. Vijf procent van alle kinderen had tenminste drie componenten
en voldeed daarmee aan de criteria voor het metabool syndroom. Het merendeel van de
kinderen had normale nuchtere glucose- en insulinespiegels. Daarentegen waren de ASP
spiegels sterk verhoogd. De gemiddelde ± SD ASP spiegel was 107 ± 45 nmol/l (normal
< 58 nmol/l). ASP spiegels waren positief gecorreleerd aan de vetmassa en negatief 
gecorreleerd aan de triglyceridenspiegels in het bloed. Groeihormoonbehandeling had een
gunstig effect op het vetpercentage en op de HDL:LDL ratio. GH had geen signifi cant effect
op de ASP spiegels.
Samenvatting
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Onze resultaten tonen aan dat de meerderheid van de jonge kinderen met PWS een
hoog vetpercentage en dyslipidemie heeft, wat aanduidt dat de kinderen een ongunstig
cardiovasculair en metabool risicoprofi el hebben. Daarentegen hadden bijna alle
kinderen een normale systolische en diastolische bloeddruk, evenals normale insuline-
en glucosespiegels. Gezien de rol van ASP in de opname van glucose en de synthese
en opslag van triglyceriden in vetcellen, zou ASP niet alleen een belangrijke rol kunnen
spelen in het verhoogde vetpercentage van kinderen met PWS, maar zou ook kunnen
helpen bij het binnen de normale grenzen houden van de glucose- en insulinespiegels.
Groeihormoonbehandeling had een gunstig effect op het vetpercentage en op de HDL:LDL 
ratio, maar had geen effect op bloeddruk, glucosehomeostase en lipiden. Groeihormoon
had geen effect op de hoge ASP spiegels, wat een verklaring zou kunnen zijn voor het feit
dat het vetpercentage niet normaliseert tijdens groeihormoonbehandeling.
Hoofdstuk 9
Lange termijn effectiviteit en veiligheid van groeihormoonbehandeling
bij kinderen met Prader-Willi syndroom
Kinderen met PWS hebben een verminderde lengtegroei en een afwijkende
lichaamssamenstelling met een hoog vetpercentage en een lage spiermassa. Enkele studies
toonden aan dat groeihormoonbehandeling resulteert in een normale eindlengte, indien
gestart voor de puberteit. De verbetering van de lichaamssamenstelling wordt beschouwd
als het belangrijkste effect van groeihormoon bij kinderen met PWS. Echter, er waren
nog geen studies verricht naar de lange termijneffecten van groeihormoonbehandeling
op de lichaamssamenstelling bij een grote groep kinderen met PWS. Wij hebben
een studie verricht naar de lange termijneffecten van groeihormoonbehandeling op
lichaamssamenstelling, lengtegroei, botleeftijd en veiligheidsparameters. In een landelijke
prospectieve follow-up studie werden de 4-jaarsgegevens van 55 groeihormoonbehandelde
(1 mg/m2·dag) kinderen met PWS geanalyseerd. De volgende parameters werden gemeten:
vetpercentage en spiermassa (middels een DXA-scan), lengte, gewicht, hoofdomtrek,
botleeftijd, bloeddruk, nuchtere spiegels van IGF-I, IGFBP-3, glucose, insuline, HbA1c,
totaal cholesterol, HDL-cholesterol, LDL-cholesterol. SD-scores werden berekend op basis
van algemene Nederlandse referentiewaarden (SDS) en specifi ek voor PWS (SDSPWS).
De gemiddelde ± SD leeftijd bij start van de studie was 5,9 ± 3,2 jaar. Het vetpercentage
(SDS) was signifi cant lager na 4 jaar groeihormoonbehandeling (p<0,0001). De spiermassa
(SDS) vertoonde een signifi cante stijging gedurende het eerste jaar (p=0,02), maar keerde
daarna terug naar het niveau zoals bij start. Daarna veranderde de spiermassa uitgedrukt
in SDS niet meer. Groeihormoon resulteerde dus in een stabilisatie van de spiermassa
in tegenstelling tot de situatie in onbehandelde kinderen, die gekenmerkt wordt door een
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continue daling van de spiermassa (SDS). De gemiddelde ± SD lengte normaliseerde tijdens
groeihormoonbehandeling van -2,27 ± 1,2 SDS bij start tot -0,24 ± 1,2 SDS na vier jaar. De
BMISDSPWS toonde een signifi cante daling. De gemiddelde ± SD IGF-I en IGF-I/IGFBP-3
ratio stegen beiden signifi cant naar respectievelijk 2,08 ± 1,1 SDS en 2,32 ± 0,9 SDS.
Groeihormoon had geen invloed op de botrijping, de bloeddruk, de glucosehuishouding en
lipiden. Onze resultaten tonen aan dat 4 jaar groeihormoonbehandeling met een standaard
dosering (1 mg/m2·dag) een gunstig effect heeft op de lichaamssamenstelling, lengteSDS, 
BMISDSPWS, hoofdomtrekSDS en overige lichaamsproporties, zonder ongunstige effecten
op bloeddruk, glucosehomeostase en serum lipiden. De gunstige effecten van korte
termijn groeihormoonbehandeling blijven gedurende vier jaar gehandhaafd, hetgeen wordt
gekenmerkt door een verlaging van het vetpercentage en een stabilisatie van de spiermassa.
Op basis van onze studie wordt aangeraden te streven naar IGF-I spiegels tussen 2 en 3
SDS voor optimale effecten in kinderen met PWS zonder bijwerkingen. Samenvattend is
groeihormoonbehandeling een effectieve en veilige therapie voor kinderen met PWS.
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